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Summary 
The principal object of the work described in this 
thesis has been the synthesis of compounds as standards 
for comparison with the metabolites of the anabolic steroid 
drugs methandrostenolone and oxymetholone. 
Methandrostenolone is metabolised to two major 
metabolites, one of which has been previously identified 
as 6-hydroxymethandrostenolone. The major metabolite of 
the drug in normal man has now been identified as 17-epi-
methandrostenolone, the unambiguous synthesis of which is 
described. Prior to comparison Of the previously unknown 
metabolite and 17-epimethandrostenolone the properties of 
the latter compound were extensively compared with those of 
its 17-epimer. Mass spectrometry of the free steroid and 
gas-liquid chromatography of the trimethylsilyl derivative 
were among the methods used to identify the metabolite. 
Although urine extracts were examined unsuccessfully 
for evidence of methandrostenolone sulphate as a precursor of 
17-epimethandrostenolone the chemical synthesis of sulphate 
and sulphonate derivatives of the tertiary 175-hydroxy-17-- 
methyl function was attempted. The products were unstable 
and were readily hydrolysed with retention of configuration 
but their mass spectra were similar to that of 17,17-dimethyl-
18-norandrosta-1,4,13(14)-trien-3-one, the product of the 
sulphuric acid-catalysed dehydration of methandrostenolone. 
The C-17 epimerisation of the drug could not be achieved by 
chemical means. 
a 
The previously unstudied drug oxymetholone is meta-
bolised by normal man to two major metabolites which are 
excreted as conjugates of glucuronic acid. High temperature 
catalytic reduction of the drug and its metabolites gave only 
unsubstituted 17-methylandrostanes. Consequently, it was 
not known whether the C_21  carbon atom of oxymetholone was 
retained in the metabolites. The four 17a-methyl-.5t-androstane--
2,3,17-triols were synthesised and their mass spectra compared 
with those of the metabolites. None of the tdols corres- 
ponded to either of the metabolites, which were tentatively 
identified by mass spectrometry and thin layer chromatography 
as 
and 2-hydroxymethyl-17a-methyl-5a-androstane-3 ,17-diol. 
The latter compounds were synthesised by the reductions of 
oxymetholone with a variety of metal hydrides. 
The enzymatic reductions of 5-androstane-3,17-dione, 
oxymetholone and methandrostenolone with horse liver alcohol 
dehydrogenase were examined. A low yield of 3-hydroxy-5-
androstan-17-one was obtained from the former compound and 
17 -hydroxy-2a-hydroxymethyl-17-methyl-5a-androstan_one was  
tentatively identified as a product of the enzymatic reduction 
of oxymetholone, which was partially degraded in the alkaline 




Kockakian,1 in 1935, first observed that the androgens, 
the male sex hormones, possessed the ability to stimulate 
the synthesis of cellular protein, associated with the 
secondary male characteristic of muscle development. It was 
quickly appreciated that compounds with this property would 
provide valuable medications in the treatment of conditions 
involving abnormally low tissue protein content. However, 
the natural steroids which possess this anabolic effect were 
unacceptable for clinical use, particularly with women and 
children, because of the virilising androgenic effect.2  
- 
An assay of the relative anabolic and androgenic 
effects of a compound, the anabolic/androgenic ratio, was 
developed by Eisenberg and Gordan3 and later modified by 
• Hershberger et al.4 Although there have since been many 
alterations to these original procedures and the methods are 
still open to criticism  5a  the assay provides a basis for the 
screening of possible anabolic agents. Examination of the 
• naturalandrogens showed that almost all had an anabolic/ 
androgenic ratio of ca. 1.0, so that if strongly androgenic 
they were also strongly anabolic but if only weak androgens 
the anabolic effect was weak. Thus began the search for 
steroids in which the effects were as widely separated as 
possible. According to Kruskemper5b  "the androgenic effect 
differs from the anabolic effect only in its location and not 
in its essence, thus anabolic steroids which possess no 
androgenic character cannot exist". 
• 
However, this opinion 












androgenic action are still sought.6  
The first anabolic steroid to be found in which the 
androgenic activity was low enough to allow its clinical use 
was 19-nortestosterone[l]. However, a comparison of the 
doses required to produce a similar effect when the compound 
was administered orally and parenterally, respectively, re-
vealed that the latter route required approximately one seventh 
of the oral dose.7 This was explained by the fact that the 
orally administered drug was rapidly transported to the liver 
and deactivated by 17-oxidation[2]. 
Esterification of 19-nortestosterone led to a series 
of drugs[3] in which the relatively brief activity of the 
parenterally administered free steroid was significantly 
prolonged. 5C Variation of the ester residue, particularly 
an increase in length, had the effect of increasing the duration 
of action and the anabolic/androgenic ratio.2 The ester 
confers lipid solubility upon the steroid and consequently the 
longer the hydrocarbon chain the more lipid-soluble the steroid 
and the slower the diffusion into the blood stream where 
rapid hydrolysis to the active compound occurs.8 The esters 
of 19-nortestosterone constitute a large group of the anabolic 
steroids in current clinical use. 
The deactivation of testosterone and its derivatives by 
oxidation of the 17-hydroxyl group is prevented by the intro- 
duction of a 17a-alkyl substituent. This modification has 
resulted in a large group of orally active anabolic steroid 
drugs. l7-Hydroxy-l7-methylandrosta-1, 4-dien-3-one(meth- 













methyl-5a-androstan-3-one(oxymetholone) [51, an investigation 
of both of which is reported here, are members of this group. 
A further group of compounds, less obviously related 
to the natural androgens, have been found to possess high 
anabolic/androgenic ratios and some are in clinical use.2  
Many of these steroids, such as l7R-hydroxy-17-methy1-5a-
androstane-(3, 2-c)-pyrazole[ 6] possess a heterocyclic ring 
fused to ring A at positions 2 and 3 and may be prepared from 
oxymetholone. 
A wide variety of effects have been ascribed to the 
anabolic steroids, the chief of which are the positive influence 
on the protein content of the genital and extragenital organs, 
the inhibition of hypophyseal gonadotropin function, the anti-
oestrogenic effect, the gestagenic effect and the intrauterine 
masculinising effect on female embryos.Sd All anabolic 
steroids do not exhibit these properties to the same degree 
but any overall theory of their mechanism of action would need 
to encompass an explanation of the mechanisms by which they 
are responsible for each effect. The effect of the anabolic 
steroids on protein metabolism is the only one about which 
tentative statements may be made at present, protein synthesis 
being one of the better-studied areas of molecular biology. 
However correlations between the structure and degree of 
activity of anabolic steroids cannot be exact since they are 
based upon tests in which the use of different animal species, 
variations in steroid dosages, in methods of administration 
and in interpretation of data may lead to variable results. 5d 
Hormones affect metabolic processes by their ability 
to determine the rates of reactions and consequently a 
particular hormone must have a high affinity for the system 
to be controlled. Steroid hormones, like many drugs, are 
bound to specific plasma proteins by non-covalent forces,9  
the significance of which is not yet fully understood. The 
ability of steroids to bind with plasma proteins is thought 
to be related to the requirement- for efficient transport to 
the target organJ°  As has already been illustrated with 
reference to 19-nortestosterone, a hormone must possess a 
structure such that it can survive for sufficient time to 
exercise its hormonal activity at the target organ before its 
deactivation by metabolic processes. The strength of binding 
with plasma proteins may be a factor in the rate of metabolic 
deactivation of structurally sensitive steroids as well as a 
control mechanism of hormonal activity at the target organ, 
only the free fraction being available to exert its effect. ° 
At the target organ the hormone may act on the surfaces 
of cells or intracellular phase boundaries thereby altering 
the permeability to substrates, it may interact with the 
enzyme systems or affect the synthesis of enzyme proteins from 
precursors.5d Anabolic steroids might promote a positive 
nitrogen balance by stimulation of protein synthesis, by de-
celeration of protein degradation or by a decrease in the 
conversion of amino acids to urea. Various studies have 
shown that protein degradation is not impeded but that anabolic 
steroids produce a definite enhancement of synthesis. 11,12
Examination of the mechanism of protein synthesis shows that 
anabolic steroids might intervene to exert their stimulatory 
5 
effect at many points in the process. An increase of the 
ribonucleic acid content of cells and of the activities of 
amino acid activating enzymes has been demonstrated but further 
work is necessary before the precise point at which anabolic 
steroids exert their effect can be determined. 5d 
In order to exhibit anabolic activity steroids must 
thus be able to bind to plasma proteins for transport to the 
target organ, they must not be metabolised too rapidly and 
they must be capable of exerting an effect on the protein 
synthesising system. It is possible that each of these re-
quirements may involve different structural features and that 
only those steroids which possess suitable combinations of 
these show activity. 
10 
 This might explain why many anabolic 
steroids possess similar fl-ring substituents but may have a 
comparatively large variety of substituents in the A-ring. 
The first attempts to synthesise steroids with favour-
able anabolic/androgenic ratios involved relatively minor 
modifications to the natural-steroids 17-hydroxy-5a-androstan-
3-one and testosterone, which are highly biologically active. 
In later work substituents such as alkyl groups and halogen 
atoms were introduced.Sd Observations of the androgenic 
activity of 5ct-androstan-17-01,13 its 17a-methyl aerivativel4 
and 5a-androstane15 and of the progestational activity of a 
series of 17_alkyl_3_deoxy_19_nortestosteroneslE dispelled the 
classical belief that functional groups at C-3 and C-17 were 
necessary for biological activity. Bowers et aiJ0  synthesised 
a series of 3-deoxy compounds with at least one centre of un-
saturation in the A-ring to facilitate the requirement for 
protein binding. This work showed that a high electron 
density at either C-2 or C-3 or both in 170-hydroxy-5a-
androstane was  factor which strongly promoted anabolic 
activity. Klimstra et a1.17 studied the effect of the 
location of the oxygen atom in ring A on the anabolic activity 
of a series of androstane derivatives and found that 1-oxy 
substituted compounds were highly active. 
Methandrostenolone was first prepared18 in 1955 during 
a survey of the use of microorganisms which effected 1,2-de-
hydrogenation. Animal experiments showed that the compound 
had a high anabolic/androgenic ratio. and strongly promoted 
nitrogen retention with relatively small hormonal side effects. 
As the drug Dianabol(Ciba) it has found wide application as 
an oral anabolic agent. The introduction of a 1,2-double 
bond into 17a-methyltestosterone resulted in increased bio-
logical activity, compared to the less active 5,6- and 6,7- 
dehydro compounds.Sd 
Recent work19 on the X-ray crystallographic structure 
determination of 170-hydroxyandrosta-1, 4-dien-3-one [7],  the 
first steroid containing the 1,4-dien--3-one system to be 
studied by this technique, is of particular interest with 
regard to the relationship between the structure and biological 
activity of methandrostenolone and other steroids which possess 
this A-ring. Measurements of the valence angles and bond 
lengths showed that the A-ring is bent towards the a-side 
of the molecule to a much greater extent than can be assessed 
from molecular models. This change in conformation of the 








The conformations of FPI 
testosterone and 170- 
hydroxyandro sta-1, 4- 
dien-3-one determined 
by X-ray crystallo- 
graphy. 
7 
19-methyl group with respect to the rest of the molecule. 
The angle between the planes containing C-19, C-10 and C-13, 
C-lB is 10.10 in i-hydroxyandrosta-1,4-dien-3-one[7] com-
pared to 0.80 in testosterone[8], resulting in an increase 
of 0.5A in the distance between C-18 and C-19 in the former 
compound. 
In addition, the length of the 13-18  bond, was found19  
to be 1.51A,  unusually short compared with the theoretical 
C(sp3)-C(sp3) bond distance (1.526A). The other three 
bonds to C-13 are all longer, giving an average bond length 
to C-13 of 1.541, only slightly longer than normal. The 
short 13-18 length was ascribed to the bowing of the steroid 
towards the a-side which relieves crowding around the methyl 
groups and to interaction  of the angular methyl groups and 
the phenol of p-bromophenol used as a' complexing agent to 
obtain the X-ray spectra.  
The conformations of testosterone[8] and its 1-dehydro 
analogue[7] are shown in figure 1. Since the structure of 
methandrostenolone has not been studied by X-ray crystallo-
graphy the effect of the additional 17a-methyl group upon the 
conformation cannot be assessed. However it is probable that 
the A-ring will be bent towards the a-side of the molecule 
as in 17-hydroxyandrosta-1, 4-dien-3-one. 
Oxymetholone was synthesised20 in 1959 as an inter-
mediate in the preparation of 2a,17-dimethyl-17-hydroxy-5ct-
androstan-3-one during a programme designed to study the 
effects of alkyl substituents on biological activity in the 
androstane and 17a-alkylandrostane series. It was found to 
Figure 2. Dreiding models of inethandrostenolofle, 
oxymetho lone and 17 -hydroxy-17-methyiL--
5a-androstane-(3, 2-c)--pyrazole. 
be a potent oral anabolic agent with minimal androgenic 
activity and is marketed as Adroyd (Parke-Davis) and Anandrol 
(Syntex). 
At first sight the structure of oxymetholone[5] 
appears to be quite different from that of methandrostenolone 
[4]. However, a Dreiding model of the former compound shows 
that the hydrogen bonding between the hydroxymethylene 
hydroxyl group and the 0-3 carbonyl group leads to the 
formation of a flat six-membered ring fused to the A-ring. 
The model also shows that this additional "ring" is bent to-
wards the a-side of the molecule, which suggests the possib-
ility that the ability of oxyme±hoione and methandrostenolone 
to produce anabolic activity may be related to their geometry 
at the A-ring extremity of each molecule { see figure 21. 
This hypothesis is in accordance with the concept, 
outlined earlier (page 5), that different structural features 
of the molecule may be responsible for different requirements 
for hormonal activity. Thus, both methSndrostenolone and 
oxyrnetholone possess the 17P-hydroxy-17-methyl function, which 
confers oral stability, and both contain a flat ring at the 
other end of the molecule, bent towards the a-side. This 
feature might then be responsible for the effect on the 
protein synthesising system. In this case the difference 
between the lengths of the molecules of methandrostenolone 
and oxymetholone, the latter having an extra ring, between the 
two active sites mentioned above could be expected to be un-
important.Sd Oxymetholone is similar, with respect to the 
additional flat "ring", to the group of anabolic steroids in 
9 
which a heterocyclic ring is fused to C-2 and C-3 [figure 21. 
The metabolic pathways of the body act as defence 
mechanisms to facilitate the removal of potentially dangerous 
foreign compounds.  21a  The major metabolic transformations, 
such as oxidation, reduction and hydrolysis result in the 
introduction of new functional groups and may lead to acti-
vation, as typified by the formation of 19-nortestosterone 
from its esters, or deactivation by the introduction of 
centres for further catabolic reactions. The other major 
mode of detoxication is conjugation, in which functional 
groups are masked by reaction with endogenous substrates, 
which are chiefly sulphuric and glucuronic acids in steroid 
metabolism. The polarity of the molecule is thus increased, 
it is less lipid-soluble and more easily excreted. The 
metabolism of steroids and other foreign compounds is effected 
mainly by enzymes found in the liver and the metabolites are 
excreted in the urine. 
The metabolism of the natural androgens has been well 
studied22'23 but that of the majority of synthetic anabolic 
steroids has yet to be established,50 Recently, however, 
several groups of workers have been engaged in the examination 
of the metabolism of a variety of these compounds.2427 
Probably the most important factor which has contributed to 
the rise in the number of such investigations is the rapidly 
increasing use of mass spectrometry. 
Knowledge of the metabolism of anabolic steroids is 
of interest for a variety of reasons. The question of whether 
metabolism may lead to compounds with activity similar to that 
.1 
ID] 
of the parent drug or with completely different activity is 
of considerable importance.5@ Identification of the meta-
bolites may yield information regarding drug toxicity2Th28 
and in some situations may be the only means of establishing 
drug administration. 
Foreign compounds such as drugs usually give rise to 
a considerable number of different metabolites because of the 
variety of biotransformation and conjugation pathways which 
may operate. The metabolic pattern and the toxicity of a 
drug may he altered by genetic, physiological or environmental 
factors which affect the rate of reactions and thus the relative 
importance of each metabolite.  22b  Of. interest in the clinical 
situation are the physiological effects of age, sex, 
nutritional state, pregnancy and disease and the environmental 
effects of stress due to adverse conditions, exposure to 
ionising radiation and the ingestion of other foreign compounds. 
In order to draw valid conclusions from studies of the 
metabolism of anabolic steroids under such conditions a know-
ledge of the metabolism of the compounds in the normal healthy 
individual is essential. These investigations have been 
limited by the sensitivity of the techniques available for 
detection and identification of metabolites since the admini-
stration of large doses of steroids to normal subjects not 
undergoing treatment is unjustifiable. Methods employing 
small doses of radioactively labelled steroids have been used 
successfu11y2931 but suitably labelled compounds are generally 
difficult to obtain and the danger from exposure to radio-
activity would, under most circumstances, preclude the study 
•11 
of the metabolism of children and pregnant women. 32 
Adhikary and Harkness33 have developed a method by 
which microgram quantities of steroids can be detected as 
the parent steranes. The technique, known as carbon 
skeleton chromatography, involves the high temperature 
catalytic reduction of the steroid to its hydrocarbon skeleton 
and analysis of the trapped reduction products by gas-liquid 
chromatography)4 The metabolism of synthetic steroids which 
possess skeletons not found among the naturally-occurring 
steroids, such as 19-nortestosterones and 17-alkylandrostanes, 
is particularly suited to examination by this method. 35,j6 
Crude metabolic extracts are partially separated by con- 
ventional chromatography on thin layers or paper A small 
sample from each fraction is examined by carbon skeleton 
chromatography for metabolites bearing the skeleton of the 
drug. Those fractions which contain metabolites can thus 
be isolated, further purified and examined by other means in 
order to establish their identity. 
Catalytic reduction of steroids at 1702000C is a 
harsh procedure and only 5-10% of tn-oxygenated àndrostanes 
are recovered as the steranes, compared to 50% recovery from 
mono-oxyandrostanes. 4 The reliability of the method has, 
however, been extensively investigated by the reduction of 
known steroids and of the metabolites of drugs which have also 
been examined by conventional methods.32343637 The success 
of the technique as applied to the metabolism of steroid drugs 
with skeletons other than those of the natural products depends 







metabolism. It has been repeatedly shown that the carbon 
skeletons of the steroids remain largely intact during meta-
bolism' 1'840  consequently the method has been used for 
the study of the metabolism of normal therapeutic doses of 
anabolic steroids. 32,37 
Carbon skeleton chromatography is a useful technique 
for the location of microgram quantities of metabolites of 
anabolic steroid drugs in biological extracts. However 
standard compounds which have been synthesised by unambiguous 
routes are essential for the complete identification of any 
metabolites, particularly those isolated in very small.. 
amounts.  41  The work described here includes the synthesis 
of compounds as standards for the metabolites of methandrost-
enolone and oxymetholone. 
The metabolism of methandrostenolone was first in-
vestigated by Rongone and 3ega10ff42 in 1963 following the 
successful isolation of A-ring-reduced metabolites from 17a-
methyltestosteron 4 and 17h -oxa-D-homoandrosta-1, 4-dien-3-one 
(A1-testololactone).44 After administration of methandrosten-
olone[4.] two metabolites were isolated, both of which how- 
ever possessed the intact Al4_dien_3_one system. The major 
metabolite was positively identified as 6-hydroxymethandrost- 
enolone[9] by comparison with the authentic material. The 
second metabolite was not structurally identified although 
the data indicated that it was an isomer of methandrostenolone 
rather than a hydroxylated product. 
Sandor and Lanthier studied the metabolism of a 



















140_methandrostenolone in the dog. They found that the 
drug had a long biological half life (132 minutes) in com-
parison to cortisol (52 minutes)46 and attributed this to the 
resistance of the A-ring and C-17 substituents to enzymatic 
transformation. Most of the metabolic products were uncon-
jugated; Adhikary and Harkness37 likewise found no conjugated 
metabolites of methandrostenolone in the human. The majority 
of the radioactivity (85.49/o) administered to the dog was 
excreted in urinary metabolites within 72 hours of injection 
although only 38% was recovered in the crude chloroform 
extracts. The remaining material was extracted with solvents 
of higher polarity. Since the material in these extracts was 
similar to that extracted with chloroform it was suggested 
that the phenomenon was due only to partition of the highly 
polar metabolites between chloroform and water. Low re-
coveries of metabolites of methandrostenolone37 and methyl-
testosterone 43  by chloroform extraction have been reported 
elsewhere. Two metabolites of methandrostenolone were 
isolated 45  from the dog and it was postulated that these 
were C-6 oxygenated products. 
The 65-hydroxylation of steroids containing the A4-en-3- 
one and 414_dien_3_one systems is now an established biochem- 
ical pathway. Cortisol[10],4'48  cortisone[ll]4 and 9a-
fluoro-1113 , l€a, 17a, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione 
(triamcinolone)[12]50  have been shown to be metabolised to 
their 6-hydroxy derivatives by a variety of tissues 9''52  
More recently the biochemical 6-hydroxylationsof 17 -hydroxy-










6-diene-3,20-dione 17-acetate [13] ,31 4-chloro-170-hydroxy-
17-methylandrosta-1, 4-dien-3-one [141, 2454  1l , 21-dihydroxy- 
6a-fluoro--l6a-methylpregna-1,4-diene-3,20-dione[ls]55 and 
testosterone[8 ]56  have also been reported. 
The metabolism of compounds containing the 1,4-dien-
3-one system was first investigated 760 following the dis-
c0very61 that the antiinflamrnatory drugs prediilsone and 
prednisolone were more active than their 1,2-dihydro analogues, 
cortisofé and cortisoL Failure to demonstrate any ring-A 
reduction products from prednisone and prednisolone, in 
contrast to the metab01i5m62,63 of cortisohg and cortiscl,. 
led to the suggestion57'58 that the increased biological 
activity was due to the resistance of the 1,4-dien-3-one 
system to enzymatic attack. Later, however, Caspi and 
Pechet64 isolated metabolic products of prednisolone[161 
containing the 3a-hydroxy-4, 5-dihydro[ 17], 3a-hydroxy--4, 5ct--
dihydro [18] and 1-en-3-one-4,5-dihydro[19]A-rings. Various 
studies, in vivo6 and in vitro, 66-68 have demonstrated the 
inhibition of A-ring reduction by 1,2-dehydrogenation in the 
corticosteroids. The principle metabolite of one of the 
most active of these compounds, triamcinolone[12],  is the 
unconjugated 6-hydroxy derivative 
50 
Metabolic reduction of the 1,4-dien--3-one system of 
A*-testololactone[20] has been shown to occur to give the 
A1-ene3a-hydroxy-4,5-dihydro[2l]44  and A1-ene-3-keto-4, 5- 
dihydro[22]6 derivatives. The A-ring remained intact in 
37-51% of the material isolated after the administration of 
17-hydroxyandrosta-1, 4-dien-3-one,53 its 17-cyclopentenyl 
4 C 
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ether and androsta-1,4-diene-3,17-diOne to normal men. 26 
Less than 5% by weight of the metabolites contained the 
fully A-ring-reduced 3a-hydroxy-4,5-dihydro structure. The 
remainder of the products were 5-androst-l--enes with 3ct- 
hydroxy or 3-keto substituents. 
Schubert and Wehrberger24 have examined the meta- 
bolism of the 4-chioro analogue of methandrostenolone, 4-chloro- 
1 -hydroxy-17-methylandrosta-1,  4-dieh-3-one [14], and isolated 
ca. 20% of the dose as crude metabolic fractions from which 
they obtained twenty-one metabolites accounting for 1.5% 
of the administered drug. The major metabolite was reported 
to be the sulphate conjugate of the unchanged drug which, 
with the 6-hydroxy and 16-hydroxy derivatives[23,24], 
accounted for 86% by weight of the metabolites. Of the 
eighteen other metabolites only one, 17-hydroxy-17-methyl-
androsta-4, 6-dien-3-one[25], was positively identified. All 
but one of the seventeen unidentified metabolites were 
thought to contain the intact 1,4-dien-3-one A-ring of the 
drug. Schubert and Schumann 4' 0 have since identified the 
6,16-dihydroxy derivative [26] as a metabolite of this steroid. 
The microbial metabolism of testosterone, 17a-methyl-
testosterone, methandrostenolone, 4-cbloro-17a-methyltesto-
sterone and 4-ch1oro-17-hydroxy-17-methylaidrosta-1, 4-dien- 
3-one has recently been reported by Schubert et al. 71 The 
17-methyl steroids[27] were hydroxylated by Aspergillus 
fluvus at C-15, in contrast to the B-ring hydroxylation of 
testosterone. The ratio of 15a- to 15-hydroxylation[28,29] 
appeared to depend upon the nature of the A-ring substituents. 
[27] [29] [28] 
<II- Xa" ----) lal 
[30] [31] [4] 
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Methandrostenolone[4] was metabolised by Clostridium 
paraputrificum to the compound 
[30] which was further transformed to 17a-methyl--5- 
androstane-3a,17-diol[31] . The A1-douhle bond of 4-chloro-
17-hydroxy-17-methylandrosta-1, 4-dien-3--one [14] was not 
reduced by this organism[32]. Methandrostenolone was not 
metabolised by Rhodoturula glutinis, although its 4-chloro 
analogue[14] was transformed to the 61-ene-3 -hydroxy-4-
chloro-5a-steroid[33] and the other compounds were reduced 
to 3-hydroxy-5a-androstanes. 
The question of whether the 1,4-dien--3-one system 
is aromatised to a significant extent during metabolism is 
important because of the changed biological activity of the 
resulting metabolite  5e  and because an. oestrogen would not be 
detected as a metabolite of a 17a-methylandrostane by carbon 
skeleton chromatography. Aromatisation of 17$-hydroxy-
androsta-1,4-dien-3-one,72 androsta-1, 4-diene-3,17-dione73 
and methandrostenolone5e by placental enzymes has been 
demonstrated but no oestrogens were detected following the 
incubation of methandrostenolone with rat liver slices. 7
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In a study70 of tritium-labelled 4-ch1oro-17-hydroxy-17-
methylandrosta-1,4-dien-3--one in normal non-pregnant women 
less than 1% of the radioactivity was detected in 17a-methyl--
oestra-1,3,5(10)-triene-3,16a,17--triol, consistent with the 
known low level of aromatisation of neutral steroids-73  
After the administration of 4g of methandrostenolone 
to a woman with advanced adenocarcinoma of the lung Rongone 
and Segaloff recovered 7.25% of the dose as two crystalline 
17 
metabolites.42 The major metabolite, G-hydroxymethan-
drostenolone, accounted for 80% of the extracted material. 
During their study of the reliability of carbon skeleton 
chromatography Adhikary and Harkness also identified two 
metabolites of methandrostenolone from normal men who were 
given the therapeutic dose of 5mg of the drug.37  However, 
in this case G-hydroxymethandrostenolone was present as 
only a third of the extract. The predominance of the 6-
hydroxylation pathway in the first investigation may be due 
to a variety of factors stemming from the condition of the 
subject. Experiments with rats have shown that microsomal 
enzymes are stimulated by pretreatment with steroid hormones 
to a degree related to the anabolic activity of the compound.75  
A large dose of an anabolic steroid might thus stimulate its 
own hydroxylation. It is also well-known that many drugs 
stimulate or inhibit microsomal metabolism of other drugs 76-79  
an effect which is important in multiple prescription,22c and 
that hydroxylation is dependent upon the condition of the 
person to whom the drug is administered. 28 
Adhikary and Harkness used carbon skeleton chromato- 
graphy to examine the metabolites of the therapeutic dose 
of 10mg of the anabolic steroid drug oxymetholone in normal 
man.32'37 The metabolism of this compound has not been 
reported elsewhere. The retention times of the reduction 
products from oxymetholone were identical to those from 
methandrostenolone,36 indicating that the additional C-C bond 
to the 2-position in oxymetholone is labile under the hydro- 
genation conditions employed. Thus the presence or absence 
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of the additional carbon atom in the two metabolites could 
not be inferred. 
Aromatic methyl[34] and ethyl ethers[35] are de-
alkylated to the corresponding phenol[36,37] by microsomal 
enzyme systems21 and oestrone[38]  has been assumed to arise 
from 3-methoxyoestrone[39] by this pathway. 
 80 
 Rat liver 
microsomes have been shown91 to 0-demethylate 17a-ethynyl-
17-hydroxy.-- 3-methoxyoestra-1,3,5(10)-triene(mestranol)[ 40] 
to ethynyloestradiol[/-i.l] and the slow release of the active 
phenol is thought to be the reason for the reported enhance-
ment of the activity of ethynyloestradiol by formation of 
the 3-ether. Adhikary32 suggested that the 0-2 substituent 
of oxymetholone[5] might be removed in this manner to yield 
2-hydroxy metabolites[42]. However a study of the metabolism 
of 1- 
14
in the rat 
showed that no biological dealkylation of this compound 
82 
occurred. 
The microbial transformations of 2-hydroxymethylene-
17P-hydroxyandrost-4-en-3-one [43], its 17a7methyl [44] and 
17a-ethynyl [45] analogues with a Variety of organisms were 
investigated by Nielson et al.83 Pethcillium lilicanum re-
duced the 17-hydroxy[43] and 17-hydroxy-17-methyl[44] com- 
pounds to the 2a-hydroxymethyl derivatives [46,47]. The 17$- 
hydroxy-17-ethynyl compound [45] was similarly reduced by 
Rhizopus stolonifer.84 Neither of these organisms introduced 
additional hydroxyl functions. 6-Hydroxyl and 16a-hydroxyl 
groups were introduced by other organisms, together with 



















Goldman85 has investigated the effects of oxymetholone 
as an inhibitor of 3-hydroxysteroid dehydrogenase and 
3-ketosteroid isomerase in the rat. He found that NA]JH was 
formed from NAD and the steroid at a rate which suggested that 
oxymetholone was itself dehydrogenated in the system. 
In view of the successful--isolation of two major 
metabolites from both methandrostenolone32,37,42,45 and 
oxymetholone32'37 and the previous characterisation42 of only 
one of these products it was deemed appropriate to commence 
a systematic study into the nature of the unknown metabolites. 
The limited information concerning the identities of the 
three compounds has now been summarised and the results of the 
investigations are described in the following sections. 
20 
2. The Extraction, Location and Purification of the 
Metabolites of Methandrostenolone and Oxymetholone 
Adhikary32 studied the use of high temperature 
catalytic reduction of steroids for the identification of 
the metabolites of steroid drugs containing carbon skeletons 
not found among the natural products. He confirmed the 
previous reports4245 of two major metabolites of methan-
drostenolone and demonstrated that the hitherto unstudied 
anabolic agent, oxymetholone, was converted to two major 
metabolites in normal men. 
The production, extraction and isolation of the meta-
bolites of methandrostenolone and oxymetholone were carried 
out at the Department of Paediatric Biochemistry, Royal 
Hospital for Sick Children, Edinburgh by Dr. R.A. Harkness, 
Dr. P.M. Adhikary, Mr. A.M. Torrance and Mr. B. Kilshaw. 
Each healthy male volunteer received the normal thera-
peutic dose of one 5mg tablet of methandrostenolone or one 
10mg tablet of oxymetholone. An examination, described 
later (section 3.7), of the rate of excretion of the less 
polar, previously unidentified metabolite of methandrosten-
olone showed that excretion reached a maximum and fell to a 
constant low value within the first 24 hours following drug 
administration. Consequently urine was not normally collected 
beyond this period after administration of either drug. 
The two metabolites of methandrostenolone are not 
conjugated with glucuronic or sulphuric acids and are re-
covered from urine by chloroform extraction (free fraction). 
No metabolites of oxymetholone were however detected in the 
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Figure 3. The freely extractable urinary metabolites 
of methandrostenolone separated by thin 
layer chromatography and detected by carbon 
bkeleton chromatography. The chromato-
graphic behaviour of the named reference 
compounds is shown by the top squares. 
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free fraction. Both are excreted as glucuronide conjugates 
and are recovered by hydrolysis of the urine with -g1ucu-
ronidase prior to chloroform extraction (glucuronide 
fraction). 
The chloroform extracts of the free and glucuronide 
fractions were washed with dilute sodium hydroxide solution 
and then with distilled water until neutral, • dried over 
anhydrous sodium sulphate and evaporated to dryness. The 
residues were dissolved in ethanol and chromatographed on 
thin layers of silica gel G in the solvent system, chloroform- 
methanol (9:1 or 19:1). The plates were divided into 1cm 
bands and the material eluted from each band. These eluates 
were halved, evaporated to dryness and one set of residues 
dissolved in ethanol (0.1rnl). lOpi of this solution from 
each fraction was used for high temperature catalytic re-
duction at 180-1900C over a 1-3% w/w platinum catalyst. The 
reduction products were analysed by gas chromatography on 1% 
SE-30 or 1% NGA columns. A hydrocarbon standard consisting 
of 17-methyl-5a-and 17-methyl-5-androstanes was derived from 
the drug by the same method. Those bands which contained 
material with the same hydrocarbon skeleton as the drug were 
thus identified and further purified by thin layer and paper 
chromatography. Carbon skeleton chromatography was repeated 
at each stage of the purification to confirm the presence of 
compounds with the skeleton of the drug. 
The more polar of the two metabolites of methandroten-
olone [see figure 3] behaved similarly to 6$-hydroxymethand-
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Figure 4. The conjugated metabolites of oxyinetholone 
separated by thin layer chromatography and 
detected by carbon skeleton chromatography. 
The chromatographic behaviour of oxymeth-
olone is shown by the top rectangle. 
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segaloff;42  it was not further studied. The second 
metabolite, M, appeared identical to methandrostenolone 
when compared by thin layer and paper chromatography. How-
ever, gas-liquid chromatography on SE-30 and QF-1 columns 
showed that M had a slightly shorter retention time than 
methandrostenolone.32 Approximately 5% of the dose was 
isolated as 6-hydroxymet1iandrostenolone and M, in the ratio• 
1:2, assuming that the response of both compounds to carbon 
skeleton chromatography was the same. 
About 5% of the dose of oxymetholone was isolated as 
two metabolites [see figure 4], both more polar than the 
drug and in the ratio 1:1 assuming equal response to carbon 
skeleton chromatography. 
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3.1 The Synthesis of 17-Epirnethandrostenolone 
3.1.i. Rongone and Sega1off42 purified sufficient of their 
unidentified metabolite of methandrostenolone for analysis 
by ultraviolet and infrared spectroscopy, both of which in-
dicated that the compound possessed the 1,4-dien-3_one  system. 
Elemental analysis showed that its composition was closer to 
that of methandrostenolone than an oxygenated product but 
the melting point (222-2240C) demonstrated that it was not 
methandrostenolone (m.p. 164-1660C), In view of this 
evidence it was suggested that the metabolite might be an 
isomer of methandrostenolone. 
Adhikary32 recovered about 3.75% (.La. ±60pg) of 
administered methandrostenolone as a metabolite, M, with 
similar polarity to the drug in thin layer and paper chroma-
tographic systems. M was only distinguishable from 
methandrostenolone by gas-liquid chromatography [table 11. 
Column SE-30 OF-i 
Compound Retention time (mins.) 
Methandrostenolone 23.0 25.3 
Metabolite M 22.0 23.9 
Table 1. The retention times of methandrostenolone and its 
less polar metabolite M on SE-30 and CF-1 columns 
From the preceding evidence it was postulated that M 
might be the 17-epimer of methandrostenolone, 17-epimethand-- 
rostenolone. This compound could be expected to exhibit 
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to methandrostenbloñe since epimerisation of the C-17 sub-
stituehts should have Very little effect on the shape of 
the molecule. The synthesis of 17-epimethandrostenolone 
has not been previously reported. 
3.l.ii. Previous syntheses of 17-flestosterone and 17-
methyle2itestosterone - 
During the synthesis of testosterone[8] by reduction 
of the 17-carbonyl group of dehydroepiandrosterone[48] Ruzicka 
and Kgi,86 in 1936, obtained a small amount of 17-epitesbo- 
sterone [49]. Similarly, in 1939 Miescher and Klarer87 is-
olated 17-methylepitestosterone[50] in very low yield during 
the synthesis of methyltestosterone L51] by the Grignard re-
action of methylmagnesium iodide with dehydroepiandrosterone 
[48]. These compounds were found to possess very low 
androgenicity in comparison to their highly active 0-17 
epimers. There was no interest in 17a-hydroxyandrostane 
derivatives until Sondheimer et al.  88  devised methods for 
the preparation of 17-epitestosterone and 17-methylepitesto-
sterone in yields large enough to permit their testing as 
anabolic agents. No such activity was detected and so, al-
though many steroid drugs possess the 17$-hydroxy-17-methyl 
function few 0-17 epimers with the 17a-hydroxyl group have 
been reported. Ananchenko et al. 89 found that a series of 
D-horno-17a-a1kyl-17a-a1cohols were less androgenic and less 
anabolic than their 17a-hydroxy epimers. 
No methods had been devised for the preparation of 17-
hydroxyandrostanes in reasonable yields prior to those of 












Diagram 1. Previous synthesis of 17—epitestosterone 
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subject to predominantly a-face attack the methods of 
Ruzicka and Kgi8G  and Miescher and Klarer87 were of no 
preparative value. Conversion of a 17-alcohol[52] to the 
toluene-p-sulphonate derivative[53] and subsequent acetolysis 
and saponification led to the 17a-ol[54] in ca. 5% yield. 90,91 
The preparation of 17a-hydroxy cmpounds[55] by perbenzoic 
acid oxidation of 17-isopregnane derivatives[56] was 
reported92 but the yields were low because the equilibrium 
between the pregnanes[57] and 17-isopregnanes[56] lies well 
towards the former. 
The synthesis of 17-epitestosterone [4.9 1 devised by 
Sondheimer et al.88 [diagram 1 ] involved a new route to 616- 
androstene derivatives since previous routes to these compounds 
required the 17a-ols as starting materials. Dehydroepian-
drosterone acetate[58] was converted to its cyanohydrin de-
rivative, which was dehydrated and hydrolysed under alkaline 
conditions to yield 3-hydroxy-A 46-.etiadienic acid[59]. 
This compound was decarboxylated to the 65 lE_dien.-3_ol[6O] 
by refluxing with quinoline and copper chomite, and 
oxidation under Oppenauer conditions gave the 416_dien_3_ 
one[61]. Perbenzoic acid oxidation occurred preferentially 
at the D-ring to yield the 16a,17a-oxide[62] which was 
reduced with lithium aluminium hydride to the 3,17a-diol[63]. 
Oxidation with manganese dioxide 'gave 17-epitestosterone[49] 
in 42% yield from the dienol[60]. 
1• 88 17-MethylepltestosteroneL50j was synthesised by an 
analogous route based on the decarboxylation of 3-hydroxy-












Diagram 2. Previous synthesis of 17—methylepitestosterofle. 
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3-hydroxypregn-5-en-20-one acetate[65] by bromination, re-
action with sodium iodide and a Favorskii rearrangement. 
The 17-methylene-5-en-3P-01[661 was obtained byrefluxing 
with quinoline in the presence or absence of copper chromite. 
Oppenauer oxidation gave the 4_en.3_one[67] which was oxidised 
with perbenzoic acid to the 17a,20-oxide[681. Lithium 
aluminium hydride reduction gave the 17-methyl-17--ol[69] which 
was oxidised with manganese dioxide to give 17-methylepitesto-
sterone[50]. 17-Ethylepitestosterone has been prepared by 
a similar route.93  
3.1.iii. 17-Methyleneandrost-5-en-3--ol[ 66J 
The discovery9495 of the reaction between alkylidene 
phosphoranes[70] and carbonyl compounds[71] simplified the 
synthesis of 17-methylepitestosterone by offering an alter-
native route to the 17-methylene cornpound[661. 
Sondheimer and Mechoulàm 6 first investigated the use 
of the Wittig reaction for the synthesis of steroidal methylene 
compounds and reported that the reaction proceeded most smoothly 
when methylenetriphenylphosphorsne[70,RI =RZ=H] was employed. 
The ylide was generated in ethereal solution with butyllithium 
as the base according to the procedure described by wittig. 4' 95 
A solution of the steroidal ketone in ether was added and the 
reaction carried out under reflux in tetrahydrofuran after 
removal of the ether by distillation. Reaction of 3-hydroxy-
5a-androstan-17-one with 3 equivalents of the Wittig reagent 
gavb a 32% yield of the corresponding 17-methylene compound. 
When the quantity of Wittig reagent was increased to 5 equi-
valents a 58% yield was obtained; consequently a very 
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considerable excess of reagent was recommended for the 
reaction of polyfunctional compounds. Treatment of dehydro- 
epiandrosterone[48] with 3 equivalents of the reagent gave 
the 17-methylene derivative[66] in 36% yield. The effect 
of protection of the 3-hydroxyl group on the yield was in-
vestigated but the free ketol proved to be the most suitable 
starting material. 6  
In 1962 Corey and Chaykovsky97 reported the preparation 
of methylsulphinyl carbanion[72] from the reaction of sodium 
hydride and dimethyl sulphoxide[73]. Greenwald et al.  98  used 
this base for the preparation of the Wittig reagent[70] and 
found that both the rate and yield of the overall reaction 
were greatly improved in comparison to those of the reaction 
in customary solvents. Potassium t-butoxide was introduced 
for the generation of niethylsulphinyl carbanion by Drefahl 
99,100 who obtained 17-methyleneandrost--5-en-3-d1[66] 
in 80% yield. 
In their synthesis of the 17-methylene compound [66] 
Drefahl et al-100  maintained the mixture of steroid and ylide 
solutions at room temperature for 12 hours before heating at 
800C for 15 hours and subsequent extraction of the product. 
Several variations of this procedure have now been tested 
and thin layer chromatography of the reaction mixture showed 
that all the starting material [48] was consumed after the 
solutions were mixed, heated directly to 800C and maintained 
at this temperature for 1 hour. Rigorous exclusion of water 
was necessary for successful formation of the ylide. 
The presence of the byproduct of the reaction, triphenyl-











by intense absorptions at Vflax  1210, 1125 and 730cm in the 
infrared spectrum. Alumina chromatography has been 
96,100 used to purify the product but, several recrystallis- 
ations from methanol proved more convenient and consistently 
gave 75-80% yields of pure compound, judged by the absence of 
the triphenyiphosphine oxide bands in the infrared spectrum. 




1101 anda two proton signal at ¶5.36 respectively, 
characteristic of a terminal methylene function. When 
acetone was employed as recrystallising solvent co-crystals 
of triphenylphosphine oxide and the steroid [66], which melted 
at a similar temperature to the pure steroid, were obtained. 
3.]. .iv. 17-Methyleneandrost-4-en-3-one [67] 
The 0ppenauer oxidation,102  used by Sondheimer et al P8 
converted the A5-en-3-01[66] to the 4-en-3-one[67] in a 
single step, although it probably involved initial formation 
of the ,y-unsaturated ketone[75] which would be immediately 
isomerised in the basic medium.103 This reaction proved un-
suitable because of the difficulty of freeing the product [67] 
from traces of cyclohexanone and its condensation products, 
which resulted in large losses of steroid. Consequently, 
the A5-en-3-ol[ 66] was oxidised to the A5-en-3-one [75] with 
chromic acid in acetone.103104 Mineral acid has been 
used103 to isomerise the 5,6-double bond to the conjugated 
4,5-position but when this reagent was employed much de-
gradation occurred. However anhydrous oxalic acid105 proved 
successful for the isomerisation. 




M, m/e 330 
C 
--32 CHO co HO 3 
3 m/e 298 
m/e 299 OCH
3 






CH 0-  





OCH3 CE-  
H C CH  2  
CH 
3 +3 
base peak, m/e 101 
Diagram 3. Mass spectral fragmentations of 17-methyleneandrost-
5-ene-3-difllethyl ketal. 
29 
during removal of the organic solvents after chromic acid 
oxidation saturated sodium bicarbonate solution was added 
immediately after the reaction had been quenched with 
methanol. The solvents were then removed and the product 
extracted by the usual procedure. Infrared analysis of 
the crude product showed a very low intensity ,•q-unsaturated 
carbonyl absorption, Vifiax  1715cn(, in comparison to the C-H 
stretch at vmax2990_29lOcm and several intense bands in 
the fingerprint region not found in the spectrum of the A5- 
en-3-one[75]. N.m.r. spectroscopy indicated that the double 
bond was entirely in the 4,5-position (74.64,6-H) and that 
the 17-methylene function was intact ('r5.36). The shift of 
the C-19 methyl signal (78.98) compared to that of the 65-
en-3-one[75] (i'9.17) was consistent with the assignment of 
two singlets (76.89, 6.80) to a 3-dimethyl ketal[76]. 
Alumina chromatography of the crude product led to 
almost immediate elution of a white crystalline compound, the 
infrared and n.m.r. spectra of which showed the features 
described above. Zalkow et al.106  reported signals at 76.86 
and 6.81 in the n.m.r. spectrum of 5a-cholestane--3-dimethyl 
katal. These authors stated that the reaction medium 
should be absolutely anhydrous to obtain a high degree of 
ketal formation, however the n.m.r. spectrum showed that the 
crude product contained about 60% of the ketal[76]. 
The mass spectrum of the low pblarity product taken 
from the column confirmed that it was 17-methyleneandrost- 
5-ene-3-dimethyl ketal[76]. The ethylene ketal, which is 
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Diagram 4. Mass spectral fragmentations of 
17_methyleneandrost-4en30ne. 
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pronounced fragmentation that it overshadows the effects 
of other functional groups .107a The dimethyl ketal function 
in 17-methyleneandrost-5-ene-3-dimethyl ketal acted in the 
same way and gave rise to the base peak at rn/c 101 by the 
route shown in diagram 3. As in the case of the ethylene 
ketal of androst-5-en-3-one -0 the 5,6-double bond favours 
cleavage of the 3,4-bond by allylic activation [route a] 
whereas an ion cannot arise from 2,3-bond cleavage [route h] 
because of the unfavourable allene intermediate which would 
be involved. The only other ions of importance in the mass 
spectrum of the ketal were the molecular ion (m/e 330, 9%) 
and those at rn/c 299 (18.5%) and m/e 298 (22%), These two 
latter ions arise from loss of a methoxy radical and the 
elements of methanol, respectively. 
Approximately 40% of the crude product was eluted from 
the column as the ketal[ 76]. However, the next component 
was identified as the 64-en'--3-one[67] (12%) which could have 
arisen only by hydrolysis of the ketal and conjugation on 
the alumina. It was identical with the compounds obtained 
by Oppenauer oxidation of the A5-en-3--o1[66] and by oxalic 
acid isomerisation of the A5-en-3--one[75]. The mass spectrum 
of 17-methyleneandrost-4-en-3-one was more complex than that 
of the dimethyl ketal[76]. The molecular ion (m/e 284) was 
• also the base peak and the spectrum included peaks at 
m/e 242108  and m/e 124109 characteristic of the A4-en-3-one 
syster?0 [see diagram41. 
Unreacted A5-en-3--01[66] was next eluted from the 














Mt m/e 360 m/e 282 
m/e 267 
Diagram 6. Mass spectral fragmentations of 6-hydroxy-17-
methyleneandrost-4-en-3--Ofle. 
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this compound [see diagram 51 were the molecular ion 
(m/e 286), which was also the base peak, and ions at rn/c 
271, m/e 268 and m/e 253, which arose from loss of a 
methyl radical, water and the two moieties together, 
respectively. 
A second unknown product was then eluted, the infra- 
red spectrum of which showed that it contained a hydroxyl 
group max3500cm in addition to the 17-methylene function. 
The conjugated carbonyl absorption ('maxl68Ocni) was 
slightly different from that of 17-methyleneandrost-4-en-3- 
one (vmaxl675cm). As well as the C-If proton signal, 
which was shifted downfield by 3Hz compared to the corres-
ponding signal in the A4-en-3-one [67],  and the 17-methylene 
resonance, the compound gave a single proton triplet at 
5.65 (J = 3Hz). The 18-methyl shift (T9.16) was similar 
to that of the other 17-methylene steroids encountered but 
the 19-methyl resonance (t8.54) was at considerably lower 
field. Similarly the n.m.r. spectrum °  of the known 6$- 
hydroxyandrost-4-en-3-one has a triplet at ¶5.65 (J = 3Hz) 
corresponding to the 6a-proton and the 19-methyl signal is 
low (T8.62). The molecular ion of the unknown product 
We 300), which was also the base peak, was consistent 
with one additional hydroxyl group [see diagram 6]. The 
only other intense ions in the mass spectrum were those re-
sulting from loss of a methyl group, water and both at 
rn/c 285, m/e 282 and m/e 267, respectively. The compound 
was thus identified as E-hydroxy-17-methy1eneandrost-4-en-- 
3-one [77 ]. 6$-Hydroxycholest-4-en-3-one has been reported 
oc










to be among the products of the dichromate oxidation of 
cholesterol .112a 
Mild acid hydrolysis of the ketal[76] gave a mixture 
of the enones [75,67] which was isomerised to the 64-en-3-
one[67] with oxalic acid. 
3.1.v. 17a, 
Sondheimer et al.88  used perbenzoic acid for the 
conversion of 17-methyleneandrost.'-4-en.-3-one[67] to the 17a, 
20 oxide[68]. More recently epoxidising agents, such as m-
chloroperbenzoic acid, which remain active for long periods 
when stored at room temperature; have been developed. m-
Chloroperbenzoic acid, manufactured by the FMC Corporation, 
was used for the first epoxidations of the 17-methylene 
compound, according to a method developed by the manufactur-
ersJ12a The reagent had a minimum assay of 80% active 
oxygen when produced but at the time of use the assay was 60%, 
determined by iodimetric titration. 
The products of the epoxidation reaction were examined 
most conveniently by thin layer chromatography and n.m.r. 
spectroscopy. After development of the plate with sulphuric 
acid spray and heat the epoxide [68] was readily .recognisable 
as a greenish-yellow spot, slightly more polar than the 
initially pink spot of the starting material [67] and con-
siderably less polar than the blue spot given by 17a-hydroxy-- 
17-hydroxymethylandrost-4-en-3-one [78]. Epoxide formation S  
was easily detected by n.m.r. spectroscopy by the disappear-
ance of the 17-methylene signal (15.36) and the appearance 
of a pair of doublets at 17.34, 7.26 AB = 4Hz) assigned to 
33 
the protons of the 20-methylene function. The C-20 protons 
of the glycol[78] gave a pair of doublets at ¶6.43, 6.38 
(J AB 11Hz). 
When the epoxidation was carried out at room temper-
ature for periods of between 1 and 3 hours unreacted starting 
material [67] was isolated at reaction concentrations of ca. 
0.0024 moles of active oxygen per 0.0036 moles of steroid. 
per litre of methylene chloride but at concentrations of 
0.136 moles of active oxygen per 0.136 moles of steroid per 
litre of solvent the major product was the glycol[78], 
formed by cleavage of the epoxide under excessively acid 
conditions. However, at concentrations in the region of 
0.07 moles of active oxygen per 0.08 moles of steroid per 
litre good yields of the epoxide [68] only slightly contamin-
ated with the unreacted 17-methylene compound [67] and the 
glycol [78], were obtained. Purification was unnecessary at 
this stage because the products of reduction of these contam-
inants were easily removed after the following reaction. 
The epoxidation was repeated using new batches of m-
chloroperbenzoic acid manufactured by either B.D.H. Chemicals 
Ltd. or by Ralph N. Emanuel Ltd. The heat of. reaction was 
now sufficient to boil the solvent and a fluorescent green- 
red colour developed. The product of epoxidation under 
these conditions contained a- mixture of the starting material 
[7] and the two hydroxymethyl compounds [78,79],  but no 
epoxide[68]. There was no improvement when the temperature 
was maintained below 25°C during the addition of the peracid 
and at ice temperature the reaction did not proceed at all. 
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A colour change similar to that described above was 
noted in an experiment, described later (section 3.15.11), 
in which the glycol[78] was heated with sulphuric acid. De-
hydration and methyl migration again occurred to give 17ar 
hydroxymethyl-l7-methyl--l8.-norandrosta-4, 13( 14)-dien-3--one 
[79], the hydroxymethyl protons of which gave a pair of 
doublets at T6.70, 6.60 (j'63  = 10Hz). 
Titrimetric analysis of the fresh peracids showed 
•that the average active oxygen content was 86%, in com- 
parison to the 60% activity of the older reagent. Since 
the diluent in this latter material might have been the 
parent acid, fresh peracid was mixed with m-chlorobenzoic. 
acid to give a sample with 60% activity. However, this re-
agent also gave overreaction under the previous conditions. 
Ruzicka et al.113  obtained at least three different 
products from the oxidation of 17-ethylideneandrost.-4--en-3-
one with 1.5 equivalents of monoperphthalic acid (0.088 mole 
of active oxygen/0.057 mole of steroid/litre) but oxidation 
with 0.9 equivalents of perbenzoic acid (0.237 mole of 
active oxygen/0.264 mole of steroid/litre) gave predominantly 
the 17a,20-epoxide.  88  Reaction of 0.9 equivalents of per-
benzoic acid, prepared according to the method of Moyer and 
Manley, 114  with 17-methyleneandrost-4-en-3-one (0.024 moles 
of active oxygen/0.027 moles of steroid/litre) for 2-3 hours 
gave a mixture of the epoxide[68](35%), unreacted starting 
material[67](50%) and the glycol[78](15%). A longer reaction 
time led to complete degradation of the epoxide. 
Satisfactory yields of 17a, 20-oxido-21-norpregn-4-en- 
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Diagram 7. Mass spectral fragmentation of 17a,20-oxido-21-
norpregn-4--en--3--one. 
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3-one, contaminated with some unreacted starting material 
but with negligible glycol were finally, achieved with the 
86% active m-chloroperbenzoic acid at concentrations of ca. 
0.019 moles of active oxygen per 0.018 moles of steroid 
per litre of solvent. 
The mass spectrum of the epoxide[68] [see diagram 71 
contained the expected molecular ion at m/e 300 together 
with intense ions arising from loss of the epoxide oxygen 
atom (m/e 284) and of the epoxide function (m/e 270, base 
peak). Other important ions in the spectrum were those 
characteristic of the A4-en-3-one system (m/e 258 and m/e 
124). 
3.1.vi. 17-Methy1androst-4-en-3 ,17-diol[80] 
Sondheimer et al.88 reported the formation of a 
mixture of the C-3 epimeric 17-methylandrost-4-ene-3,17-
diols by lithium aluminium hydride reduction of the 17a,20-. 
epoxide [68]. Reduction of an unhindered C-3 carbonyl group 
has been shown to give approximately 90% of the equatorial 
30-alcohol in most cases,115  because of attack from the less 
crowded ct-face of the steroid molecule. However, a,-un--
saturation can have a profound effect on the stereochemistry 
of reduction, as illustrated by cholest-4-en--6-one and 
cholest-5-en-4-one, both of which have been reduced116 to 
the ct-alcohols. These results are explained  116 by distortions 
caused by the double bond, which tend to pull the carbonyl 
group into the plane of the molecule and so decrease the 
crowding on the 0-face. The choice of solvent and reaction 






products of hydride reductions.117a 
The product of the lithium aluminium hydride re-
duction of the epoxide[68], which was easily purified by 
virtue of its poor solubility in acetone in comparison to 
the reduction products of the 17-methylene compound [67] and 
the glycol[78], gave only one spot on thin layer chromato-
graphy. However, it was doubtful whether a mixture of the 
3a- and 3-alcohols could have been separated in the solvent 
system employed. The n.m.r. spectrum of the product showed 
that the double bond was no longer conjugated (14.72, 4-H) 
and a multiplet at 95.85 (w1 = 18Hz) was in good agreement 
with the reported spectrum °  of androst-4-en-3-01 (15.85, 
m,w1 = 15Hz,3ct-H). Since the 3-proton of androst.Li._en_ 
3a-ol resonates °  at 15.91 (m,wi = 10Hz) it was impossible 
to determine, from this region of the spectrum, whether the 
product contained any of the 3a-ol because of the 'band width 
of the 3a-proton and the poor solubility of the sample. The 
19-methyl signal of the product (18.95) was similar to that 
of androst-4-en-3-ol ('r8.99 0) but there was no evidence 
of a 19-methyl signal similar to that of androst-4-en-3a-ol 
(19.01110). Consequently the product of the lithium aluminium 
hydride reduction of 17a,20-oxido-21-norpregn-4-en-3_one was 
assumed to be 17-methylandrost-4-ene-3,1-7-dio1[80]. 
oppenauer oxidation of the enediol [80] gave 17-methylepitesto-
sterone[50] which was reduced with sodium borohydride118 to 
give a product which was predominantly the 3p-01[80] but also 
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M, m/e 304, 58% 
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Diagram 8. Mass spectral fragmentations of the epimeric 
17-methylandrost-4-ène-3 ,17-diols. 
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The mass spectrum of 17-methy1androst-4-ene-3.17-
diol [see diagram 8] contained a very low intensity molecular 
ion (M+, m/e 304), the base peak arising from loss of water 
from the molecular ion (m/e 286). Metastable peaks (m*) 
showed that the base peak lost a methyl radical and water 
by the three pathways shown in diagram 8. 17a-Methylandrost- 
4-ene-30,17-diol was obtained by sodium borohydride reduction 118  
of methyltestosterone and its mass spectrum contained the 
same ions as that of its C-17epimer. However the inten-
sities of the characteristic ions relative to the be peak 
in each spectrum were quite differeit [diagram 81. 
3.1 .vii. 17-Epimethandrostenoionc48l] 
Muller et a1. 9 described the use of 2,3-dichloro-5, 
6-dicyano-1,4•-benzoquinone (DDQ) for the preparation of 17a, 
21-dihydroxypregna-1, 4-diene-3,11, 26-trione 21-acetate from 
the 3-keto-5- and 3a-hydroxy-5-- steroid precursors. A 
concentration of 3-4 moles of DDQ per mole of 3a-hydroxy-5--
steroid was recommended for dehydrogenation to the dienone; 
consequently, since the enediol [80] already contained one 
of the required A-ring double bonds the quantity of DDQ was 
reduced to 2.2 moles per mole of steroid. 
Alumina chromatography was used to remove several low 
polarity products of this reaction from the two major products 
which were of very similar polarity. These compounds were 
separated into two fractions, each rich in one of the corn- 
ponents,by further chromatography. The two pure compounds 
were obtained by recrystallisation. A single proton resonance 
at ¶4.28 in the n.m.r. spectrum and a carbonyl band at 
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Diagram 9. Mass spectral fragmentations of the epirneric 
17-methyltestOSterOnes. 
1675cm in the infrared spectrum indicated that the less 
polar product was aA4-en-3--one. Its melting point (180- 
1820C) was in agreement with the literature melting pointlflb 
of 17-methylepitestosterone [50 ] and the mass spectrum (Mt, 
m/e 302) confirmed the identification of the compound. 
Diagram 9 illustrates the close similarity between the mass 
spectrum of this compound and that of its C-17 epimer, methyl-
testosterone. 
The crystalline compound isolated from the most polar 
fraction was identified as the 1,4-dien--3-one, 17-epimethan- 
drostenolone[81]. The properties of this compound and its 




Melting points were determined on a K oiler hot 
stage apparatus and are corrected. Infrared spectra Of 
carbon disulphide solutions were recorded on a Unicam S.P. 
200 spectrometer and ultraviolet spectra were recorded on 
a Unicam S.P. 800 spectrometer. Nuclear magnetic resonance 
spectra of deuteriochloroform solutions were recorded on a 
Perkin Elmer R10 (Go M Hz) spectrometer or a Varian HA 100 
(100 N Hz) spectrometer with tetramethylsilane as an internal 
standard. Optical rotations were measured on a Perkin Elmer 
model 141 automatic polarimeter at 589nm in methanol solutions. 
Analyses were determined on a Perkin Elmer model 21+0 instrument, 
Merck silica gel GF254 was used for thin layer chromato-
graphy and the eluting system was benzene-ethanol (9:1) unless 
otherwise stated. The plates were developed with sulphuric 
acid in ethanol (1:19) spray and then heated. Alumina refers 
to Spence type H alumina of Brockman activity 2 and 5% de-
activated alumina to alumina deactivated with 5% by volume of 
a 10% solution of acetic acid. 
Mass spectrometry was carried out on an AEI MS 902 
instrument operated at 70ev by Mr. D. Thomas. Microgram 
samples for mass spectrometry were weighed on a Calm 1400 
range selector electrobalance. Very small samples, 
particularly of metabolites, were transferred to a quartz 
direct insertion probe as solutions in chloroform and the 
solvent removed by evaporation. 
Gas liquid chromatography was carried out on a Perkin 
Elmer 801 instrument with 6 ft. all-glass columns of " 
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internal diameter and a Pye 104 instrument with 6 ft. all- 
glass columns of 1" internal diameter. Stationary phases 
were the methylsilicones, 011-1 and QF-1 and the methyl-. 
siloxane polymer, SE-50. Various column temperatures be-
tween 220 and 25000 were used and are stated in the text. 
The detector and injector were maintained at slightly higher 
temperatures than the column. Preparative gas chromato-
graphy was carried out with the aid of a column splitter over 
the end of which a 6" length of glass tubing (5mm internal 
diameter) was placed. Samples condensed approximately half 
way along the glass tube and were located as a slight mist 
covering a 1211 band. Both ends of the tube were removed to 
leave a section (ca. 111 ) containing the steroid which was 
then eluted, evapoxated to dryness and redissolved in a 
small volume of solvent. This sample was either rechromato-
graphed or transferred to a direct insertion probe for mass 
spectrometry. 
Methandrostenolone and oxymetholone were extracted 
from commercial tablets of the respective drugs by first 
grinding the tablets to a fine powder with a pestle and 
mortar. The powder was transferred to a flask and benzene 
was added. After periodic shaking of the mixture during ca. 
30 minutes the insoluble carrier material was removed by 
filtration and the filtrate was evaporated to dryness to 
give the pure steroid. 
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3.2 erimental Section 
3.2.1. 17-Methndrost-z-3-01[66]100  
Methyltriphenyiphosphonium bromidJ20 (25.0g) and 
potassium t-butoxide:t-butanol (1:1 complex, 13.04g) were 
dissolved in dry dimethyl suiphoxide (80id) under nitrogen 
with gentle warming. A solution of 3-hydroxyandrost--5-.en.- 
17-one (4.04g) in dimethyl sulphoxide (80m1) was added. The 
reaction mixture was maintained at 8000  for 1 hour, diluted 
with ice and 10% sodium chloride solution and extracted twice 
with ether. The ether extracts were combined, washed with 
water, dried over anhydrous magnesium sulphate and evaporated 
to dryness to give the crude product (5.09g), heavily con- 
taminated with triphenyipho sphine oxide. Recrystalli sati on 
from methanol yielded pure 17-methy1eneandrost-5-en-3-o1 
(3.17g, 79%); m.p.  134-1350(lit.,88133-1340); vmax 
1655, 895cm 1; n.m.r. (60M Hz) t9.20 (c-is methyl), 8.98 
(0-19 methyl), 6.45 (3a-H), 5.36 (17=0H2), 4.64 (6-H). 
3.2.ii. 17-Methy1eneandrost-5-en-3-one[75]10404  
17-Methyleneandrost-5-en--3--01 (3.07g) was dissolved 
in ice-cold acetone (215rn1), maintained at 00,  and SN chromic 
acid (6.14ml, Jones reagent) was added with rapid stirring. 
After 45 seconds the reaction was quenched with methanol 
(120ml), water was added, the organic solvents were removed 
on a rotary evaporator and the steroid was extracted twice 
into ether. The combined ether extracts were washed with 
saturated sodium bicarbonate solution and with water until 
neutral, dried over anhydrous magnesium sulphate and evap-
orated to dryness to give a crude product (2.83g). Crystal- 
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lisation from ethanol gave 17-methyleneandrost---5-en--3_one 
(0.898g, 29.5%); M.P. 109-117; vmax 1715, 1685, 1655, 
895cm. 
3-2-iii. 17-Methyleneandrost-4-en-3-one[ 6jJ 
Isomerisation of st-5--en-- 
hydrochloric acid 
17-.Methyleneandrost-5-en-3-one (0.8g) was dissolved, in 
ethanol to give a pale yellow solution. Gaseous hydrogen 
chloride was bubbled through for a few seconds and the dark 
brown solution was left to stand at room temperature for 
1 hour. It was then poured into water, extracted with 
ether and the ether solution washed with saturated sodium 
bicarbonate solution and with water, dried over anhydrous 
magnesium sulphate and evaporated to dryness to yield a 
brown glass. Crystallisation from acetone-pentane yielded 
white crystals of 17-methyleneandrost-4-en-3-one (0.39); 
m.p. 125-130°  (lit., 88 129-1310); v max 1675,1665,1625,895cm; 
n.m.r. (60 M Hz) 'r9.17 (C-18 methyl), 8.80 (C-19methyl), 
5.32 (17=cH2), 4.23 (4-H). 
Isomerisation of 17-methyleneandrost-5-en--3-one with 
anhydrous oxalic acid -05  
Anhydrous oxalic acid (0.2g) was added to a solution 
of 17--methyleneandrost--5-en-3---one (0.859) in ethanol (50m1). 
The solution was heated at 60 0 for 30 minutes, water was 
added and the ethanol was removed by evaporation in vacuo. 
The steroid was extracted twice into ether, the combined ether 
extracts were washed with saturated sodium bicarbonate 
solution and with water, dried over anhydrous magnesium 
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sulphate and evaporated to dryness. Crystallisation from 
acetone gave 17-methyleneandrost--4-en-3-one (0.76g) as white 
needles; m.p. 129-131
0 (lit.,88 129_1310); Vmaxl67555 
1625,895cm; n.m.r. (60. M Hz) T9.17,8.80,5.32,4.23. 
c. Isomerisation of 17-methyleneandrost-5-en--3-one via 
formation of the C-3 dimethyl ketal' 
17-Methyleneandrost-5-en-3-o1 (1.0g) was dissolved 
in ice-cold acetone (70m1)  and SN chromic acid (2.oml) was 
added to the stirred solution at 00. The reaction was 
allowed to proceed for 60 seconds, and then quenched with 
methanol (100 ml). Saturated sodium bicarbonate solution 
was added dropwise to the stirred mixture until it was 
approximately neutral. The organic solvents were removed by 
evaporation in vacuo and the aqueous residue was extracted 
three, times with ether. The combined ether extracts were 
washed with saturated sodium bicarbonate solution and then 
with water until all the chromium salts had been removed, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to give a yellow glass; vmax2990 2910(s), 1715(w), 
1400-800 (strong bands)cm, containing the dimethyl ketal 
of 17-methyleneandrost-5-en-3-one (60%); n.m.r. (60 M Hz) 
¶9.20 (C-18 flyj), 8.98 (C-19 methyl), 6.89,  6.80 (s,s,-OCH3, 
5.35 (17=CH2)7 4.64 (6-H). The crude product also 
contained 17-methyleneandrost-5-en-3-one; n.m.r. (60 M Hz) 
¶9.17 (C-18 methyl), 8.80 (C-1.9 methyl), 5.35 (17=CH2), 
4.64 (6-H). T.l.c. showed that the major product, the 
ketal, was less polar than the 65-en-3-01, A5-en-3-one. 
and A4-en-3-one. 
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The crude product (1.059) was dissolved in toluene 
and chromatographed on alumina (309). Elution with toluene 
(150m1) gave white crystals (0.386g, 37%) of 17-methylene-
androst-5-ene-3-dimethyl ketal; m.p. 112.5-113.5(acetone); 
vmaxl655,1ll0,l065,895cn1'; n.m.r. (60 N Hz) ¶9.20 (c-is 
methyl), 8.97 (C-19 nj), 6.89, 6.80 (s,-OCH3, -ocH7), 
5.37 (17=CH2), 4.64 (6-H); Ma spectrum, M m/e 330. 
Further elution with toluene (150ml) gave a brown 
gum (6.7mg) which was discarded. The following six 
fractions eluted with toluene (900m1) gave 17-methyleneandrost.-
4-en-3-one (0.126g, 12%) as colourless crystals from acetone; 
m.p. 130.5-1350 (lit. ,88 129-131); \)maxl675,l655,896cm'; 
n.m.r. (60 M Hz) ¶9.16 (C-lB (c-19 
5.36 (17 = cH2), 4.27 (4-H); Mass spectrum, M and base 
peak, m/e 284. 
Continued elution with toluene (150m1) yielded a green 
glass (15.1mg) which was discarded. Two further fractions 
eluted with toluene gave white crystals of 17-methyleneandrost-. 
5-en-3-ol (0.228g, 22%); m.p. l24-l3 (lit. 88 133-1340); 
vmaxl655,895cm' n.m.r. (60 M Hz) ¶9.20 (C-lB 8.98 
(C-19 methyl), 6.50 (3a-H), 5.36 (17=CH2), 4.61 (6-H); Mass 
spectrum, M+  and base peak, m/e 286. 
A further fraction (8.2mg) èluted with toluene (250m1) 
was discarded, as was the material (31.3mg)  eluted with 
toluene-ôhloroform (9:1; 500m1). Toluene-chloroform (1:1, 
250m1) eluted colourless crystals (43.8mg, 4%) of 6-hydroxy-
17-methyleneandrost-4-en-3-.one; m.p. 170-175 (acetone); 
vmax3500,1680,1655,895cm'; n.m.r. (60 II Hz) ¶9.16 (c-lB methyl), 
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8.54 (C-19 5.67 (t, 3Hz, 6a-H), 5.37 (17=CH2), 
4.22 (4-H); Mass spectrum, M and base peak, m/e 300. 
17-Methyleneandrost-5-ene-3-dimethy1 ketal (0.309) 
was dissolved in acetone (looml) and dilute sulphuric acid 
(5m1) was added. The solution was stirred for l hours and 
then extracted three times with ether. The combined ether 
extracts were washed with saturated sodium bicarbonate 
solution and with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to yield a mixture of 17-
methyleneandrost-5-en-3-one and 17-methyleneandr6st-4-en-3-
one; vmax1715,1675cn(h n.m.r. (60 M Hz) 74.67 (6-H), 4.28 
(4-H). The mixture was isomerised with anhydrous oxalic 
acid, as described in section 3.2.iii.b., to the 4-en-3-one. 
d. The 0ppenauer oxidation of 17-methyleneandrost-5-en-3r3-oi 88 
17-Methyleneandrost-5-en-3-01 (0-5179) was dissolved 
in toluene (40m1) and cyclohexanone (7m1) and traces of 
moisture were removed by distillation of the, solvent until 
clear. A solution of aluminium isopropoxide (1.116g) in 
toluene (35m1) was added to the gently refluxing steroid 
solution. The mixture was refluxed for 3 hours, water was 
added and the organic solvents were removed by steam distil- 
lation with a Soxhlet extractor for 1* hours. The aqueous 
phase in the reaction flask was extracted twice with chloro-
form, the combined chloroform extracts washed with dilute 
hydrochloric acid, saturated sodium bicarbonate solution and 
with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness. The product, a yellow glass (0.823g), 
crystallised on standing but smelled strongly of cyclohexanone. 
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Recrystallisation from acetone gave white crystals of 17-
methyleneandrost-4-en-3.one (80mg, 161/6); n.m.r, (100 M Hz) 
¶9.17 (c-lB methyl), 8.80 (0-19 methyl), 5.36 (17=cH2), 
4.27 (4-H). 
3.2.iv 
m-chloroperbenzoic acid (60% active oxygen, 0.35g, 
1.21 mmole active oxygen) was added to a solution of 17-
methyleneandrost-4-en-3-one (0.5g, 1.76 mmole) in methylene 
chloride (20m1). The reaction was allowed to proceed for 
2 hours at room temperature. Excess peracid was destxoyed 
with 10% sodium sulphite solution and the reaction mixture 
was neutralised with saturated sodium bicarbonate solution, 
washed with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness. Crystallisation from acetone yielded 
17a, 20-oxido-21-norpregn-4-en-3-one (0.459); m.p. 180-1840  
it.,88 179-182); \)max1675cm'; n.mr. (ioo M Hz) 79.14 
(C-is methyl), 8.82 (0-19 methyl), 7.34, 7.26 (d,d,JAB  4 Hz, 
a-epoxide,C-CH2-0), 4.28 (4-H); Mass spedtrum, M, in/c 300. 
3-2-v. 17a-Hydroxy-17-hydroqmethylandrost_4_en-.3..one[7j 
m-Chloroperbenzoic acid (60% active oxygen, 3.99, 
13.6 mmole active oxygen) was added to a solution of 17-
methyleneandrost-.4-en-3-one (3.86g, 13.6 mmole) in methylene 
chloride (100ml) and the reaction carried out as described 
above. T.i.c. showed that the major product of this reaction 
was more polar than the epoxide and gave a bright blue spot. 
Recrystallisation from acetone gave 17a-hydroxy-17-hydroxy-
methylandrost-4-en-3-one (3.19); m.p 2360 (lit. ?8 234-2360); 
n.m.n (100 N Hz) i9.01 (c-is methyl), 8.89 (0-19 methyl), 
6.43, 6.38 (d,d,J 11 Hz, 17-CH2-), 4.25 (4-H). 
47 
3.2 vi. 
of 17a220-oxido-21-nor-Qregn-4-en-3-one  88 
A solution of 17a,20-oxido-21-norpregn-4-en-3-one 
(0.45g) in dry ether (25m1) was slowly added to a suspension 
of lithium aluminium hydride (0.20g) in ether (20m1). The 
mixture was refluxed for 30 minutes and excess reagent 
destroyed by careful addition of water. The aqueous layer 
was separated and washed with ether, the combined ether 
extracts were washed with water, dried over anhydrous mag- 
nesium sulphate and evaporated to dryness. Recrystallisation 
from acetone gave 170-methylandrost-4-ene-3 , 17-diol (0-36g); 
m.p. 225-2280; vmax34l0cm; n.m.r. (100 M Hz) ¶9.31. (c18 
8.95 (C-19 8.83 (C-20 mefly), 5.85 (m,w1  
18 Hz., 3a-H), 4.72 (4-H); Mass spectrum, M, m/e 304; 
calculated for C20H3202 304.240217, found 304-239655- 
3-2-vii. 17-Methylepitestosterone[91 
17-P4ethylandrost-4-ene-3 ,17-diol (75mg) was dissolved 
in dry tolueñe (5m1) and cyclohexanone (lml). Aluminium iso-
propoxide (151.2mg) in toluene (5m1) was added to the gently 
refluxing steroid solution. The reaction mixture was re-
fluxed for 1 hour, allowed to cool and water and concentrated 
hydrochloric acid were added. The organic layer was 
separated from the aqueous phase, evaporated to dryness and 
the residue dissolved in chloroform. The aqueous phase was 
extracted twice with chloroform and the combined chloroform 
solutions washed with saturated sodium bicarbonate solution 
and with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness to yield a yellow syrup which smelled 
strongly of cyclohexanone. Much of the contaminating material 
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was removed by evaporation in vacuo and by passing a stream 
of dry nitrogen over the product, at 800,  for 1 hour. 
Crystallisation from acetone gave long needles of 17-methyl-
epitestosterone (30mg); m.p. 167-168° %(11tJ1Th1820); td,c,, 
one spot, less polar than the starting material; Mass 
spectrum, M, m/e 302. 
3.2. viii. I bction 
of 17-methy1eb1jestosterone118  
A solution of 17-methylepitestosterone (15mg) in 
methanol (0.6m1) and ethyl acetate (0.15m1) was mixed with a 
solution of sodium borohydride (5mg) in methanol (0.6m1) and 
ethyl acetate (0.15m1)  and kept at room temperature for 24 
hours. Glacial acetic acid (0.2m1) was added followed by 
dilute hydrochloric acid. The steroid was extracted into 
ether and the ether solution washed with saturated sodium 
bicarbonate solution and with water, dried over anhydrous 
magnesium sulphate and evaporated to dryness to give a white 
crystalline product (10.6mg); n.m.r. (100 M Hz) i9.31 (0-18 
methyl), 8.94 (0-19 methyl), 8.82 (0-20 methyl), 5.86 (m,w1  
2 
18 Hz, 3a-H), 4.72 (4-H). A small peak at 19.01 (C-19 
methyl) indicated that the product contained a small pro-
portion of 17-methylandrost-4-ene-3a, 17-diol. Re crystal-
lisation from acetone gave l7-methylandrost-4-ene-3,l7-diol 
(2.5mg); m.p. 226-2280; [MID + 80 (c = 0.18). 
3.2. ix. 17ct-Methylandrost-4-ene-37io1 8  
A solution of methyltestosterone (0.41g) in methanol 
(16.4m1) and ethyl acetate (4.1mm) was mixed with a solution 
of sodium borohydride (0.106g) in methanol (16.4m1) and ethyl 
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acetate (4.lml) and the reaction carried out as described 
above. The white product (0.4439) was sparingly soluble in 
ether and crystallisation from acetone gave 17a-methylandrost-- 
4-ene-3a,17-diol (0.19g); m.p. 167-169
0  (litj'8 166_1700); 
n.m.r. (100 M Hz) t9.13 (0-18 8.94 (0-19 methyl), 8.81 
(0-20 methyl), 5.86 (m,wi 14 Hz,_3a-H), 4.,72 (4-H); t.l.c., 
similar polarity to 170-methylandrost-4-ene-3,17-diol; [a]D 
+ 140  (0=0.25); Mass spectrum, M, m/e 304. 
3.2.x. 17-E2imethandrostenolone[81_1 119  
A solution of 17Hmethylandrost-4-ene-3L1.7-dio1 (0.359, 
1.15 minole) and D]DQ (0.579, 2.5 mmole) in dry dioxane (20m1) 
was refluxed for 6 hours. The solvent was removed by 
evaporation in vacuo and the residue dissolved in benzene and 
filtered through a layer of alumina (lOg). Elution with 
benzene removed three low polarity components and then a 
mixture of two components was eluted with benzene-chloroform 
(1:1); the latter mixture was retained. Rechromatography 
of this fraction achieved partial separation and each compound 
was isolated by crystallisation from the fraction in which it 
was most abundant. The less polar compound (40mg) was 
identified as 17-methylepitestosterone; m.p. 180-182° (lit.}' 
1820); vmax3410,1675cn(1 ; n.m.r. (100 M Hz) i9.28 (0-18 
methyl), 8.81 (0-20 methyl), 8.81 (0-19 methyl), 4.28 (4-H) 
and the second compound (140mg) as 17-epimethanØdrostenolone; 
m.p.2210; vmax3410,1665,1636,9locm';  n.m.r. (100 M Hz) T9.26 
(0-18 methyl), 8.82 (0-20 methyl), 8.77 (0-19 methyl), 3.92 
(d, 2Hz, 4-H),.3-78 (d of d, J12 10 Hz, J24 2 Hz, 2-H), 2.94 
(d, 10 Hz, 1-H); [a] + 30 (0=0.50); Ms spectrum, M, rn/c 
300; calculated for 020H2802 300.208919, found 300.210430. 
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3.3. The comparison of methandrostenolone and 17-than- 
drostenolone 
Adhikary reported32 that on the microscale methandro-
stenolone was only distinguishable from its less polar 
metabolite (M) by a very small difference in retention times 
on g.l.c. [see table 1, page 23]. Consequently methandro- 
stenolone and its 17-epimer were compared prior to comparison 
of 17-epimethandrostenolone and M. 
3.3.i, Thin layer chromatography 
Methandrostenolone and its C-17 epimer were not 
separated by the solvent systems, benzene-ethanol (9:1)  and 
chloroform-methanol (9:1). Because of the presence of the 
A1'-dien-3-one chromophore both compounds were visible when 
the plates were viewed under ultraviolet light. Development 
with sulphuric acid produced identical orange-brown spots 
after heating. 
3.3-ii. Infrared spectroscopy 
The infrared spectra of both epimers of methandrosteim- 
olone were very similar and only minor differences could be 
discerned in the fingerprint region. Absorptions at v max  1665 
and 1630cm, characteristic of the A1'4-dien-3-one system 
were present in the spectra of both compounds. 
Aranchenko et al.  89  were unable to distinguish between 
the C-171 epimeric 17ä-alkyl-3-methoxy-D-homooestra-1, 3, 5(lo),8-
tetraen-17a--ols by infrared spectroscopy but noted small 
differences in the spebtra of C-17aepimeric l7a-alkyl-19--nor-
D-homotestosterones. 
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3.3-iii. Melting points 
The melting point of 17-epimethandrostenolone (221 0)
differed considerably from that of inethandrostenolone (163°). 
Other pairs of 0-17 epimers which have been found to show 
such a difference, the 17a-alcohol having the higher melting 
point in all cases are testosterone (155 
o 
)
llTh  and 17-epi-
testosteone (2210) 111bmethyltt0ster0ne (16110)111b and 17- 
methylepitestosterone (l82°)Illb and 17a-methylandrost-4--ene- 
3 ,17-diol (166-1690) and 17$-methy1androst-4-ene-3 ,17-diol 
(225-228°). 
3.3.iv. Optical Rotations 
Until approximately twenty years ago there was con- 
fusion about the 0-17 configuration of natural steroids such 
as testosterone, which was originally assigned the 17a-hydroxyl 
configuration.92'11 When the true structures of such corn- 
pounds were determined it was found that inversion from the 
17- to the 17a-configuration was accompanied by a laevoro- 
tatory shift of the optical rotations of the compounds Die 
Optical Rotations [a] °1  1  [a]
0 [a1g-[ 
Testoster  ones Th +109 +71.5 -37.5 
MethyltestosteroneslTh +76 +67 
Methandrostenolones +20 +3 -17 
17-Methylandrost4--ene--30,17-diols +lL +8 -6 




The optical rotations of the C-17 epimers of methandro-
stenolone and 17-metbylandrost-4-ene-3 , l7-diol showed 
differences typical of the structures of the compounds 
[table 2]. 
3.3.v.  Nuclear magnetic resonance s ectroscoDv 
The resonances of the three A-ring protons were 
identical in the spectra of both epimers of methandrosten-
olone, 13.92 (d, 2 Hz, 4-H), 3.78 (d of d, J12 10 Hz, J24  
2 Hz, 2-H), 2.94 (d, 10 Hz, 1-H), as expected. However 
comparison of the methyl resonances of the three pairs of 
epimeric 17-hydroxy-17-methyl compounds synthesised [table 31 
showed that the chemical shift of the C-18 methyl group was 
characteristic of the configuration at C-17. Indeed 
C-lB methyl C-19 y1 C-20 metflyl 
configuration at C-17 ctOH -0H a_OICThrOH ct-0F{H 
I4ethandrosteno1ones 9.26 9.07 8.77 8.77 8.81 8.82 
Methylte stosterones 9.28 9.09 8.81 8.79 8.81 8.79 
17-Methylandro st-4- 
ene-3 , 17-diols 9.31 9.13 8.95 8.94 8.83 8.81 
Table 3. The chemical shifts (t values) of the_C-ljand 
C-20 methj roups of pairs of 17-epjneric steroidal 
alcohols. 
Anancheriko et al.89 have used the chemical shift of the C-lB 
methyl group to assign the configuration at C-17a in sub-
stituted D-homooestrenes and D-homo-19-nortestosterones. 
Their interpretation was based upon unpublished work on the 
spectra of cycliccarbinols by Berezin and Musher, who found 
that the resonance line of a methyl group was shifted to 
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weaker field the closer the protons were to the oxygen of 
a hydroxy]. group. 
3.3-vi. Gas-liquid chr2&ah 
Methandrostenolone and 17-epimethandrostenolone were 
chromatographed separately and as mixtures on OV-1 and QF-1 
columns at several temperatures between 225 and 250°C. The 
latter epimer had a fractionally shorter retention time (0.978 
of the R of methandrostenolone) when the compounds were 
chromatographed separately, but a mixture could not be re- 
solved on 0V-1. Slight separation of the heads of the peaks 
of each component was obtained on QF-1 at 240°, but this was 
only possible for an approximately equimolar mixture of the 
epimers. Hexamethyldisilazane was injected onto the QF-1 
column in an attempt to reduce tailing and thus improve sep- 
aration but the chromatography was not improved. The epimeric 
17-methytestosterones could not be resolved on an OV-1 column. 
The use of trimethylsilylation has resulted in the 
successful g.l.c. of many steroids which would otherwise 
have been unsuitable because of poor volatility and insta-
bility at the temperatures necessary for chromatography. Re-
placement of active hydrogen atoms by the trimethylsilyl ether 
function leads to decreased polarity and increased volatility 
12]a 
because of reduced intermolecular hydrogen bonding. Since 
the introduction of the trimethylsilyl group may accentuate 
minor differences between closely related compounds,12  
silylation of the epilners of methandrostenolone was attempted. 
A method employing hexamethyldisilazane and dimethyl-
chiorosilane at room temperature, which has been used success- 
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fully for the preparation of the trimethylsilyl ethers of 
corticosteroids122 was examined. The products of this 
reaction should be particularly suitable for direct injection 
into a g.l.c. instrument or mass spectrometer because of the 
absence of acetamide derivatives which lead to high back-
grounds.122 However, silylation of the tertiary C-17 hydroxyl 
group was .not achieved under these conditions. 
In 1970 Brooks et al.25 reported details of the 17-
trimethylsilyl ethers of twelve steroid drugs, including 
methandrostenolone, which contained 17a-methyl,-ethyl,-propyl, 
-allyl and -ethynyl substituents. These derivatives were 
prepared by the method of Makita and Wells,  123  who used hexa-
methyldisilazane and trimethylchlorosilane as the silylating 
reagents. Methandrostenolone and 17-epimethandrostenolone 
were successfully silylated by this method, although g.l.c. 
showed that the reaction did not go to completion. The 
derivatives of the epimers were well resolved and the peak 
shapes were also improved by the absence of tailing. When 
chromatographed on OV-1 at 235° the retention times of the 
derivatives compared to those of the free steroids were 
1.077± 0.014 (9 runs) for methandrostenolone and 0.791 ± 0.015 
(7 runs) for 17-epimethandrostenolone. Consequently the 
C-17 epimers of methandrostenolone were easily differentiated 
by g.l.c. of their trimethylsilyl ethers. 
In later experiments the methods of Chambaz and 
124 125 Horning and Sakauchi and Horning, developed for the 
silylation of compounds containing highly hindered hydroxyl 
groups, were investigated. Trimethylsilylimidazole and tn-- 
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methylchlorosilane were employed in the former method and 
in combination with bistrimethylsilylacetarnide in the latter, 
and the reaction mixtures were heated in both cases. P.l.c. 
showed that under these conditions the only products of the 
silylations of the epimers of methandrostenolone were the 
low polarity derivatives, uncontaminated by free steroid. 
This was verified by g.l.c. 
3.3-vii. Mass spectrometry 
The use of mass spectrometry in biological, pharmacolo-
gical and medical investigations has increased rapidly in 
recent years because of the very low sample requirements of 
the. technique. l2 When mass spectrometry was first used 
for the study of steroids it was thought that compounds 
differing only in their stereochemistry at one position, such 
as epimeric hydroxy steroids,127 would be indistinguishable.128  
However, the refinement of techniques, particularly for the 
introduction of samples into the spectrometer, has enabled 
many epimeric pairs of compounds to be differentiated. 128 
All-glass inlet systems and direct introduction of the sample 
into the ion source result in diminished thermal reactions 
and thus in ions characteristic of electron-induced frag-
mentation. 
The problem of the differentiation of epimeric alcohols 
by mass spectrometry was examined by Biemann and Seibl129  
who observed that the spectra of epimeric cyclic alcohols, 
including steroidal alcohols, were generally very similar 
but that there were distinct differences in the abundances 
of the molecular ion (M+)  and the ion arising from loss of 
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water (M-18). In the spectra of secondary alcohols these 
authors found that M+  was more intense (and M-18 less 
intense) for the equatorial alcohol, which was less crowded 
and therefore more stable than of the axial alcohol. 
The converse was true for the spectra of tertiary alcohols, 
in which the axial alcohol gave the most intense Mt This 
was interpreted as an effect of the crowding produced by the 
equatorial alkyl group which was larger than the hydroxyl 
group. 
The mass spectrometry of epimeric steroidal alcohols 
has been extensively, studied by a group of Russian workers 9' 
130-133 8 In an investigation 89 of the C-17a configuration 
of 17a-alkyl-D-homooestra-1, 3,5(10) ,8-tetraen--17a--ols and 
17a-alkyl-19-nor-D-homotestosterones they compared the ratios 
of the intensities of the N-lB and ions and found that 
this ratio was much greater for one compound in each pair 
than for the other. Applying the "crowding" concept of 
Biemann and Seibl 
129
they concluded that the ratio was 
greatest for those compounds in which the 17a-alkyl group 
was P (equatorial) and thus closest to the C-18 methyl 
group. This assignment of configuration was confirmed by 
comparison with assignments made on the basis of chemical 
reactivity and n.m.r. spectroscopy. Examination132 of the 
spectra of 17-alkyloestradiols and 17-alkyl-19--nortestosterones 
showed that the difference in the ratio of M-18 to M for 
pairs of epimers was much less pronounced than in the D-homo 
series, but that dehydration of the 17a-hydroxy compound 
still proceeded more readily than that of the 17P-epimer. 
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Figure 5. The mass spectra0of a) methandrostenolone and b) 17-epimethandrostenolone 
at 125 C and 120 C, respectively. 
U 
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the mass spectra of the 17a-epimers of 17a-methyl-D-homo-
testosterone or between those of 17a-ethyl-D-homotestosterone 
could be detected. Comparison of the mass spectra of methyl- 
testosterone and its 0-17 epimer [diagram 91 showed no 
significant difference in the intensities of the M-18 and 
ions. 
Differences between the mass spectra of epimeric 
secondary alcohols in the progesterone series were studied 
by Zaretskii et al.13' who concluded that the ratio N-18/M 
would be greater than unity for those alcohols in which the 
hydroxyl group was axial and less than unity for equatorial 
alcohols. GrosLic 134 and Rinehart obtained similar results 
for the particular steroids (lla- and ll-hydroxyprogesterone) 
studied by the Russian workers131 but found that other 
hydroxy-substituted progesterones had more intense molecular 
ions than dehydration ions, regardless of the configuration 
of the hydroxyl group. These results14  illustrate the 
necessity for standard compounds of known configuration, 
since it had been suggested  131  that the ratio M-18/N could 
be considered diagnostic of configuration if a.known compound 
was not available for comparison. 
Comparison of the mass spectra of methandrostenolone 
[figure 5a] and 17-epimethandrostenolone [figure 5b] showed 
that M+ was greater than P4-18 for the former compound and 
less than P4-18 for the latter. Thus the "crowding" effect 129 
between the 17-methyl and 0-18 methyl groups of 17-epimethan-
drostenolone operated to destabilise the molecular ion 
[figure 61j. Spectra were obtained at a variety of temper-
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than unity for methandrostenolone and greater than unity 
for its 17-epimer [table 41. The fact that this 
relationship was true over a range of temperatures was 
important for application to metabolic samples since the 
presence of contaminants could alter the temperature corres-
ponding to maximum ion pressure. 
The high mass region of the spectrum is particularly 
useful for information concerning the nature of substituents}35  
In the spectra of methandrostenolone and its 17-epimer -the 
ions in this region were generally of low intensity in 
comparison to the base peak at m/e 122. Peterson,136  in a 
study of the mass spectra of a variety of highly substituted 
pregnanes and pregnenes, observed that the base peaks of 
progesterones[ 82] and 6-methylprogesterones [83] were at 
m/e 124 and m/e 138 respectively. He concluded that these 
ions arose from fragmentation across the 6-7 and 9-10 bonds 
with transfer of two hydrogen atoms to the charged A-ring 
fragment. The mass spectra of androst-1--en-3-ones[84]  and 
androst-4--en-3-ones[85] were studied by Shapiro and 
DjerassiJ37 •These compounds give rise to very intense 
ions, generally the base peaks, at m/e 122[86]  and m/e 124 
[87], respectively. 
Experiments with compounds appropriately labelled with 
F deuterium have established that the m/e 122[86]  and m/e 124 
[87] ions in the spectra of 4'-en-3-ones and 41 -en-3-ones, 
respectively, arise by related pr0ce55e5137"38 [diagram 101. 
The 9-10 bond is first cleaved and migration of the 8-
hydrogen atom to C-10 occurs with formation of an 8-9 double 
• • bond[88]. In the A'-enone series the 5a-hydrogen atom 
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m/e3ó0 m/e282 m/e267 m/e242 m/e282 m/e267 m/e242 Temn. 
(% base peak, m/e 122) M M-18 M-18-'15 M-58 m/e300 m/e300 m/e267 (°c) 
Methandrostenolone 15.6 6.4 3.7 11.0 0.41 0.27 3,0 125 
27.1. 7.2 4.2 13.9 0.27 0.16 3.3 90. 
24.2 6.9 5.2 19.0 . 0.29 0.22 3.7 90 
Mean ratios, methandrostenolone 
. 
0.32 0.21 3.3 
1.1 62.2 11.1 2.2 56.5 10.1 0.20 150 
17-imethdrosten- 1.5 94.2. .17.7 . 4.4 62.8 11.8 0.25 160 
clone. . .. 
0.9 71.0 14.3 4.2 78.9 15.9 0.29 120 
Mean ratios, 17-epimethandrostenolone 
. 66.1 12.6 0.25 
Table 4. The intensities (% base peak) of four characteristic ions in the spectra 
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Diagram 11. Mass spectral fragmentation of 
methandrostenolone and its 17-epimer. 
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Diagram 12. Mass spectral fragmentations of methandrostenolone 
and its 17-epimer. 
.60 
This, migration cannot occur in the 64-enone series and thus 
rotation of the 7-8 bond occurs such that a C-il hydrogen 
atom migrates to C-6 with formation of the ion, m/e 124[871. 
Consequently, the base peak (m/e 122) in the spectra of 
methandrostenolone and its 17-epimer must arise by the same 
mechanism [diagram ii] as the nile 124 ion in the spectra of 
A4-en-3-ones. 
Zaretskii et arJ30 studied the mass spectra of the 
epimeric 3-methoxy-17a-trideuteromethyl-D-.homooestra-1, 3,5(10), 
8-tetraen-17a-ols and found that dehydration of the 17aa-
alcphol gave the endocyclic A16_double bond whereas de-
hydration of the 17a-alcohol occurred less readily and gave 
a mixture of the endo- and exocyclic double bonds. The M- 
18-15 ion in the spectrum of the a-alcohol was shown to 
arise from elimination of either the C-17 or C-18 methyl 
groups. Consequently,, the intensity of this peak was greater 
than that of the corresponding peak in the spectrum of the 
0-alcohol, which was diminished because of formation of the 
17-methylene 14-18 ion. 
As expected, the ratio M-18-15/M was greater for 
17-epimethandrostenolone than for methandrostenolone [table 4], 
showing that endocyclic elimination of water [89] was pre- 
dominant in the former molecule [81][diagram 12]. Elimin- 
ation of the C-19 methyl group presumably contributed to the 
M-18-15 ion in the epimers of methandrostenolone, since 
Popov et alJ39 have shown, by deuterium labelling, that the 
C-19 methyl group is eliminated from 5a-androstan--17-one 
three times as readily as the C-18 methyl group; 
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Fragmentation of the fl-ring of C-17 alcohols is 
well 140 and Ananchenko et al.89 observed 
that cleavage of the 13-17a bond in 17a-alkyl--3-methoxy-D-
homooestra-1, 3,5(10) ,8-tetraen-17a-ols occurred most readily 
for the less crowded -hydroxy epimers. The ion arising 
from fragmentation across the 13-17 and 15-16 bonds (m/e 242, 
P4-58) was significant in the spectrum of methandrostenolone 25 
but of very low intensity in that of the 17a-hydroxy epimer 
[see figure 6]. It thus appears that methandrostenolone 
and 17-epimethandrostenolone fragment preferentially by 
different mechanisms, fl-ring cleavage being more favourable 
for the former and dehydration and methyl elimination for 
the latter. Comparison of the ratio M-58/M-18-15 for the 
epimers showed that it was greater than unity for methandrost-
enolone and less than unity for 17-epimethandrostenolone 
[table 43. Fragmentation across the 13-17 and 14-15 bonds 
to give a very low intensity ion at m/e 227 occurred in both 
epimers. 
Spectra of methandrostenolone contained a low in-
tensity metastable ion at m/e 265.2 associated with the 
fragmentation, M to M-18. Those of 17-epimethandrosten- 
olone contained a very low intensity metastable ion at m/e 
252.7, corresponding to the transition, M-18 to M-18-15. 
Neither compound gave both metastable ions. 
Although the molecular ions of most trimethylsilylated 
compounds are very weak  1210  the mass spectra of these de-
rivatives have proved useful for the detection of certain 
functional groups, such as the A5-en-3-01 system, the silyl 
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Diagram 13. Mass spectral fragmentation of A5-en-3-
trimethylsilyl ethers. 
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Diagram 14. Mass spectral fragmentation of 17-substituted- 
• • •17-trimethylsilyl ethers. 
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rn/c M-129. By the use of deuterium labelling Diekman and 
Djerassi 141 have shown that the m/e 129 fragment contains 
carbons 1, 2 and 3 of the A-ring with the trimethylsilyl 
ether function [diagram 131. 
Brooks et al. 25 found that the mass spectra of the 
trimethylsilyl ethers of steroid drugs, including methan-
drostenolone, contained abundant ions at m/e 128+R, 
characteristic of a tertiary 17-hydroxy steroid where R = 
alkyl, alkenyl and alkynyl [diagram 14]. The spectra of 
the trimethylsilyl ethers of methandrostenolone and 17-epim-
ethandrostenolone were very similar, the base peak of both 
being at m/e 143 (128 +15). The molecular ion (m/e 372) 
was of low intensity in both spectra and the only other 
ions of importance were those at m/e 73 [(CH3)3si1, m/e 75 
[6H=Si(CH3)2] and m/e 282[N-(CH3)3SiOH]. The influence 
of the trimethylsilyl group on the direction of fragmentation 
was obvious from the almost complete loss of m/e 122, the 
base peak of the free steroids. 
3.3-viii. Gas chromatography-ma spectrometry 
The stability of methandrostenolone and its 17-epimer 
during g.l.c. was examined by preparative chromatography 
followed by mass spectrometry of the condensed effluent. 
A sample of methandrostenolone was chrornatographed and the 
effluent collected as the peak was recorded. The condensate 
was eluted, rechromatographed and the effluent again collected, 
eluted and then subjected to mass spectrometry. The 
retention times were the same for both chromatograms and the 






















Figure 7. The mass spectra of a) methandrostenolone at 80
0C and b) its 17-epimer 
at 950  after preparative g.1.c. 
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methandrostenolone [figure 5a]. 17-Epimethandrostenolone 
was examined in the same way and again the rechromatographed 
material had the same retention time as the peak from which 
it was collected. The mass spectrum of the twice-chromato-
graphed 17-epimethandrostenolone [figure 7b] was similar to 
that of the pure compound [figure 5b]. 
Table 5 shows the ratios of the intensities of the 
characteristic ions from the spectra of methandrostenOlone 
and 17-epimethandrostenolone after preparative g.l.c. The 
mean values of the intensity ratios from spectra of methan-
drostenolone obtained at 80 and 90°C were similar to those 
obtained from spectra of the unchromatographed compound 
[table 4, page 59]. Spectra of 17-epimethandrostenolozie 
were taken over a wide range of temperatures (60-150°C) and 
although the intensity ratios did not differ so greatly from 
those of methandrostenolone as did those of the unchromato-
graphed compound [table 4 ] the spectra of the two epimers 
were still significantly different. 
The reason for the diminished m/e 282/m/e 300 and 
m/e 267/m/e 300 ratios, corresponding to an apparent in-
crease in the stability of the molecular ion of 17-epimethan-
drostenolone after preparative g.l.c. is uncertain. How-
ever, a temperature effect in the mass spectrometer may have 
been responsible since the g.l.c. retention time and the 
mass spectra, which contain no ions other than those of 
17-epimethandrostenolohe, do not suggest degradation of the 
steroid on the column. 
Combined gas chromatography-mass spectrometry (g.c.-
rn.. s.) has been used extensively for the identification of 
Intensities m/e00 m/e282 
(% base We 122) N P4-18 peak, 
rn/e267 m/e242 m/e282 m/e267 m/e242 T8rft 
M-18-15 P4-58 'n/e300 m/e300 m/e267 ( C 
Methandrostenolone 27.8 13.0 7.0 15.7 0.47 0.25 2.2 80 
30.4 13.1 4.4 13.9 0.43 0.14 3.0 90 
Mean ratios, Methandrostenolone 0.45 0.20 2.6 
9.5 80,9 16.7 7.1 8.5 1.8 0.48 60 
17-epimethandrosten- 18.9 100.0 22.2 8.9 5.3 1.2 0.40 80 cm 
olone 
33.3 86.7 19.4 8.3 2.6 0.58 0.43 90-100 
54.8 83.5 21.9 11.0 1.5 0.40 0.56 no 
77.3 72.7 27.3 13.6 0.94 0.29 0.50 150 
Mean ratios, 17-epimethandrostenolone 3.8 0.85 0.46 
Table 5. The intensities (% base peak) of four characteristic ions in the spectra of 
methandrostenolone and its 17-epimer after preparative g.1.c. 
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mammalian steroids from plasma, urine and faeces. 126b 
Since it had been demonstrated that methandrostenolone and 
its 17-epimer gave their characteristic, distinguishable 
mass spectra after g.l.c. the metabolism of methandrost- 
enolone appeared to be ideally suited to examination by 
g.c.-m. S. 
A Pye 104 gas chromatograph linked to an MS-20 spectro- 
meter was used to obtain spectra from methandrostenolone 
and 17-epimethandrostenolone. In order to protect the 
membrane separator the oven temperature was restricted by 
a thermal cut-out at 2400  and losses may have occurred 
through condensation in the transfer line which was operated 
at 200°C. However, the apparatus was particularly un- 
satisfactory for the analysis of steroids because of its poor 
resolution at m/e values greater than 200. Consequently, 
it was impossible to count the spectrum to the molecular 
ion because of the background noise from column bleed com- 
bined with the low intensities of the high mass ions. A 
computer link-up was not available for analysis of the 
spectra and thus the metabolism of methandrostenolone could 
not be examined by g.c.-m.s. 
The technique of single-ion monitoring can be used to 
locate those compounds which are known to give rise to a 
characteristic fragment. Lawson and Brooks 27 have examined 
the metabolites of methandrostenolone by g.c.-m.s. of the 
trimethylsilylated urine extracts, with monitoring of the - 
m/e 143 ion. By this method they have reported the detection 
of nanogram amounts of 6hydroxymethandrostenolone in the 
free fraction and tentatively, a compound with one additional 
double bond, one with a reduced double bond, two isomers of 
6-hydroxymethandrostenolone and an isomer of methandrosten- 
olone. In the conjugated fraction they found two major 
metabolites, one which appeared to contain a 6-hydroxy-44-
en-3-one system and the other a 3-hydroxy analogue of this. 
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3.4. Experimental section. The synthesis of trimeyl- 
silyl ethers. 
A mixture of equal volumes of a 40% solution of 
hexamethyldisilazane in benzene and a 10% solution of di-
chiorodimethylsilane in benzene was added to the solid 
steroid and the reaction allowed to proceed overnight at 
room temperature. The solvent was removed by evaporation 
in vacuo and the residue extracted with n-hexane. The 
precipitated silicon compounds were removed by filtration 
and the solvent evaporated to give a suitable concentration 
of steroid, which was injected directly into the g.1.c. 
instrument. 
Tertiary alcohols, such as methandrostenolone and its 
17-epimer were not silylated by this method. 
3.4.ii. 25' 123 Hexamethyldisilazane (io drops) and tn- 
methylchlorosilane (1 drop) were added to a solution of the 
steroid (1mg) in dry pyridine (4 drops). The mixture was 
left at room temperature overnight and then the solvents were 
removed by evaporation with a stream of nitrogen. Ethyl 
acetate was added to the residue and the solid byproducts. 
removed by filtration. 
T.l.c. of the filtrates after silylation of methan-
drostenolone and 17-epimethandrostenolone showed two similar 
components in each sample, the major of very low polarity 
and the other corresponding to the free steroid. G.1.c. 
of the products Of botH reactions showed two components,the 
minor having the retention time of the free steroid. Both 
products gave maximum ion pressures in the mass spectrometer 
at temperatures well below those required by the free steroids 
indicating the increased volatility. The spectra of both 
compounds showed the expected low intensity molecular ion 
We 372) and base peak (m/e 143). 
3.4.iiiJ24 Trimethylsilylimidazole (3 drops) and trimethyl-
chiorosilane (2 drops) were added to methandrostenolone (ca. 
1mg) in a glass tube. The tube was stoppered and heated 
on a water bath at 80-90°C for several minutes. T.l.c. of 
the reaction mixture, from which there was no precipitation, 
indicated complete formation of the low polarity derivative. 
3. 4.ivJ25  Bistrimethylsilylacetamide (3.75p1), triniethyl-
silylitnidazole (3.75F1l) and trimethylchlorosilane (2.541) 
were added to the solid steroid (lo-loopg) in a glass tube. 
The tube was stoppered and placed in an oven at 95-100°C 
for 30 minutes. n-Hexane (5 drops, ca. 0,lml) was added 
to achieve a suitable concentration and the sample was 
injected into a g.l.c. instrument. 
Both g.l.c. and t.l.c. indicated 100% silylation of 
methandrostenolone and its 17-epimer by this procedure. 
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3.5. The com2arison of 17methandrostenolone and the 
previously unidentified metabolite of methandrosten- 
olone 
The isolation and purification of samples of the 
metabolite (M) of methandrostenolone, each of which was 
estimated by ca±'bon skeleton chromatography to contain about 
16Oig (3.5% of the dose of methandrostenolone) has been 
described in section 2. The analytical methods applicable 
to this size of sample were t.l.c., g.l.c. and mass spectro-
metry of the free and trimethylsiJylated metabolite. 
T.l.c, of several samples of N showed that each was 
a mixture of components, some of which gave different colour 
reactions with sulphuric acid from methandrostenolone and 
its. 17-epimer. The majority of components in each sample 
were of similar polarity to each other and to the two epi-
meric standards in a solvent system (benzene-ethanol, 9:1) 
different from that with which the metabolic samples were 
isolated (chloroform-methanol, 9:1). Some of the components 
in this band gave the same colour reaction as the standards 
(orange-brown). No information was obtained from t.l.c. 
of a trimethylsilylated extract, probably because the con-
centration of the metabolite in the sample was too low. 
G.l.c. of the metabolic samples on OV-1 at 2200C con-
firmed the presence of peaks at the retention time (16.2 
minutes) of methandrostenolone or its 17-epimer. Chromato-
graphy, on OV-1 at 235°C,  of similar samples after trimethyl-
silylation showed peaks at the retention time of 17-epimeth-
androstenolone trimethylsilyl ether (8.40 minutes) but none 
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Figure 8. The mass spectra of two samples of the metabolite N, a) at 125°C and 
b) at 1100  after preparative g.l.c. 
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ether (11.56 minutes). 
Since mass spectra characteristic of methandrosten-
olone and its 17-epimer were obtained after preparative 
g.1.c. of the compounds this technique was used for 
additional purification of two samples of M prior to mass 
spectrometry. However, the mass spectra of these samples 
and of others which were not so purified contained very 
intense peaks at m/e 194 and m/e 109 at and below 90°C. 
At higher temperatures these ions, due to unknown impurities, 
declined and those at m/e 282 and m/e 122 increased. The 
spectra of samples of M [see figures Sa and Sb] contained 
all the characteristic and most intense ions of methandrost-
enolone and 17-epimethandrostenolone [see figures 5 and 71 
as well as a variety of ions, below m/e 300, which did not 
belong to either of these compounds. 
The ratios of the characteristic ions (m/e 300, m/e 
282, m/e 267, m/e 242) [table 6] were similar to those of 
17-epimethandrostenolone and differed from those of the 
17-01 [see tables 4 and 5 ] . Spectra of authentic 
methandrostenolone and its 17-epimer could not be obtained 
above 1500C because of low ion pressures. Similar behaviour 
of the ions corresponding to 17-epimethandrostenolone was 
observed in the spectra of metabolic extracts. The mass 
spectrum of the trimethylsilyl ether of N was similar to 
that of the derivative of 17-epimethandrostenolone with the 
molecular ion at m/e 372, the base peak at nile 143 and an 
intense ion at m/e 282. 
The examination of the free and trimethylsilylated 
metaboltte N of methandrostenolone by gas chromatography and 
Intensities m/e300 
(% base 122) peak, m/e 
m/e282 m/e267 m/e242 m/e282 m/e267 m/e242 Temp. 
N-lB M-18-15 M-58 m/e300 m/e300 m/e267 (°c) 
7.7 53.8 15.4 15.4 7.0 2.0 1.0 90 
Metabolite M 5.0 57.5 15.0 15.0 11.5 3.0 1.0 110 
4.5 54.5 15.9 15.9 12.1 3.5 1.0 125 
6.5 54.9 19.4 22.6 8.5 3.0 1.2 140 
Mean ratios, Metabolite N 9.8 3.9 1.0 
4.4 47.8 13.0 4.4 10.9 3.0 0.34 .50 
Metabolite . 6.3 52.1 14.6 6.3 8.3 2.3 0.43 70 
after 3.9 44.5 14.5 5.6 .11.4 3.7 0.39 80 
prparàtive g.1.c. 21.6 58.9 15.7 5.9 2.7 0.73 0.38 90 
23.3 56.7 16.7 6.7 2.4 0.72 0.40 110 
47.6 57.2 . 19.1 . 9.5 1.2 0.40 0,50 140 
Mean ratios, Metabolite N 6.2 1.8 0.41 
Table 6. The intensities (% base peak) of four characteristic ions in the spectra 
of samples of the metabolite M. 
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mass spectrometry thus identified it as 17-epirnethandrosten-
alone by comparison with the authentic compound, synthesised 
by an unambiguous route. There was insufficient metabolic 
material for analysis by techniques which require larger 
samples but comparison with the melting point, infrared and 
elemental analysis data reported by Rongone and 3ega10ff42 
indicated that their less polar metabolite was also 17-epi-
methandro stenolone. 
Schubert and Wehrberger24  isolated twenty-one metabolites 
in their study of the metabolism of the 4-chloro analogue 
of methandrostenolone (Oral-Turinabol) in women. Four of 
these accounted for 92.2% of the material recovered as meta-
bolites; the major metabolite (45.7%) was extracted from 
the 'sulphate" fraction and identified as the unchanged drug. 
The 6-hydroxy derivative (29.6%) was obtained from the free 
fraction and the 16p-hydroxy derivative (11.0%) from the 
glucuronide fraction. The fourth metabolite (5.9%) was 
isolated from the free fractiàn but it was not characterised. 
The remaining seventeen metabolites, none of which accounted 
for more than 2.5% of the total, accounted for the remaining 
isolated material (7.8%). 
The unidentified metabolite (5.9%) from the free 
fraction was shown to possess the same A-ring as the drug 
itself. Its melting point (202-2050) was considerably higher 
than that of Oral-Turinabol (148-1500), a similar variation 
to that between methandrostenolone (1640) and its 17-epimer 
(2210). The chromatographic behaviour of the metabolite 
was not very different from that of the parent drug and its 
molecular weight, from mass spectrpmetry, was 334. The 
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molecular ion of Oral-Turinabol is m/e 335 but if the 
metabolite was the. 17-epimer of the drug it might be 
expected to have a low intensity molecular ion which could 
have led to incorrect interpretation of the spectrum, of 
which no further details were reported. The chemical shifts 
of the methyl groups in the n.m.r. spectra of the metabolite 
and the drug were given 2
4  [see table 7] and show that al-
though the C-19 and C-20 methyl signals were at similar 
positions in both compounds the C-IS methyl signal was 
shifted upfield by 70.15 in the metabolite. An upfield 
shift of ¶0.19 of the C-lB methyl resonance of 17-epiinethan-
drostenolone compared to its 17-epimer was observed [table 71. 
Consequently, it is possible that the unidentified metabolite 
of Oral-Turinabol may be the 17-epimer of the drug, although 
Schubert and Wehrberger24 suggested that artefact formation 
might explain the n.m.r. spectrum. One of the seventeen 
minor metabolites also gave similar n.m.r. methyl shifts. 
Oral- 94  Metabolite Methan- 17-Epimeth-
Turinabot of Oral- 24  drosten- androsten-Turinabol olone olone 
C-19 methyl, 7 8.72 8.69 8.77 8.77 
C-20 methyl, ¶ 8.85 8.79 8.82 8.81 
C-18 methyl, T 9.09 9.24 9.07 9.26 
Table 7. The chemical shifts (T values) pf the C-iS, C-19 
and C-20 methyl groups of Oral-Turinabol, a meta-
bolite of Orpl-Turinabol, methandrostenolone and 
its C-17 epimer. 
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3.6. The examination of commercial methandrostenolone 
Because only 3.5% of the dose of methandrostenolone 
could be isolated as 17-epirnethandrostenolone it was 
necessary to establish that commercial methandrostenolone 
(Dianabol) does not contain, a small percentage of the epimer. 
Methandrostenolone is prepared industrially by two routes, 
both of which require methyltestosterone as the starting 
material.5° The A1- double bond may be introduced by 
chemical dehydrogenation or by specific microorganisms. 
Methyltestosterone is synthesised by the reaction of 
a methyl Grignard reagent with the 17-keto group of dehydro- 
lllb epiandrosterone, a reaction which is almost totally 
stereospecific for the formation of the 17-ol because of 
hindrance from the C-18 methyl group to attack from the $-side 
of the molecule.. lc,117 . However 17-methylepitestosterone 
was isolated in very low yield during a large-scale synthesis 
of methyltestosterone.87 In addition, it has been re-
portedl42143 that the 170-hydroxy-17-methyl configuration 
is only formed in small yields when the molecule contains a 
12a-hydroxyl group which hinders a-face attack. Similarly, 
mixtures of the 17a-hydroxy-17a-methyl epimers are formed in 
the Grignard reaction of a 17a-keto-D-homo .steroid. 44  
The dehydrogenation of methyltestosterone has been 
accomplished by a variety of microorganisms145 and there is 
no evidence to suggest that epimerisation might occur at 
this stage. However, if commercial methandrostenolone is 
free from the 17-epimer it must be concluded that mammalian 
metabolism is capable of accomplishing the 17-epimerisation 
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Figure 9. The mass spectra of a) tablet thethandrostenolone and b) mixture of 
methandrostenolone and its 17-epimel- (95:5), both at 100 C. 
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enzyme system, able to carryout the transformation, could 
be found. Microbial introduction of the tertiary 17a-
hydroxyl group is rare but has been reported 
 146 for pro-
gesterone, deoxycorticosterone and 11-dehydrocorticosterone 
with Tricotheciurn roseum and for progesterone with Trichoderma 
viride and with Dpflrlium dendroldes. However these organisms 
are not used for the conversion of methyltéstosterone to 
methandrostenolone. 
Crystalline methandrostenolone extracted from tablets 
of Dianabol had the same melting point as authentic methan-
drostenolone and a mixed melting point was not depressed. 
The infrared and n.m.r. spectra were similar to those of 
methandrostenolone and g.l.c. of the trimethylsilyl ether 
gave no peak corresponding to the derivative of the 17-epimer. 
Mass spectra of methandrostenolone from tablets [figure 9a] 
were, compared with those of the authentic material [figure sail 
and of mixtures of methandrostenolone and its 17-epimer 
(19:1)[figure 9b]. The spectra of tablet methandrostenolone 
were identical with those of the authentic compound whereas 
the mixtures showed small but significant differences, 
particularly in the ratio m/e 282/m/e 300 [see table 8]. 
Mixture 2, which gave ratios closer to those of pure methan-
drostenolone than did mixture 1, was known to contain less 
17-epimethandrostenolone. The fact that the ratios m/e 282/ 
m/e 300 and m/e 267/m/e 300 were greater for the mixtures 
than for the pure 17-ol, and m/e 242/m/e 267 was less for 
the mixtures was predictable from a knowledge of the preferred 
fragmentations of both epirners. 
Following this demonstration of the purity of commercial 
methandrostenolone material from this source was used in some 
of the experimental work to be described. 





(% base peak,m/e 122) M-18 M-18-15 M-58 m/e300 (°c) 
24.2 8.1 4.0 12.9 0.33 0.17 3.2 100 
19.5 6.3 3.7 10.9 0.32 0.18 3.0 110 
Tablet 20.0 7.5 3.8 11.6 0.38 0.19 3.1 110 
Methandrostenolone 28.6 8.6 5.7 14.3 0.30 0.20 2.5 120 
19.1 7.1 3.6 11.9 0.37 0.19 3.3 120 
11.0 3.0 2.0 6.0 0.27 0.18 3.0 130 
22.2 8.3 4.2 13.9 0.37 0.19 3.3 130 
40.3 16.7 .8.3 29.9 0.41 0.21 3.6 140 
- 50.0 20.9 10.5 24.4 0.42 0.21 2.3 145 
16.0 5.0 3.5 11.0 0.31 0.22 3.1 150 
7.5 3.0 2.0 6.0 0.40 0.27 3.0 180 
11.4 5.7 5.7 11.4 0.50 0.50 2.0 200 
Mean ratios, tablet methandrostenolone 0.37 0.23 3.0 
Methandrostenolone + 7.0 8.5 2.5 3.0 1.2 0.36 1.2 90 
17-Epimethandrostenolone 11.0 16.5 6.0 7.0 1.5 0.55 1.2 100 
(ca. 19:1) 11.7 18.1 6.4 8.5 1.5 0.55 1.3 125 
Mixture 1 18.6 28.9 12.4 14.4 1.6 0.65 1.2 180 
Mean ratios, mixture 1 1.5 0.53 1.2 
Methandrostenolone + 30.0 13.3 5.0 15.0 0.44 0.17 3.0 85 
17-Epimethandrostenolone 19.7 16.4 6.6 13.1 0.85 0.34 2.0 100 
(ca. 19:1) 15.0 12.0 4.0 9.0 0.80 0.27 2.3 110 
Mixture 2 24.5 17.0 6.0 15.5 0.69 0.25 2.6 120 
38.0 18.0 8.5 26.5 0.47 0.22 3.1 130 
Mean ratios, mixture 2 0.65 0.25 3.3 
Table 8. The intensities No base peak) of four characteristic ions in the mass spectra of 
tablet methandrostenolone and of mixtures of methandrostenolone and its 17-epimer 
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3.7. Precursoproduct studies on the metabolism of 
methandrostenolone 
The conjugation of steroids with glucuronic or 
sulphuric acids and excretion of the conjugates in the urine 
is a major pathway in the metabolism of natural and synthetic 
compounds.21 7 The metabolism of methandrostenolone is 
unusual both because the two major metabolites are excreted 
as free steroids32 and because there is no biochemical pre-
cedent for the epimerisation of a tertiary hydroxyl group. 
The stability of the Al4_dien_3_one system towards bio-
chemical transformations has been reported as a result of in-
vestigations of the metabolism of a variety of drugs with 
this functional group.24 26 50 In view of this stability 
the obvious mode of metabolism of methandrostenolone is 
hydroxylation, which occurs to give the 6-hydroxy derivative. 
Since the few 17-hydroxy epimers of androgenic and 
anabolic steroids which have been tested were found to possess 
very little biological activity identification of the 17-epimer 
of methandrostenolone as the major metabolite of the drug in 
normal men suggests that mammalian metabolism is capable of 
detoxifying an otherwise exceptionally stable drug by form- 
ation of the virtually inactive 17ct-01. The metabolism of 
very few synthetic steroid drugs with the 17-hydroxy-17-methyl 
function has been studied and it is probable that the "epimeri-
sation pathway" has not been observed before because most of 
these compounds, unlike methandrostenolone, contain other 
substituents which are more readily metabolised by conventional 
pathways. 
It is probable that the epimerisation of methandrosten- 
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clone may be accomplished by the action of one or more 
enzymes. Confirmation of this would require isolation of 
the purified "epimerase" and verification of its specificity 
and activity by in vitro experiments which was impracticable 
during this study. Consequently the problem of the mechanism 
of epimerisation was approachedy the assumption of the 
existence of an "activated intermediate". This intermediate 
could then be sought in the urine following administration of 
methandrostenolone and the epimerisation attempted by 
chemical synthesis and reaction. 
Sulphate conjugates of steroids are abundant and yet no 
such conjugates of the metabolites of methandrostenolone could 
be isolated. Consequently the possibility that methandrosten-
olone sulphate might be an intermediate in the 17-epimerisation 
reaction was considered. The sulphate group is a good leaving 
group and attack by a hydroxyl group from the a-face might 
thus lead to 17-epimethandrostenolone. The object of the 
precursor-product studies was to examine whether methandrosten-
olone sulphate was produced and then converted to the epimer, 
in which case the sulphate would only be isolated soon after 
administration of the drug. 
Urine was collected at intervals of four hours up to 
sixteen hours after the administration of 10mg of methandrosten-
olone and then at one eight hour and two twelve hour intervals 
up to forty-eight hours. The urine collections were halved 
to provide duplicates and each was extracted with its own 
volume of chloroform to giveS the free fraction containing the 
product, 17-epimethandrostenolone, as described previously 
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Figure 10. Histograms showing the variation of the weight 
of 17epimethandrostenO1One extracted from 




aqueous phase to form the pyridinium salts of any steroid 
sulphates which might be present. These were extracted 
with chloroform and hydrolysed with hydrochloric acid to 
give the sulphate fraction which might contain a precursor, 
methandrostenolone sulphate. A second study was carried 
out in which urine was collected for twenty-four hours but 
duplicates were not performed. 
The free and sulphate fractions were examined by 
carbon skeleton chromatography for steroids with the same 
polarity as methandrostenolone and bearing the 17-methyl sub- 
stituent. The material in these bands was then analysed by 
quantitative g.l.c. with pregnanediol diacetate as an inter-
nal standard. 
The histograrfis [figures lOa and lOb] show the appro-
ximate weights of 17-epimethandrostenolone found in the free 
fractions in each successive four hours after administration 
of the drug. The correspondence between the two duplicates 
[broken lines, figure lOa] in the first two four hour periods 
was poor, although in the following samples it was good. How-
ever, both studies showed that maximum excretion of 17-epimeth- 
androstenolone occurred within the first eight houl's. In a 
study of the metabolism of 17a.14C_methandrosteno1one in the 
dog Sandor and Lanthier4 found that the bulk of the urinary 
metabolites were excreted unconjugated in the second twenty- 
four hours following intravenous injection. The different 
modes of application of the drug probably largely account for 
this difference in excretion rates.. 
In the first study a sulphate fraction corresponding to 
each free fraction was analysed. The majority of these 
fractions did not contain a component with the same retention 
time as methandrostenolone and although several of the 
earliest fractions gave a small peak at this retention time 
the quantity of material was insufficient to establish the 
identity of the peak by silylation. After individual 
analysis the fourteen sulphate fractions were combined and re-
chromatographed to give a peak (ca. llig) which could have 
been one of. the epimers of methandrostenolone. The total 
sulphate fraction from the second study was analysed and 
gave a peak corresponding to only 0.33i9 of material at the 
retention time of methandrostenolone. 
These results failed to demonstrate the existence of 
methandrostenolone sulphate and hence a precursor-product 
relationship between this conjugate and 17-epimethandrosten-
olone could not be found. To demonstrate such a relationship 
would have required the extraction of material with the 
retention time of methandrostenolone from the sulphate fraction, 
such that the histogram of extracted steroid against time 
reached a maximum prior to the corresponding histogram of 
17-epimethandrostenolone extracted from the free fraction. 
Because 17-epimethandrostenolone was found to be excreted so 
rapidly urine collections would need to be made at very 
short intervals during the first eight hours after admini-
stration in order to observe a maximum in the sulphate 
fraction prior to that in the free fraction if a precursor- 
product relationship did exist. - 
An experiment was carried out to determine whether small 
quantities of free steroids might be carried over into the 
sulphate fraction by partition of chloroform in water during 
the initial chloroform extraction of free steroids. 17-Epi- 
methandrostenolone (130j9) was partitioned between equal 
volumes of chloroform and water, the chloroform layer dis- 
carded and the aqueous layer subjected to the "sulphate 
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extraction procedure". The final residue was trimethyl- 
silylated and examined by t.l.c._which showed at least seven 
components, one of which was of low polarity and gave a 
• similar colour reaction to methandrostenolone and its 17- 
epimer. G.l.c. indicated that the mixture contained seven 
components, one with a retention time similar to that of 17- 
epimethandrostenolone trimethylsilyl ether. Consequently, 
the very small peaks at the retention time of methandrosten-
olone in the sulphate fractions may have been 17-epimethan-
drostenolone carried over from the free fraction. 
[en., 
3.8. Experimental Section 
3.8.1. Precursor-product studies 
Methandrostenolone (10mg) was taken orally in the 
morning and urine collected at 4 hour intervals for the first 
16 hours, then after an interval of 8 hours and finally at 
12 hour intervals up to 48 hours after administration of the 
drug. Each urine collection was halved to provide dupli- 
cates and both portions were extracted with chloroform to 
give the free steroids and then treated by a procedure de-
signed to extract and hydrolyse any,  steroids which might be 
present as the sulphate conjugates. 7c Those 17-methylandros-
tane components, with similar polarity to mothandrostenolone, 
in both fractions were identified by carbon skeleton chromato-
graphy and isolated as described previously (section 2). 
The residues from the 'free fraction' and the 'sulphate 
fraction' were then examined by g.l.c. 
Chromatography was carried out on a Pye 104 gas 
chromatograph with glass columns packed with 2*% OV-1 stat-
ionary phase and operated at 2350C with a nitrogen flow 
rate of 40m1 per minute. Free methandrpstenolone gave an 
asymmetric peak because of tailing caused by the hydroxylic 
nature of the compound and its low volatility. The acetates 
of small samples of primary and secondary steroid alcohols 
may be conveniently prepared for g.l.c. by exposure of the 
free steroids to a dry atmosphere of pyridine and acetic anhyd-
ride but much harsher conditions are necessary for the 
synthesis of the acetates of tertiary alcohols (see section 
3.13.iv). When this piece of work was carried out tn-
methylsilylation was unsatisfactory because the method 
employed (see section 3.4.ii) did not result in 100% for-
mation of the derivative and the background, when the 
silylated metabolic samples were chromatographed, was very 
high. Consequently, samples were analysed without prior 
derivative formation; after analysis of the free metabolite 
the trimethylsilyl derivative of one fraction was prepared 
and chromatographed to identify the epimer present in the 
sample. A peak with the retention time of 17-epimethandros- 
tenolone trimethylsilyl ether was obtained. Although free 
methandrostenolone did not give a symmetrical peak good 
agreement was obtained when methandrostenolone solutions of 
known concentration were compared with similar solutions of 
standard compounds with an electronic integrator and by the 
weights of the cut-out peaks. 
Pregnanediol diacetate was used as an internal standard 
for the quantitative analysis of the metabolic samples. It 
had a longer retention time than the epimers of methandrosten- 
olone and chromatographed well at 2350. Compounds with 
shorter retention times were examined but were unsuitable be-
cause of the presence of contaminants with short retention 
times in the metabolic samples. 
The inside of each tube containing a metabolic residue 
was washed with a small volume of dry ether and carefully 
evaporated to dryness with nitrogen, to concentrate the sample 
in the bottom of the tube. Pregnanediol diacetate (ca. 2mg) 
was weighed accurately on a Calm electrobalance, transferred 
to a graduated flask and made up to lOOmi with Analar acetone. 
An aliquot of this solution (0.5m1 or 0.25m1,  containing ca. 
10.ig or 5a9, respectively, of the standard) was added from a 
S 
Sample Time aft er x y x 
Y(1g) X=Yc X per Mean X 
admini- y 4 per  
stration 
(ig hours hours 
(hours) 
Free fraction, 17-epimethandrostenolone 
1 0-4 36018 70347 0.499-  9.77 4.88 4.88 7.29 2 0-4 46735 47065 0.993 9.77 9.70 9.70  
3 4-8 6058 6001 1.011 10.415 10-53  10-53 8.39 4 4-8 437 728 0.600 10.415 6.25 6.25  
5 8-12 2479 7662 0.323 10.415 3.36 3.36 3.17 
 6 8-12 1755 6157 0.285 10.415 2.97 2.97 
7 12-16 1798 16086 0.112 10.415 1.17 1.17 0.93 8 12-16 1038 15856  0.065 10.415 0.68 0.68  
9 16-24 1870 27033 0.069 10.415 0.72 0,36 0.40 
10 16-24 1073 6496 0.165 5.2075 0.86 0.43  
11 24-36 1919 14322 0.134 5.2075 0.70 0.23 0.14 
12 24-36 48 2351 0.024 5.2075 0.12 0.04  
13 36-48 2606 17965 0.145 5.2075 0.76 0.25 
146-48 118 9167 20750.29.09 °" _ 
Sulphate fraction, material with retention time of 
methandro stenolone 
1 0-4 200 5807 0.035 10.415 0,37 0.37 0 .19 
2 0-4 11 5587 0.002 5.2075 0.01 0.01  
3 4-8 122 6805 0.018 5.2075 0.09 0.09 0.09  
4 4-8 - 1672 - 5.2075 - - 
5 8-12 - 11018 - 5.2075 - - 00 
6 8-12 27 9761 0.003 5.2075 0.02 0.02  
7 12-16 630 11475 0.055 5.2075 0.29 0.29 0.29  
- 8 12-16 - 8880 - 5.2075 - - 
9 16-24 - 9924 - 5.2075 - - 
10 16-24 -- 4193 - 5.2075 - - - 
11 24-36 - 9186 - 5.2075 - - 
12 24-36 .- 8107 - 5.2075 - - 
13 36-48 - 7159 - 5.2075 - - 
14 36-48 - 99 - 5.2075 - - 
Table 9. Results of the analysis of the "free" and the 
"sulphate" fractions from urine following the 
administration of methandrostenolone 
burette to the tube containing the residue to be analysed 
and the solvent removed by careful evaporation with nitrogen 
at room temperature. 
The residue, containing XMg of the compound to be 
analysed and Ypg of the standard was then dissolved in a 
small volume (ca. bill) of Analar acetone and injected into 
the gas chromatograph. The areas of the peaks, x and y, 
corresponding to the unknown and to the standard, respectively, 
were measured with a Kent Chromalog 2 Integrator and X was 
determined from the proportional relationship:- 
= 




Free fraction, 17-epimethandrostenolone 
1 0-4 3466 2128 1.63 9.2 15.0 15.0 
2 4-8 2699 4254 0.635 9.2 5.8 5.8 
3 8-12 3546 5594 0.635 9.2 5.8 5.8 
4 12-16 - 3926 - 9.2 - - 
5 16-24 2267 4810 0.472 9.2 4.3 2.2 
Sulphate fraction, material with retention time of 
methandrostenolone 
1-5 0-24 347 9703 0.036 9.2 0.33 
(inc.) 
Table 10. Results of the analysis of the "free and the com- 
bined "sulphate" fractions from urine fo1bowin 
the ad-ministration of methandrostenobone 
Tables 9 and 10 show the results of two studies which 
are represented in histogram form in figures 10a and lOb. 
Fraction 4, table 10 was examined twice and in both cases 
no material with the retention time of inethandrostenolone 
was found. 
3.8. ii. atment of 17- 
"suj2jate extraction pro ce"147  
17-Epimethandrostenolone (131M9) was ground to a fine 
powder and washed into a separating funnel with water (300m1) 
and chloroform (300m1). The mixture was shaken well and 
the chloroform layer discarded. The aqueous layer was then 
made 0.3M  in pyridinium sulphate pyridine (16m1) and con-
centrated sulphuric acid (5.4m1)] and extracted with chloro- 
form (320m1). The aqueous layer was discarded and the 
organic layer washed with distilled water (2 x 32m1), dried 
over anhydrous magnesium sulphate and evaporated to dryness. 
The residue was dissolved in water (10.9m1) and concentrated 
hydrochloric acid (0.lml) was added to the solution, which 
was left to stand for 5 minutes before extraction with chloro- 
form (2 x llml). The combined organic extracts were washed 
with iN sodium hydroxide solution (llml) and with water (2 x 
llml), dried over anhydrous magnesium sulphate and evaporated 
to dryness to give a brown residue. The trimethylsilyl de-
rivative of the residue was prepared according to the method 
described in section 3.4.iv. T.l.c. of this derivative 
showed seven spots, the least polar of which gave the colour 
reaction of methandrostenolone and its 17-epimer. Seven 
components with retention times between 6.4 and 23.8 minutes 
on 2*% OV-1 at 235°C were detected by g.10c0 One of the 
components had a retention time (11.4 minutes) similar to 
that of the trimethylsilyl ether of 17-epimethandrosten--
-. olone. 
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3.9. The investigation of compounds whicjjLtbe inter- 
mediates in the epimerisation of methandrostenolone 
3.9.i. It has been shown (section 3.7) that material re-
sembling - methandrostenolone sulphate could not be isolated 
from the urine, following administration of methandrosten-
olone, in more than negligible quantities, which may have 
been due to carry-over of free steroid rather than to 
extraction and hydrolysis of a sulphate. If methandrosten- 
olone sulphate existed but was unstable to the extraction 
procedure methandrostenolone should have been detected in 
the free fraction because chemical hydrolysis of a sulphate, 
with few exceptions, leads to fission of the 0-S bond and 
retention of configuration rather than to fission of the 0-0 
bond with inversion. 1 
There is a possibility, however, that a transitory 
sulphate intermediate might exist. The enzymes responsible 
for the sulphation of steroids, the steroid sulphotransferases, 
have been found in significant amounts only in the liver, 
adrenals and jejunal inucosa in the adult human, 149 whilst 
those which catalyse the hydrolysis of steroid sulphates, 
the steroid sulphatases, are known to occur in the liver 
and adrenals as well as the testes and ovariesJ50 Conse-
quently, if enzymes of these types are involved in the epi-
merisation of methandrostenolone it is possible that a 
sulphate might exist transitorily in organs in which both 
types of enzymes are found. 
The epimerisation of a tertiary hydroxyl group is 
such an unusual reaction that, although very little can be 
said about the mechanism of the biological reaction without 
enzyme studies, it was of interest to explore the possibility 
of effecting such a transformation by chemical means. 
i 151 Originally t was considered that steroid sulphates were 
final products of metabolism but several workers have now 
shown that these conjugates can participate in a variety of 
biochemical reaction.151"52  It has been demonstrated that 
the conversion of cholesterol and pregnenolone to biologically 
active steroids may take place at the level of the sulphate 
153-156 
esters. Consequently the synthesis of methandrosten- 
olone sulphate was attempted. 
3.9-ii. Methods of synthesis of steroid sulphates 
Many methods have been developed for the synthesis of 
steroid sulphates following the appreciation of their impor- 
tance as products of metabolism. Three reactions, in each 
of which the active sulphating agent is the pyri dine- sulphur 
trioxide complex, have formed the basis for the majority of 
these syntheses-157,158 The complex may be generated in situ 
by the reaction of chlorosulphonic acid with pyridine, and the 
steroid to be sulphated simply added to the reaction. This 
method has been widely used157 but suffers from the disadvan-
tage that it is sometimes difficult to remove chloride ions 
completely from the final products.159 An alternative method 
involves.the preparation of pyridine sulphate and the use of 
an internal dehydrating agent, usually acetic anhydride, to 
generate the pyridine-sulphur trioxide complex. 157 This 
method is effective provided that the concentration of acetic 
anhydride relative to pyridine sulphate is not too great, in 
which case the steroid acetate is the primary product. 160 A 
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third method for the generation of pyridine-sulphur trioxide 
involves the direct reaction of solid sulphur trioxide with 
pyridine in chloroform. This reaction is rather, violent 
and has not been much used because of the difficulty of 
handling sulphur trioxide.157 A method which utilises 
sulphamic acid as the sulphating reagent has been described 
by Joseph et al. 161 
Methods of steroid sulphation which utilise the isolated 
adduct of sulphur trioxide with a nitrogenous base are con- 
venient because of the absence of chloride ions. The pre-
paration of pyridine-sulphur trioxide was described by 
Baumgarten162 in 1926 and its properties and reactions have 
been reviewed by Gilbert. 163 A commercial preparation of 
pyridine-sulphur trioxide, m.p. 141-143°, was initially em-
ployed in the work to be described and Roy and Trudinger15.9  
described a convenient method of preparation of the complex, 
M.P. 1 750 In view of the discrepancy between these re- 
ported melting points material was synthesised according to 
the latter method and found to have a melting point of 140
0 . 
Melting points ranging between 97 0 and 1750 , depending on 
* 163 the method of preparation, have been reported for pyridine- 
sulphur trioxide. Gilbert  163  has explained these discrepan-
cies in terms of the salt-like nature of the complex, its low 
volatility and low solubility in all common solvents making 
purification exceeding difficult. 
Roy and Trudinger159 stated that the method which they 
described for the preparation of pyridine-sulphur trioxide 
was also suitable for the synthesis of the adduct of sulphur 
trioxide7 with other bases, such as trimethylamine. 
Consequently the synthesis of triethylamine-sulphur trioxide 
was attempted by this method. Unlike the pyridine adduct, 
the product of the addition of chlorosulphonic acid to tri-
ethylamine was soluble in chloroform and so anhydrous ether 
was added to achieve precipitation. The white crystalline 
material was recovered by filtration and purified according 
to the method, described by Dusza et al, 6 for the purifi- 
cation of commercial triethylamine-sulphur trioxide. How- 
ever, the purified product had a melting point above 2500  
whereas that of triethylamine-sulphur trioxide is 92
0 
. 
Hence tniethylammonium salts of steroid sulphates were pre-
pared by the addition of triethylamine to reaction mixtures 
containing pyridine-sulphur trioxide. Because of the greater 
basicity of triethylamine it readily replaces pyridine as the 
cation. 
Several other methods have been described for the pre-
paration of steroid sulphate esters. That of Mumma et afl 166  
which utilises dicyclohexylcarbodiimide for the generation of 
the active sulphating species from sulphuric acid was used 
for an attempted sulphation of methandrostepnlone, described 
later. 
The literature contains many references to methods 
suitable for the preparation of sulphates of primary and 
secondary steroid hydroxyl groups, but there are few refer-
ences to the suiphation of tertiary steroid alcohols J67 
Dusza et al. 
164 were able to synthesise the sulphates of the 
tertiary 17a-hydroxyl group of 17a-hydrox3tprogesterone and 
related compounds by a method employing triethylamine-sulphur 
trioxide. Joseph et a1J61 have prepared the sulphates of 
92 
the 17-hydroxyl group of 17a-ethynyl-3-inethoxyoestra-1,3,5 
(10)-trien-17-ol and 17a-ethyloestra-1, 3,5(lO)-triene-3,17- 
diol with sulphamic acid. However reports of tertiary 17$- 
sulphates in which the 17a-substituent is an alkyl group are 
more scarce. 167 ID
, 168 Alo prepared the di sodium salt of 17w- 
rnethylandrost-5-ene-3,17-diol disulphate, which compound was 
found to be unstable at ambient temperature and only stable 
below 8 0• It has long been known that steroids can be bio- 
chemically sulphated at the 3,17 and 21 positions
16971  but 
Wengle and Bostr5m172 have shown that the introduction of a 
methyl or ethyl group at the 17w-position inhibits the 
sulphation of the 170-hydroxyl group. 
3.9-iii. The synthesis of sulphates of methandrostenolone 
The properties of the triethylarninonium salts of 
steroid sulphates make them desirable derivatives compared to 
some of the more common salts. 164 Because of the apparent 
failure of attempts to synthesise the triethylamine-sulphur 
trioxide complex, salts of triethylamine were prepared by ex- 
change with pyridinium salts. Several variations of the 
basic method •of preparation of the steroid sulphate from 
pyridine-sulphur trioxide and triethylamine were employed in 
attempts to synthesise the derivative of methandrostenolone. 
Sulphates are very polar compounds and would be expected 
to have exceedingly low R  values in the solvent systems 
normally employed for t.1.c. of theless polar free steroids. 
Infrared spectra of steroid sulphates in potassium bromide 
discs have often been recorded but a variety of solvents may 
be used for solution spectra provided that a suitable cation 




Figure 11. The mass spectra of a) the products of the suiphation of 




















characteristic of the sulphate moiety, occur at V  max  l24O and 
1225cm, sometimes not fully resolved because of their 
intensity, and at v  max  lO7O_l0OcmJ47al73 A series of 
intense bands, characteristic of the S-0-C bonds and thus 
dependent on the nature of the steroid appear in the region 
V max l05O-650cmJ73 
Methandrostenolone was reacted with pyridine-sulphur 
trioxide and triethylamine in pyridine for two hours at 
room temperature. The addition of ether gave a slight pre-
cipitate which could not be recovered by filtration; con-
sequently the solvents were removed by evaporation and the 
resulting crystals washed with ether. EmiliozzJ74 described 
the isolation of androsterone triethylammonium sulphate by 
distillation of the solvents in vacuo below 600. The product 
of this reaction of methandrostenolone was initially examined 
by t.l.c. and infrared spectroscopy, both of which indicated 
that no reaction had occurred. 
The n.m.r. spectrum of the same product showed in-
significant shifts of the methyl peaks from the positions of 
those.of the free steroid. However, the spectrum included 
a triplet at i8.65 (J = 7Hz) and a quartet at t6.84 (J = 7Hz) 
which integrated for 20% of the sample. These resonances 
were neither free triethylamine [79.03 (t, 7.2 Hz), 7.57 (q, 
7.2 Hz)] nor diethyl ether [78.81 (t, 7.2 Hz), 6.52 (q, 7.2 
Hz)] but were similar to the positions reported 
164  forthe 
ethyl protons in sterdid triethylammonium sulphates [i8.67 
± 0.08(t), 6.92 ± 0.08 (q)]. The mass spectrum of the 
product [figure lla] was different from that of methandrosten-
olone [figure 5a],  particularly in the appearance of a meta- 
94 
stable ion at ni/c 252.7, attributable to the transition, 
m/e 282 to m/e 267, the near disappearance of m/e 242 and 
the appearance of a low intensity ion at rn/c 239. 
The sulphate of methandrostenolone was also prepared 
by the method of Erniliozzi,'7  as described by Roy and 
Trudinger,159 in which the reactants were heated to give a 
solution prior to the addition of triethylamine. Once again, 
examination of the product by t.l.c. and infrared spectro-
scopy suggested that it was unreacted methandrostenolone but 
the mass spectrum was similar to that of the product of the 
previous reaction [figure la]. The figures obtained from 
elemental analysis were not in exact agreement with those 
calculated for methandrostenolone triethylammonium sulphate 
but were of the correct order. Hydrolysis of this product 
in an aqueous medium containing a trace of base gave a com-
pound with the mass spectrum, n.m.r. spectrum and melting 
point of methandrostenolone. 
Finally a procedure recommended for the formation of 
the triethylammonium sulphates of steroids with hindered 
hydroxyl.groups,164 in which the reactants were heated at 
70_900 for three hours was examined. The ethyl protons in 
the n.m.r. spectrum of a sample of methandrostenolone tri-
ethylammonium sulphate prepared by this method were twice as 
intense as was required for 100% formation of the derivative. 
This was explained by the fact that chemical exchange occurred 
between the ammonium proton of the salt and any free triethyl- 
amine which had not been removed by evaporation. Consequently, 
all the ethyl protons, whether in the cation or the free. base 
95 
appeared at the resonance positions of the cation, and the 
ammonium proton appeared as a very broad band in the region 
¶3.6 - 2.8. Thus, unless all free triethylamine was re-
moved n.m.r. spectroscopy could not be used to calculate the 
percentage formation of the triethylammonium sulphate. The 
pyridinium salt of methandrostenolone sulphate was prepared 
and gave a mass spectrum similar to the products of the 
previous sulphation reactions. 
3.9.iv. Interpretation of the results of the sui2jions of 
methandrostenolone 
Rationalisation of the results of the experiments des--
cribed in the above section was difficult because information 
from the different methods of examination of the products 
appeared to conflict. In all cases t.l.c. and infrared 
spectroscopy indicated that no reaction had occurred, as did 
the lack of any shift of the methyl signals, particularly the 
C-lB methyl resonance, in the n.m.r. spectra. However the 
appearance of the quartet and triplet at the reported chemical 
shifts 
164
of the triethylammonium moiety, and the elemental 
analyses were indicative of successful formation of methan-
drostenolone sulphate. Mass spectrometry provided the most 
conclusive evidence for formation of a derivative, since each 
product gave a similar spectrum which was not that of free 
methandrostenolone. The recovery of methandrostenolone 
after hydrolysis of the derivatives eliminated the possibility 
that decomposition might have occurred prior to mass spectro-
metry. 
The literature contains little concerning the mass 































Figure 12. The mass spectra of methanthAostenolone triethylaminonium sulphate 
a) at 1000 and b) at 2000 . 
spectrometry of steroid sulphates, probably because the 
temperatures required to obtain adequate signal response 
lead to decomposition of the salts presently used and hence 
the method is of limited value for the characterisation of 
these compounds. 147bJoseph and Dusza have subjected a 
number of triethylammonium sulp1ates to mass spectrometry, 
the detailed results of which are not available. How-
ever, ions at m/e 48, m/e 64 and m/e lQl, indicative of the 
SOP, S0 and (C2H5)3N fragments, respectively, • were found 
although no molecular ions were observed. 47b The spectrum 
at 1000  of methandrostenolone triethylamrnonium sulphate 
[figure 12a] prepared by the method described by Roy and 
Trudinger159 was similar to those of all the samples studied 
[see figure llaj and-showed no evidence of the three above- 
mentioned ions. In the spectrum of the same sample at 2000 
[figure 12b] the high mass fragments had declined and among 
the prominent peaks were those at m/e 48, m/e 64 and m/e 101. 
161 - 
Joseph et al. reported that the base peak in the mass 
spectrum of 3-hydroxy-2-methoxyoestra-1, 3,5(lO)-trien-17-one 
potassium sulphate was the molecular ion of the free steroid, 
but that the S0 and S0 ions were not observed because the 
temperature was insufficient to cause decomposition of the 
potassium salt obtained by cleavage of the S-O bond. 
The results described thus indicated that methandrost-
enolone pyridinium[90] and triethylarnmonium[91] sulphates 
were successfully formed and, inside the mass spectrometer, 
decomposed to give a species with intense ions at m/e 282[92] 
and m/e 267[931[see figure ha]. The metastable ion at m/e 
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252.7 showed that both ions originated from the same molecule. 
The low intensity ion at m/e 300 may have arisen from cleavage 
161 
of the 8-0 bond in the spectrometer, from unreacted methan- 
drostenolone or from derivative hydrolyzed prior to spectro- 
metry. A low intensity ion at m/e 239, which occurred in 
neither the spectrum of methandrostenolone nor that of its 
17-epimer, and the almost total disappearance of the ion at 
m/e 242 indicated that the sulphate decomposed in the mass 
spectmeter to give the 18_nor_17,17_dimethy1_13(14)_ene[92] 
(Mt, m/e 282). The mass spectrum [figure llb] of the major 
product of the sulphuric acid catalysed elimination reaction 
of methandro stenolone, 17, 17-dimethyl-18-norandro sta-1, 4,13 
(14)-trien-3-one[92] was similar to those produced by the 
sulphates of methandrostenolone [see figure na]. Elimin-
ation of the sulphate to the 17-methyl-A16_ molecule would 
give rise to a species with M at m/e 282. However this 
species contributes to the m/e 282 ion in the spectra of 
methandrostenolone and its 17-epimer, neither of which con- 
tains the ion at m/e 239. In addition, exocyclic elimination 
would be expected to accompany endocyclic elimination of the 
sulphate in which event the m/e 267 ion would not be expected 
to be as intense as observed [see figures lla and 12a]. 
Joseph et al.16 found that the mass spectrum of 3-hydroxy-
androst-5-en-17-one ammonium sulphate[94] contained no mole-
cular ion but that the base peak arose from elimination of 
the elements of ammonium sulphate to give a 63'5-diene ion[951. 
The hydrolysis of steroid hydrogen sulphates has been 
the subject of much study 148,175because of the importance of 
establishing whether or not the steroids identified after 
the hydrolysis of sulphates of biological origin are the 
products of rearrangement and hence only artefacts of the 
hydrolysis procedure. The solvolysis reaction can be ex-
pressed as nucleophilic displacement of the alcohol (R-OH) 
[96] by the ether (R0)[97] from the reactive dipolar species 
[98] which is regarded as existing in equilibrium with the 
other tautomeric forms of the hydrogen sulphate [99]. The 
effectiveness of various ethers in accomplishing the solvo-
lysis follows their order of basicity.117b Because of the 
low basicity of the phenolic oxygen atom sulphates of the 
oestrogens are so readily hydrolysed that they are difficult 
to handle.117b Prediction of the basicity of the C-17 
oxygen atom of methandrostenolone is difficult but hydrolysis 
of methandrostenolone sulphate must have occurred in carbon 
disulphide, used for infrared spectroscopy, in acetone prior 
to t.l.c. and perhaps partially in deuteriochlorofort during 
n.m.r. spectroscopy. This mode of hydrolysis, i.e. fission 
of the 0-S bond, also occurred when the sulphate was refluxed 
in an aqueous basic medium, giving methandrostenolone as the 
product. 
3.9.v. The attempted synthesis of methandrostenolone sodium 
sulphate 
A mild method of sulphation employing dicyclohexyl-
carbodiimide to generate the reactive species from sulphuric 
acid has been described by Mumma et al. 166 The synthesis of 
the sodium salt of methandrostenolone sulphate was attempted 
by this method and a product was obtained in very low yield 
after passage through two ion-exchange columns. The 
positions of the methyl peaks in the n.m.r. spectrum of the 
product differed from those of nethandrostenolone but re-
sembled those of the products of dehydration of the 17- 
hydroxyl group (see section 3.13). The nature of the pro-
duct was confirmed by its low polarity on a t.l.c. plate; 
thus the steroid was dehydrated by sulphuric acid rather 
than sulphated.. The low recovery of prQduct (ca 20%) was 
then explained by the fact that the first ion-exchange column 
was designed to remove any unreacted steroid from the sulphate, 
the former being eluted first and discarded. 
3.9.vi. The svnthesis of the sulphates of dehydroep4iijQ 
onetest2.terone methyltestosterone and 17cL- 
hydroxyprogesterone 
sza et a1J64 reported details of the n.m.r. spectra 
of a variety of triethylammonium sulphates including those 
of dehydroepiandrosterone, testosterone and 17a-hydroxy- 
progesterone. These compounds and the derivative of 
methyltestosterone were prepared and the n.m.r. spectra 
recorded. All contained a quartet and a triplet in the 
correct positions for the sulphates, although the peaks may 
have been intensified by chemical exchange of the ammonium 
proton with free base. The spectra of the derivatives of 
dehydroepiandrosterone and testosterone contained peaks at 
the positions rep0rted164 for the sulphates and at those of 
the free steroids whereas those of 17a-hydroxyprogesterone 
and methyltestosterone, like methandrostenolone, showed no 
shifts from the positions of the peaks in the free steroid. 
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Dehydroepiandrosterone pyridinii-im sulphate was prepared, the 
signal due to the 3a-proton being shifted downfield in the 
n.m.r. spectrum of the derivative compared to that of the 
free steroid. These results confirmed that secondary 
sulphates are more easily prepared and of greater stability 
than the derivatives of tertiary-alcohols. 
3.9-vii. The àynthesis of sulphonates of methandrostenolone  
The nucleophilic substitution of sulphonic esters of 
secondary steroidal alcohols, particularly the toluene-p--
sulphonates, has been extensively studied for mechanistic 
purposes and as a means to the epimerisation of alcohols. 117c 
Derivatives of tertiary alcohols have not been so studied; 
nevertheless the preparation of methandrostenolone tosylate 
was attempted. Recovery of the derivative by precipitation 
by the addition of water to the reaction mixture proved un-
satisfactory and so the solvent was removed by evaporation 
•
at room temperature and the crystalline product obtained by 
filtration. The tosylation product behaved similarly to the 
sulphates described previously; due to rapid hydrolysis of 
the tosylate infrared spectroscopy and t.1.c. indicated that 
the reaction had not occurred but the mass spectrum was 
similar to those given by the sulphate derivatives [see figure 
lla]. 
Nucleophilic substitution is generally accompanied by 
elimination, the ratio of products from each mechanism varying 
according to the reaction conditions.117c Accordingly the 
product of tosylation of methandrosteno]-one was adsorbed onto 
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alumina. Although alumina tends to operate as a base 
rather than a nucleophile70 and thus to cause predominant 
elimination only 5% of the product was of sufficiently low 
polarity to be eluted with benzene. The remaining 95% of 
the material on the column was eluted as a single fraction 
with similar polarity and identical mass spectrum to methan- 
drostenolone. The trimethylsilyl ether of this fraction 
was prepared and examined by g.l.c. but no trace of 17- 
epimethandrostenolone was detected. When authentic añdro-
stanolone tosylate was prepared and adsorbed onto alumina 
no elimination or inversion products were detected. The 
major product was unchanged derivative and the other product 
was the free 17-hydroxy steroid. 
The methanesulphonate of methandrostenolone was syn-
thesised and found to be insoluble in common solvents, such 
as those used for infrared and n.m.r. spectroscopy. The mass 
spectrum of the derivative was similar to those of the sulphates 
and tosylate of methandrostenolone [see figure ha]. After 
hydrolysis of the mesylate, methandrostenolone was obtained. 
3.9-viii. Conclusion 
The results described in this section indicated that 
it was possible to prepare the sulphate and suiphonate de-
rivatives of the tertiary hydroxyl group of methandrostenolone 
but that, as expected, these derivatives were unstablelES and 
decomposed to give the parent steroid in common solvents and 
when intentionally hydrolysed. Thus, chemical hydrolysis re- 
sulted in fission of the S-0 bond. The mass spectral results 
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were, however best explained by fission of the C(17)-o bond 
in the mass spectrometer, with migration of the C-18 methyl 
group to C-17 and elimination of the 14a-hydrogen atom to 
give the quaternary-substituted A13(14 )-double bond. In-
version at the 17-position would require fission of the 
c(17)-O bond and attack by a hydroxyl group from the a-side 
of the molecule before migration of the C-lB methyl group 
could occur. It is feasible that an enzyme, by virtue of 
its stereochemistry, might prevent C-18 methyl migration 
and thus allow inversion to proceed. 
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3.10. Experimental Section 
3.10.i. Pyridine-sulphur P-1- dine-sulphur trioxide159  
A mixture of chlorosulphonic acid (4m1) and ethanol- 
free chloroform (20m1) was added dropwise to a mixture of 
dry pyridine (loml) and chloroform (30m1) at 0°C. The 
reaction vessel was surrounded by an ice-salt bath and the 
rate of addition adjusted such that the temperature remained 
below 50  during the addition, which required approximately 
2 hours. The white precipitate of pyridine-sulphur trioxide 
was recovered by filtration, washed with cold chloroform 
(3 x 8m1) to remove pyridine hydrochloride and with water (2 
x 8mm). The product was dried over phosphorus pentoxide to 




3.10. ii. Methandrostenolone triethylammonium Qate 
a. Room temperature for 2 hours 
Pyridine-sulphur trioxide complex (26.9mg, Aldrich 
Chemical Co. Inc., Milwaukee, Wis. U.S.) and triethylamine 
(0.23m1) were added to a solution of methandrostenolone 
(46.0mg) in a small volume of dry pyridine and the reaction 
flask stoppered and left at room temperature for 2 hours. 
.Anhydrous ether (ca. 10 times the volume of the reaction 
mixture) was added, whereupon a cloudy white precipitate, 
which could not be filtered, was observed. The solvents 
were removed by evaporation with a gentle stream of nitrogen 
at room temperature and crystallisation occurred after 
storage in a desiccator in vacuo. The pale yellow crystals 
were filtered under suction and washed with anhydrous ether. 
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Infrared spectra of the crystals (m.p. 142--1470) and of the 
ether-soluble material were identical with that of methan- 
drostenolone. Similarly, t.l.c. of these fractions and 
the crude product showed only the free steroid. The n.m. r. 
spectrum (100 M Hz) of the crystals was similar to that of 
methandrostenolone but for an additional quartet and triplet; 
¶9.08 (C-18 methyl), 8.82 (C-20 methyl), 8.76 (C-19 methyl), 
8.65 (t, 7Hz), 6.84(q, 7Hz), [triethylamine, 19.03 (t,. 7.2 
• Hz), 7.57 (q, 7.2 Hz); diethyl ether, ¶8.81 (t, 7.2 Hz), 
6.52 (q, 7.2 Hz); triethylamonium sulphates, 164 ¶8.67 ± 
• 0.08 (t), 6.92 + 0.08 (q)]. The ethyl group was present in 
ca. 20% of the sample. Mass spectra of the crystals (the 
intensities [% base peak] in brackets refer to spectra at 1200  
[figure lla],  1250 and 1400, respectively); m/e 300 (6,7,50/), 
m/e 282 (49,100,100%), m/e 267(27,53,73%), m/e 239 (3,4,5%). 
b. 60-700 and then at room temperature for 48 hours159  
Methandrostenolone (51.8mg) and pyridine-sulphur 
• trioxide (preparation described in section 3.10.i, 50mg) were 
suspended in dry pyridine (0.25m1) and warmed to 60-70°  to 
give a pale yellow solution above clear droplets. The 
mixture was allowed to cool whereupon the droplets crystal- 
used. Triethylamine (2 drops) was added and after 48 hours 
at room temperature a single-phase pale yellow solution was 
obtained. The solvents were evaporated at room temperature 
with nitrogen and the last traces removed in a desiccator 
in vacuo to yield a yellowish-green product (73.1mg); m.p. 
143-150°; infrared spectrum and t.l.c. similar to methan- 
0 
• drostenolone; mass spectrum (intensities at 115 and 130 ); 
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m/e 300 (5,3%),  m/e 282 (57,45%), m/e 267 (26,330/6), m/e 
239 (3,3%); calculated for C25H43058N, C = 64.84, H =9.00, 
N = 2.91%, found, C = 62.02, H = 8.78, N = 2.53% (calculated 
for methandrostenolone, C = 80.00, H = 9.34%). 
c. 80-85 0  for 4 hours164  
Pyridine-sulphur trioxide (29mg, 1.1 equivalents) and 
triethylamine (4 drops) were added to a solution of methan- 
drostenolone (50mg) in a small volume of pyridine. The 
reaction vessel was fitted with a reflux condenser protected 
with a calcium chloride tube and heated at 80-85° for 4 hours. 
The orange solution was allowed to cool before the addition 
of anhydrous ether (ca. 10-20 times the volume of the reaction 
mixture). A white precipitate, which could not be filtered, 
was obtained. It was thus dissolved by the addition of 
methylene chloride and the solvents were removed at room 
temperature by evaporation in vacuo, by a stream of nitrogen 
and finally in a desiccator in vacuo. The infrared spectrum 
of the crystalline product (m.p. 144-1540) was similar to 
that of methandrostenolone, as was the n.m.r. spectrum (100 M 
Hz) but for ethyl protons at ¶8.67 (t, 7 Hz, 9H), 6.83 (q, 
7 Hz, 6H). T.l.c. of the product in the system benzene, 
acetone, water (2:1:2), upper phase, 70%-methanol, 3Q%164 
showed two similarly coloured spots at R  0.86 (major), 
corresponding to methandrostenolone and at Rf (0.5). 
3.10.iii Hydrolysis of methandrosténolone triethylammonium 
sulphate 
Methandrostenolone triethylammonium sulphate (52.5mg, 
preparation described in section 3.10.ii.b.), sodium bicarb- 
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onate (ca. 1mg) and water (2m1) were heated at 100°C for 
1 hour. After cooling, the steroid was extracted into 
ether and the ether extract washed with water until neutral, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to yield a crude product (36.2mg); m.p. 153-1570; 
n.m.r. (100 M Hz) T9.08 (C-lB 8.82 (C-.20 
8.77 (C-19 3.94 (d, 2 Hz, 4-H),, 3.79 (d of d, J12  
10 Hz, J24 2 Hz, 2-H), 2.94 (d, 10 Hz, 1TH); t.l.c., polarity 
and colour reaction identical to those of methandrostenolone; 
mass spectrum, m/e 300 (17%), m/e 282 (11%), m/e 267 (7%), 
m/e 242 (16%). 
3.10.iv. 'Methandrostenolone ridinium3,hate 
Methandrostenolone (48.8mg) and pyridine-sulphur tri-
oxide (50mg) were suspended in pyridine (0.25m1) and heated 
to give a solution. The reaction mixture was then left at 
room temperature for 48 hours. Yellowish-green crystals 
formed and were recovered by filtration and dried in a 
desiccator in vacuo. Yield 62.9mg; m.p. 122-1300; Mass 
spectrum, 115°, m/e 282 (100%), m/e 267 (70%), m/e 239 (4%). 
3.10.v. Attempted s 
sulphate 166  
Methandrostenolone (50mg) was dissolved in dimethyl-
formamide (0.2m1) and added to an ice-cold solution of di-
cyclohexylcarbodiimide (0.179) in dimethylformamide (0.3m1). 
Concentrated sulphuric acid (0.014m1) in dimethylformamide 
(0.lml) was added and the mixture kept at 00 for 15 minutes, 
with occasional agitation. It was then transferred to a 
column of DEAE cellulose (Whatman DE-11, C1 form, 4g) and 
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methanol (1 litre) was passed through the column to elute 
unreacted steroid and dicyclohexylcarbOdiimide, dimethyl- 
formamide and dicyclohexylurea. This fraction was dis-
carded. 1M methaiolic ammonium hydroxide (200m1) was passed 
through the column and the solvents removed from this 
fraction by evaporation below 40? in vacuo. The residue was 
suspended in acetone (looml) and the white precipitate of 
ammonium chloride removed by filtration. The filtrate was 
passed through a column of Dowex-50W-X8 (Nat form) and the 
eluent removed by evaporation below 4Q0• The residue was 
dried over phosphorus pentoxide to give a brown glass (ca. 
10mg); n.ni.r. (100 M Hz) showed that the U-ring differed 
from that of methandrostenolone; t.l.c. in chloroform-
methanol_water.(65:254)165 showed that the product had similar 
polarity to methandrostenolone (Hf ca. 0.88) and in benzene-
ethanol (9:1) two components were resolved, one similar to 
methandrostenolone and one less polar. 
3. 10.vi. Dehydroepiandrosterone triethylaonium 5u1phate164 
DehydroepiandrpsterOne (250mg) and pyridine-sulphur 
trioxide (250mg) were suspended in pyridine (1.25m1) and warmed 
to 60-700 until complete solution was obtained. The reaction 
mixture was cooled, whereupon crystallisation occurred, and 
triethylamine (0.125m1) was added. After 48 hours at room 
temperature the solvents were removed with a stream of nitro- 
gen and finally in a desiccator in vacuo. The infrared 
spectrum of the product was similar to that of the free 
steroid but t.l.c. showed two components, one with the same 
polarity as the free steroid and one which remained at the 
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start of the chromatogram; N.m.r. (60 M Hz) ¶9.14 (0-18 
methyl), 8.98 (C-19 hl), 8.64 (t, 7 Hz), 6.84 (q, 7 Hz), 
5.74 (broad, 3a-H), 4.61 (itt, 6-H) dehydroepiandrosterone 
triethylammonium sulphate [lit.,164 ¶9.18, 8.98, 5.75, 4.60 
and free dehydroepiandrosterOne, ¶9.11, 8.96, 6.52, 4.62]. 
3. 10.vii. Testosterone triethylammoniuin sulpha te 64  
Testosterone (250mg) was reacted with pyridine-
sulphur trioxide (250mg) and triethylamine (0.125m1) in 
pyridine (1.25m1) as described in section 3-10-vi. The 
infrared spectrum of the product was similar to that of 
testosterone, but t.1.c. showed a component remaining at 
the start of the chromatogram as well as one corresponding 
to testosterone. N.m.r. (60 M Hz) i9.17 (C-lBmethyl), 
8.83 (C-19 methyl), 8.64 (t, 7 Hz), 6.84 (q, 7 Hz), 5.71 
(17ct-H), 4.30 (4-H) testosterone triethylammonium sulphate 
9.18, 8.80, 5.63, 4.251 and ¶9.23 (C-lB methyl), 
8.83 (C-19 methyl), 6.35 (17t-H), 4.30 (4-H) testosterone 
[T9.21, 8.82, 6.35, 4.231. 
3.10. Viii. Methyltestosterone triethylammonium 5u1phate164 
Pyridine-sulphur trioxide (57mg) and triethylamine (8 
drops) were added to a solution of methyltestosterone (ioo 
mg) in a small volume of dry pyridine. The reaction vessel 
was fitted with a refiux condenser protected with a calcium 
chloride tube and heated at 80-85° for 4 hours. The orange 
solution was allowed to cool and the solvent removed by 
evaporation in vacuo below 400, then with a stream of 
nitrogen and finally in a desiccator in vacuo, whereupon 
crystallisation occurred. The product was examined by n.m.r. 
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spectroscopy (100 M Hz); T9'10 (c-is methyl), 8.80 (C-19 
methyl), 8.60 (c-20 met), 8.66 (t, 7 Hz), 6.80 (q, 7 Hz), 
5.140 (broad, N H), 4.28 (4-H) methyltestosterone triethyl-
ammonium sulphate [methyitestosterone, i9.09, 8.79, 8.79, 
4.27], 
3.10. ix. 17a-HydroxrogesterOne triethylammonium sulphate 164 
17a-Hydroxyprogesterone (100mg) was reacted with 
pyridine-sulphur trioxide (57mg) and triethylamine. (8 drops) 
in pyridine as described in section 3.10-viii. The product 
was examined by n.m.r. spectroscopy (100 M Hz); ¶9.28, (c-18 
methyl), 8.82 (c-19 methyl), 8.67 (t, 7 Hz), 7.75 (C-21 methfl), 
6.80 (q, 7 Hz), 4.27 (4-H), 4.01 (broad, N H) 17a-hydroxy-
progesterone triethylammonium sulphate [lit., 164 9.35, 8.84, 
7.72, 4.301. 
3.10.x. N.t4andEqen2JS?e tosylate 
Methandrostenolone (50mg) was dissolved in dry 
pyridine (7m1), cooled to 0 and added to a solution of 
freshly purified toluene-p-sulphonyl ch1oride2C (67mg) in 
pyridine (3.5m1) at 0°. The reaction mixture was kept at 
0 for 4 days after which time it was a faint pinkish-yellow 
colour. Pyridine was removed by evaporation at room temper-
ature with nitrogen and the solid material was washed with 
pyridine and dried by filtration and storage in a desiccator 
in vacuo. Infrared spectroscopy and t.1.c. of the pale 
yellow crystals (60mg) indicated only unreacted methandrost- 
enolone. However the mass spectrum of the crystals was 
different from that of the free steroid; 140°, rn/c 282 (77%) 
m/e 267 (60%), m/e 239 (12%). 
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3.10.xi. Reaction of methandrostenolone tosylate with alumina 
Methandrostenolone tosylate (200mg) was adsorbed onto 
alumina (59) and benzene (lOOmi) was passed through the 
column, which was then left for 3 days. Non-crystalline 
material (5.3mg) was eluted with benzene. This fraction was 
of low polarity compared with methandrostenolone and probably 
contained one or more products of elimination at C-17; it 
was not examined further. A yellow glass (45mg), which 
crystallised on standing, was eluted with benzene-chloroform 
(1:1, looml). The polarity and mass spectrum indicated 
that it was methandrostenolone; m/e 300 (31%), m/e 282 (11%), 
m/e 267 (7%), m/e 242 (17%); G.l.c. of the trimethylsilyl 
ether of this fraction showed no trace of 17-epimethandrost--
enolone. 
3.10.xii. .Androstanolone tosylate 
An ice-cold solution of androstanolone (5.09) in 
pyridine (70m1) was added to a solution of freshly purified 
toluene-p-sulphonyl chloride  112c (6.0g) in pyridine (30m1) 
at 00. The pale yellow solution was maintained at 00  for 
48 hours by which time a bright orange-pink colour had 
developed. Water was added and the precipitate recovered 
by filtration, washed with water, dried and recrystallised 
from ethanol to yield androstanolone tosylate (5.99g, 78%); 
m.p. 175.5-177°; vmax1708,l380,ll93l183cm n.m.r. (100 M 
Hz) ¶9.20 (C-lB methyl),9.02 (&-19 methyl), 7.56 (Ar-CH3), 
5.74 (t, 8Hz, 17a-H), 2.69, 2.23 (d,d,9 Hz, 9 Hz, 4 H, Ar H). 
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3.10.xiii. Reaction of androstanolone tote with alumina 
Androstanolone tosylate (3.125g) was dissolved in a 
small volume of benzene and adsorbed onto alumina (200g). 
After 48 hours the column was eluted with petrol and with 
benzene, both of which removed a single compound (1.6309) 
which, from its pdlarity, infrared and n.m.r. spectra was 
unchanged androstanolone tosylate. Elution with ethanol 
gave a mixture (0.3759)  of androstanolone and androstanolone 
tosylate (2:1);. n.m.r. (60 M Hz) t9.23 (C-la methyl), 8.96 
(0-19 methyl), 6.34 (t, 7 Hz, 17a-H) androstanolone and 
T9.20 (0-18 methyl), 9.00 (C-19methyl), 7.55 (Ar-OH3), 
5.73 (t, 8 Hz, 17a-H), 2.65, 2.20 (d,d,9 Hz, 9 Hz, Ar-H) 
androstanolone tosylate. 
3.10. xiv. Methandrostenolone mesylate 
Ice-cold methanesuiphonyl chloride (0.04m1) was added 
to a solution of methandrostenolone (51.5mg) in dry pyridine 
(0.5m1) at 0. A pale yellow colour developed and after 
18 hours at room temperature colourless crystals had formed. 
The white crystalline product (40.2mg) was recovered from the 
dark yellow mother liquor by filtration. The crystals 
(m.p. 154-1580) were too insoluble in carbon disulphide 
and chloroform to obtain infrared and n.m.r. spectra, 
respectively. The mass spectrum of the crystals, 1400, 
m/e 282 (45%), nile 267 (26%), m/e 239 (2%) showed that they 
were not methandrostenolone. 
3.10.xv. Hydrolysis of methandrostenolone myate 
The product of the preceding reaction (15.7mg) was 
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suspended in water (imi) with a trace of sodium bicarbonate 
and heated at 1000  for 1 hour. The steroid was extracted 
into ether, washed with water until neutral, dried over 
anhydrous magnesium sulphate and evaporated to dryness to 
yield a white solid (3.3mg); m.p. 150...1540; polarity and 
mass spectrum similar to those of methandrostenolone; 1300, 
m/e 300 (27%), m/e 282 (24%), m/e 267 (90/6), m/e 242 (19%). 
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3.11. The synthesis of the A" 
A-en,-3-keto and A -en&3 -hydroxyrecursors 
The original source of methandrostenolone used for this 
work was extracted from commercial tablets. However, the 
synthesis of methandrostenolone from the readily available 
precursor, methyltestosterone, was examined as a more 
accessible source of the compound. Industrially the A1-
double bond is introduced into the precursor, usually methyl-
testosterone, chemically or microbiologically.50 The methods 
of 1-dehydrogenation are well established but difficulty 
arises in the separation of the product from methyltesto- 
sterone in the event of incomplete reaction. The variety 
of synthetic modifications and separation methods described 
in the literature176_180 confirm that this is an important 
industrial problem in the synthesis of methandrostenolone. 
The androgenic nature of methyltestosterone makes its 
presence intolerable in a drug which may be administered to 
women and children. 
Among the methods which have been used to reduce the 
interference by methyltestosterone is an enzymic dehydro-
genation in which the substrate was reported to be prefer-
entially absorbed and retained by the cells whilst the product 
was slowly released into the liquid phase which was periodically 
removedJ 6 Adduct formation between steroidal A-en-3-ones, 
and 2-naphth01177 and morpholinohydrazide derivatives 178 and 
the different rates of hydrolysis of the semicarbazones179  
of A4-en-3-ones and Al 4_dien_3_ones have all been used as 
means of purification. The microbial oxidation and dehydro-
genation of 17amethylandrost-4-ene--3S,17--diOl has been 
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described as a means of avoiding the complications caused 
by the presence of methyltestosterone. 80  
The problem of the purification of methandrostenolone 
from methyltestosterone was identical to that encountered in 
the synthesis of 17-epimethandrostenolone, since each pair 
of epimers have similar polarities. Purification was 
achieved by column chromatography and recrystallisation in 
the synthesis of the latter compound. This method produced 
sufficient pure material for the characterisation of the 
metabolite of methandrostenolone but would be inefficient for 
the preparation of large quantities of the dienone. 
The use of 3-4 equivalents of DUO has been recommen-
ded for the conversion of a saturated 3-hydroxysteroid to 
the corresponding Al 4_dien_3_One.119 Consequently, for 
the preparation of the dienone from a steroid already 
partially dehydrogenated in the A-ring proportionally less 
reagent was used. However, reaction of methyltestosterone 
with 1.1 equivalents of DUO gave only slightly more than 50% 
of the dienone. Preparative t.l.c. was inefficient for 
purification of the product because the polarities of the 
compounds are so similar that overlapping bands are obtained. 
G.l.c. showed that repeated crystallisation resulted in en- 
richment of the filtrate in methandrostenolone. Dichioro- 
dicyanobenzoquinol was readily removed from the product by 
filtration, but unreacted DUO was difficult to remove. 
Filtration through alumina resulted in the adsorption of 
steroids and reagent but the method described by Caspi 
181 which employed a wash with sodium hydroxide 
solution, removed all DUO. 
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In view of the poor conversion to dienone and the 
- inefficiency of the conventional methods of purification 
other separation methods were examined. As mentioned 
previously, semicarbazone derivatives179 an 2-naphthol 
adducts  177  have been utilised. A Japanese group has des-
cribed the use of morpholinoacetohydrazide and 4-hydrazino--
formylmethyl-4-methyl-morpholinium halides for the separation 
Of methandrostenolone from methy1testosteroneJ78 They 
reported that the latter compounds formed water-soluble de-
rivatives with the 4-en-3--one, but did not react with the 
dienone, thereby making separation of the two compounds easy. 
4Hydrazinoformylmethyl-4--methylmorpholinium chloride 
was prepared, as nearly as possihie, according to the method 
of Tohda et al.178 Crystallisation could not be accomplished 
although it was obvious from the melting point reported178 for 
the compound that the crystalline form was attainable. The 
viscous oily product was assumed to be the desired reagent, 
d its reactions with a A4-en-3-one(testosterone) and a 4
dien-3-one(cholesta-114--dien-3-ofle) were examined prior to 
an. attempted separation of methandrostenolone and methyl-
testosterone. When the reagent was reacted with testosterone 
only 6.5% of the steroid  was recovered from the organic phase 
whereas 81.3% of a sample of cholesta--1,4-dien-3-one was re-
covered from this phase. . A mixture of methandrostenolone 
and methyltestosterone was then reacted with 4-hydrazino-
formylmethyl-4-methylmorpholiniulfl chloride and the organic 
extract was found to be free from the A4-en-3-one. 
Once a successful method for the separation of 614_dien_ 
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3-one from unreacted 6 4-en-3-one was available the synthesis 
of 17-epimethandrostenolone was reexamined. Theoretically, 
2 equivalents of DDQ should be required to oxidise the 3-
hydroxyl group and to introduce the A1-double bond into 170- 
methylandrost-4-ene-30,17-diol. Consequently, as in the 
original synthesis of the compound (section 3.2.x.)9 2.2 eq- 
uivalents of DDQ were used. The progress of the reaction 
was monitored by periodic t.1.c. of the reaction mixture, 
which showed that oxidation to the 3-keto group occurred 
rapidly and completely within three hours of the start of 
refluxing. However, 1-dehydrogenation was gradual and in-
complete even when the reaction was continued for twenty- 
four hours. Since Muller et al. 
119 reported the conversion 
of a 3-hydroxyâteroid to a A1'4-dien-3-one with 3-4 equiva-
lents of DDQ, although in only 30% yield, the reaction of 
the 44-ene-3-hydroxy precursor of 17-epimethandrostenolone 
with 3.5 equivalents of DDQ was examined. After refluxing 
for fourteen hours, t.l.c. of the reaction mixture indicated 
complete conversion to the dienone. Consequently, 100% 
formation of the dienone was easily achieved provided that a 
large excess of DDQ was used thus, obviating the necessity 
to use the tedious separation procedures described. 
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3.12. Experimental section 
3.12.i. 
of 
DDQ (0.579g, 1.1 equivalents) was added to a solution 
of methyltestosterone (0-79) in dry benzene (70m1) and the 
mixture was refluxed for 18 hours. The precipitated quinol 
was removed by filtration and washed with methylene chloride. 
The combined filtrate and washings were evaporated to dryness 
and the residue, a dark brown glass, was dissolved in 
methylene chloride-ether (1:3). The solution was filtered 
through a pad of alumina (log), which was washed with ether. 
After evaporation of the solvents the residue was redissolved 
in the solvent mixture and the alumina filtration repeated. 
The filtrate was then washed 181 with 2N sodium hydroxide 
solution (30m1), which removed all colouration from the 
organic layer, and with water until neutral, dried over 
anhydrous magnesium sulphate and evaporated to dryness to 
yield a pale yellow oil (0.66g). Crystallisation from 
acetone gave long white needles which were shown to be a 
mixture of slightly more methandrostenolone than methyl- 
- testosterone by t.l.c. G.l.c. of the crystals and residues 
after repeated crystallisations from acetone showed that 
the residue became richer in methandrostenolone. Preparative 
t.l.c. was attempted but overlapping bands were obtained. 
Methandrostenolone was more polar than methyltestosterone. 
3.12. ii. 4_Hydrazinofbrmylmethyl_4_methYlmoh0lin4PhlQfl_ 7  
4-Methylmorpholine (21.0g) in absolute ethanol (50m1) 
was mixed with ethylchloroacetate (19.9m1) and the solution 
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refluxed for 8 houi's. As soon as the colourless solution 
was heated it rapidly changed through yellow and orange to 
deep red. The solution was allowed to cool and 100% 
hydrazine hydrate (11.2g) was added, whereupon most of the 
colour disappeared to give a pale orange solution from which 
a white viscous oily layer separated. This material was 
soluble in water but insoluble in ethanol but repeated attempts 
at crystallisation were unsuccessful. The supernatant was 
removed and benzene added and distilled to remove traces of 
water which might have hampered crystallisation. The final 
product was a creamy-white glass. 
3.2.iii. Reaction of testosterone with 4-hyirazinol- 
metby1Lp1eyfl._____chloride178  
4_F{ydrazinoformylmethyl-4-methylmorpholinium chloride 
(ca. 500mg) was added to a solution of testosterone (196.9mg) 
in a mixture of methanol and acetic acid (9:1, 8m1). The 
mixture was warmed to 
4Q0  and then left at room temperature 
for 2* hours. Water and ether were added and the aqueous 
phase extracted twice with ether. The ether extracts were 
combined, washed with saturated sodium bicarbonate solution 
and with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness to give a residue (12.8mg). T.l.c. 
showed that the residue contained testosterone and several 
more polar contaminants. Consequently, testosterone 
(184.1mg, 93.5%) was extracted into the aqueous phase by 
complex formation. 
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3.12.iv. Reaction of ch a-14-dien--3-one with no- 
formylmethyl-4-metLylmor2holinium chloride' 
A solution of cholesta-1,4-dien30fle (55.6mg) in 
methanol and acetic acid (9:1, 2m1) was treated with the 
reagent (ca. 125mg) by the procedure described in the pre- 
ceding section. Cholesta-1,4--dien--3-one (45.2mg, 81.3%) 
was recovered from the ether extracts. 
3-12.v. Reaction of methandrostenolone and methyltestosterone 
A solution of a mixture (105.4mg) of methandrostenolone 
and methyltestostetOne in methanol and acetic acid (9:1, 2m1) 
was treated with the reagent (ca. 250mg) as described in 
section 3.12-iii. A yellow glass (76.8mg, 72.8%) was re- 
covered from the organic phase. T.l.c. showed that this 
product was pure methandrostenolone. 
3.12-vi. Reaction of 1 ene- and 
a. 2.2 Equivalents of DDQ 
DUO (178.3mg, 2.2 equivalents) was added to a solution 
of 17_methy1androst-4-ene-3,17di0l (108.4mg) in redistilled 
dioxane (24m1) and refluxed. After 3 hours, t.1.c. of the 
reaction mixture showed cdmplete conversion of the starting 
material to 17_methylepitestosterone, but no trace of 17-epi- 
methandrostenolone. T.l.c. at intervals up to 24 hours 
after the start of the reaction showed gradual, but incomplete 
formation of the latter compound. The product was recovered 
as described in section 3.12.i. and contained a mixture of 
17_methylepitestosterone and 17epimethandrO5tenOlone. 
120 
b. 35 Equivalents of DDQ 
A solution of 1methylandrost_4-ene-3,17-diol 
(475.3mg) and DDQ (1.2509, 3.5 equivalents) in dioxane 
(25m1) was refluxed for i+ hours, when t.l.c. of the reaction 
mixture showed complete conversion to 17-epimethandrosten- 
olone. The product was recovered as described previously. 
3.12. vii. Tltestostero 
of 
Methyltestosterone (5.034g) and DDQ (11.7319, 3.1 equi- 
valents) were dissolved in dioxane (lloml) and refluxed for 
6 hours when t.1.c. showed 100% reaction. The dioxane was 
removed by evaporation in vacuo and benzene was added to the 
residue, which was filtered to remove insoluble quinol. The 
quinol was washed with benzene and the filtrate and washings 
evaporated to dryness. The residue was dissolved in methy-
lene chloride and ether (1:3),  washed with 2N sodium hydroxide 
solution and then with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to yield a crystalline 
product (4.668g, 93%). T.1.c. showed that this product was 
pure methandrostenolone and hence further purification was 
unnecessary. 
3.12.viii. Purification of DDQ 
Impure DDQ (L+og, a mixture of quinol and quinone) was 
dissolved in benzene (400ml) and the insoluble quinol removed 
by filtration. The filtrate was evaporated to ca. 120m1 and 
an equal volume of petrol ether (40-600) was added to the hot 
solution. The bright red crystals of DDQ were removed by 
filtration and dried, below 40°, to give light orange 
crystals (28.5g); m.p. 212-2140 [lit., 
 112d 21301. 
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3.13. Some reactions of methandrostenolone 
The reactions of methandrostenolone with a variety 
of reagents which would primarily cause reaction in the 
D-ring rather than the A-ring were examined. Reactions of 
the dienone system were not of interest in connection with 
the metabolism of methandrostenolone and have been studied 
extensively e15ewhere117d  because of the large number of 
compounds in which this system occurs. 
3.13.1. Base 
Methandrostenolone was refluxed with sodium methoxide 
and with sodium hydroxide in methanol. In both reactions 
only unchanged methandrostenolone was isolated. 
3.13.11. Acid 
Secondary 170-alcohols [ioo] are dehydrated slowly in 
comparison with the rate of the reaction of the corresponding 
17a-ols[1011, which have the trans-coplanar stereochemistry 
necessary for Wagner-Meerwein rearrangements.117e Migration 
of the 13,14-bond, which is trans-coplanar to the 17-01f100J, 
is unfavourable because the product:: would contain a highly 
strained trans-fused cyclobutane system. Lack of anchimeric 
assistance thus means that formation of the 17-methyl-18-nor- 
t13 7)_compound[102] is slow. However, no difference has 
been observed in the rates of elimination of the two C-17 
tertiary alcohols [103];  this has been ascribed to the in-
creased stability of the C-17 tertiary carbonium ion com-
pared to the corresponding secondary carbonium ion, an effect 
which must nullify any stereoelectronic difference.117e1152a 
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Dehydration of a tertiary 17-alcohol may give products with 
a A13(14)_ or a Al2-double bond [104], the latter being the 
major product from compounds with anlL-oxy substituent [103]. 
Methandrostenolone and its 17-epimer [105] were both 
heated with 20% aqueous sulphuric acid at 100 for 2 hours. 
Each compound reacted completely to give 17,17-dimethyl-18-
norandrosta-1,4,13(14)-trien-3--one[106] as the major product 
(ca. 50%), the absence of olefinic protons in the ¶4.0-6.0 
region of the n.m.r. spectra indicating that the extra double 
bond was tetrasubstituted. Methyltestosterone[51] reacted 
under similar conditions to give 17,177dimethyL-18-norandrosta-
* 4,13(14)-dien-3-one[107] as the only product. 
The presence of a series of small peaks in the ¶3.0-
3.5 region of the n.m.r. spectrum of the product of the 
reaction of methandrostenolone with sulphuric acid indicated 
that the dienone-phenol rearrangement had occurred in about 
50% of the sample. This reaction is normally carried out in 
acetic anhydride and sulphuric acid, when the major 
product 7d,182b of a 614_dien_3_one[108] is the 1-hydroxy- 
4-methyl phenol[109]. The mechanism of the rearrangement 
under these conditions has been shown, with the aid of 
optically active compounds, to involve a spiran intermediate 
[110]. When the dienone contains certain substituents, such 
as a t6-double bond, a C-6 or C-li carbonyl group or a c-4 
methyl group, all of which hinder the above mechanism, the 
major productlJ7d is the 1-methyl-3-hydroxy phenol[lll]. 
This compound probably arises by migration of the C-18 methyl 
group to a C-i carbonium ion [112], followed by loss of the 
C-1 proton. In aqueous acids an unsubstituted A4-dien-3- 
[4] 
















one was found to give predominantly the "meta" phenol [iii], 
which may be largely due to the different polarity of the 
solvent. 117d Consequently the product of the reaction of 
methandrostenolone [4] may have contained a mixture of the 
"metal' [113] and "pan" [114] phenols, the former pre-
dominating. 
When methandrostendlone was reacted with sulphuric 
acid in acetic acid the A-ring was completely rearranged, 
together with the expected D-ring reaction. Thus, although 
the D-ring rearrangement occurred when the steroid was not 
in solution (aqueous acid), solution was necessary for 100% 
dienone-phenol rearrangement (acetic acid). Under the 
latter conditions the major product was the "para" phenol 
[114], indicated by a pair of doublets at i'3.48, 3.15, 
J = 8 Hz in the n.m.r. spectrum. The coupling constants 
between meta protons and between para protons are 1-3 Hz 
and 0-1 Hz, respectively; thus the protons in the product 
were ortho (J = 6-9 Hz). 183 
Tishler and Brody 184 studied the reaction of methan- 
drostenolone [4] with methanolic hydrochloric acid at 100°  
for 40 minutes and identified three of the products as 17,17- 
dimethyl-18-norandrosta-1, 4, 13(14)-trien-3-one[106], 1-hydroxy- 
4,17,17-trimethyl-18-noroestra-1,  3,5(10),13(14)-tetraene[114] 
and tentatively, 1-methoxy-4,17, 17-trimethyl-13a-chlorooestra- 
1,3,5(lo)-triene[115], the former being the major product. 
The latter two compounds fluoresced at 325 rim when activated 
at 280 run which is characteristic of oestrogens, whereas 
the former compound exhibited no such fluorescence. All 
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three compounds and inethandrostenolone exhibited the same 
excitation and fluorescent spectra after heating with 
methanolic hydrochloric acid and it was suggested 184 that 
the 0-13 carbonium ions of the two aromatic products were 
responsible for the fluorescent characteristics of methan-
drostenolone under these conditions. 
The immediate generation of a coloured species was 
observed when methandrostenolone was heated with sulphuric 
and acetic acids; this may have been due to the 0-13 
carbonium ion [116]. 
313-iii- £florL2yhloride 
The reaction of a steroid alcohol with phosphorus 
oxychloricle or thionyl chloride has been shown to proceed 
stereospecifically through the trans-coplanar conformation 
of the leaving groups even, when the product is the less 
stable olefin. 71' In the case of a C-17 tertiary alcohol 
trans-coplanar elimination of the 17$-hydroxyl group with 
the 16m-proton requires distortion of the fl-ring which is 
sterically hindered by the increased proximity of the 17- 
substituent and the 0-18 methyl group. Consequently exo- 
cyclic elimination is preferred. 
In a study of 17a-methyl and 17a-ethyl-D-homo-17a- 
89 ols it was observed that dehydration of the a-ols occurred 
readily in the mass spectrometer to give intense M-18 ions 
whereas the a-ols were chemically dehydrated with phosphorus 
oxychloride at a faster rate. This can be explained by the 
fact that the more crowded molecular ion (that in which the 
• larger, alkyl substituent is ) is less stable and therefore 
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this epimer necessitates increased interaction between the 
C-17 and C-18 substituents prior to formation of the endo- 
cyclic double bond. Consequently the epimer in which the 
smaller (hydroxyl) substituent is closest to the C-18 methyl 
group is chemically dehydrated fastest, the ease of exocyclic 
elimination presumably being equal for both epimers. 
The dehydration of methandrostenolone[4] with 
phosphorus oxychloride in pyridine at room temperature was 
accompanied by much degradation, no A-ring protons being 
distinguishable in the n.m.r. spectrum of the product. 
However, this spectrum showed that exocyclic elimination to 
give the 17-methylene function [117] (75.38) was more favour-
able than endocyclic elimination to the 616_double bond [1181 
(14.75). The ratio of exo- to endocyclic elimination was 
estimated to be Ca. 6:1. 
A• mixture of 17-methyleneandrosta-1, 4-dien-3-one and 
17-methyleneandrost-4-en-3-one was prepared by the reaction 
of DDQ with the latter compound and then reacted with 
phosphorus oxychloride as described above. Once again, 
degradation occurred and, although the C-4 proton of the 
4-en-3-one (i4.27) was clearly visible in the n.rn.r. spectrum 
of the crude product the A-ring protons of the dienone could 
not be detected. Similarly, the infrared spectrum showed 
the loss of the cross-conjugated carbonyl function. Thus, 
although the nature of this degradation is unknown it is 
specific for the 614_dien_3_one function and, like the 
dienone-phenol rearrangement of the A-ring in sulphuric acid, 
does not take place with a A4-en-3--one. In view of the 
extensive degradation the dehydration of 17-epimethandrosten- 
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alone was not investigated under these conditions. 
3.13. iv. Acetylatian 
Ananchenko et al. 89 demonstrated a difference between 
the chemical reactivity of the C-17a epimeric 3-methoxy-17a--
methyl-D-homooestra-1, 3,5(10) ,8-tetraen--17a-.-bls by their 
reactions with acetic anhydride -in pyridine. After reaction 
at reflux temperature for 2 hours both epimers were partially 
converted to their acetates. However, after 6 hours the 
17.a-ol was dehydrated to the 17a-methylene compound whereas 
the 17aa-ol was converted to the acetate. 89 
When methandrostenolone was treated under the same 
acetylation conditions the n.m.r. spectra of the reaction 
products after times of 2 hours and 6 hours were the same. 
The 17-acetate was the major product with only a trace of 
dehydration to the 17-methylene compound (ca. 4%). Since 
methandrostenolone would be expected to dehydrate more 
readily under these conditions the reaction of 17-epimethan-
drostenolone was not examined. 
Since the product of the acetylation of methandrost-
enôlone under the conditions described above was a non-
crystalline, dark-coloured glass alternative methods of 
acetylation were examined. The lack of reactivity of steroid 
alcohols containing hindered functions, such as the secondary 
110-hydroxyl group and tertiary hydroxyl groups, to acety-
lation with acetic anhydride in pyridine at room temperature 
may be explained by the necessity for a termolecular tran- 
sition state. Oliveto et alJ85 found that the use of 



















Diagram 15. Proposed mechanism for the oxidation of 
secondary alcohols by dicyclohexylcarbodiiznide 
and dimethyl sulphoxide. 
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Diagram 16. Proposed mechanism for the dehydration of tertiary 
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acetylatioñ of the 11$-hydroxyl group caused dehydration. 
However, the position was readily acetylated185 at room 
temperature with an acetylating reagent in the presence of 
a strong acid catalyst, under which conditions the reactive 
acetylium species is formed. 1179 
When methandrostenolone was reacted with acetic 
anhydride in acetic acid with toluene-p-sulphonic acid 185 
as catalyst complete reaction occurred at room temperature. 
Although the n.m.r. spectrum of the product showed that 
there was no dehydration under these conditions, the i3.0-
3.5 region indicated that a small amount of A-ring rearrange- 
ment occurred. The major product was methandrostenolone 
acetate but, as before, it was not crystalline. 
The mass spectrum of this product showed the expected 
molecular ion of methandrostenolone acetate at m/e 342 and an 
intense ion at rn/c 282, arising from elimination of acetic 
acid. Ions at m/e 340 and rn/c 324 were not rationalisable 
in terms of this compound. However a low intensity ion at 
rn/c 384 indicated the formation of a small amount of a 
diacetate, probably 4,17a-dimethyloestra-1, 3, 5(10)-triene-1, 
17-diol diacetate [119]. The ions [120] atm/e 340 and 
rn/c 324 would then arise by elimination of CH3COH, probably 
from a cyclic conformation of the acetate, and of acetic 
acid, respectively, from this diacetate. 
3.13.v. Sulphoxide-carbodiimide oxidation 
The oxidation of secondary steroid alcohols to ketones 
has been accomplished with dicyclohexylcarbodiimide and di- 
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of secondary alcohols in the presence of tertiary alcohols 
has been achieved in some compounds but certain tertiary 
alcohols have been found to dehydrate very readily. 186b 
Moffatt observed 186b (unpublished experiments) that methyl- 
testosterone[51] was completely dehydrated almost instant-
aneously to a 3:2 mixture of the A'6- [121] and 17-methylene 
[122] compounds. He suggested that this dehydration in-
volved an intramolecular proton abstraction mechanism 
[diagram 16] similar to that proposed for the oxidation 
[diagram 15]  but with regeneration of dimethyl sulphoxide 
rather than formation of dimethyl sulphide. 186b 
Prior to examination of the reaction of methandrost-
enolone under these conditions the reaction of methyltesto- 
sterone was carried out. Precipitation of dicyclohexylurea 
was observed almost immediately after mixing of the reagents 
but t.1.c. of the product after 2 hours showed that not all 
the steroid had reacted. Slightly less than 50% of the 
product was eluted from an alumina column as a low polarity 
band. The n.m.r. spectrum of this fraction showed that the 
17-methylene [122] and A16_compounds [121] were present in a 
1:1 mixture which accounted for 70% of the total fraction. 
A third product was identified as 17,17-dimethyl--18-noran-
drosta_4,13(14)_dien-3-one[107][19.05, .9.04 (C-17,17dimethy), 
8.85 (c-19 methyl)]. Unreacted methyltestosterone was then 
recovered from the column. These results were confirmed by 
g.l.c., which showed three short retention time peaks in the 
low polarity fraction. 
Since Moffatt186b did not include the A13(1
4)  -17,17- 
dimethyl compound [107] among the products of the reaction 
of methyltestosterone the reaction 
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was repeated without dicyclohexylcarbodiimide and without 
dimethyl sulphoxide and dicyclohexylOarbodiimide. T.1.c. 
of the products of both reactions showed no spots other 
than that corresponding to methyltestosterone. Consequently, 
17,17-dimethyl--18-norandrosta-4,13(14)-dien--3-one must be a 
product of the dimethyl sulphoxide-dicyclohexylcarbodiimide 
reaction. 
When methandrostenolone[4] was reacted with dimethyl 
sulphoxide and dicyclohexylcarbodiimide for one, hour less 
.than 10% of the sample was converted to a mixture of the 
17-methylene [123]  and A16_compounds [124]. No 613(14 )-17, 
17-dimethyl compound [106] was detected. The reaction was 
repeated and t.l.c. after three hours showed that very little 
conversion had occurred but after sixty hours all the steroid 
had reacted. The product now contained a 1:1 mixture of the 
17-methylene [123]  and .A16_compounds  [124] and 20-30% 17,17- 
dimethyl-18-norandrosta-1, 4,13(14)-trien--3-one[106]. Under 
similar conditions 17-epimethandrostenolone[81] reacted com-
pletely within three hours to give a mixture containing the 
17-methylene £1231, A16- [124] and A13(14) -17,17-dimethyl 
[106] compounds in the ratio ca. 5:3:2. 
The reactions of methandrostenolone without dicyclohexyl-
carbodiimide and without dimethyl sulphoxide and dicyclohexyl-
carbodiimide were examined. T.1.c. of both products showed 
a very intense spot corresponding to methandrostenolone and 
a very faint low polarity spot which could not have accounted 
for the 20-30% formation of 17,17-dimethyl-18-norandrosta-1,4, 
13(14)-trien-3-one in the reaction with dicyclohexylcarbodi-
imide. 
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3.13. vi. PhdsphoruspentachlOPtde 
The products of the reactions of secondary 3-, 7- 
and 17- alcohols with phosphorus pentachloride are the 
epimeric ct-chloro compounds. 117h The reaction involves the 
formation of a colinear 0 ......0 ......Cl transition state 
and consequently alcohols, such as 2a- and 6a-hydroxy steroids 
react by an SNi  mechanism with retention of configuration 
because of the unfavourable interactions which would be 
involved in the formation of the SN2 transition state.117h 
The tertiary alcohol, 12a-hydroxy--12-methyltigogenin 
acetate has been treated with phosphorus pentachloride to 
give the 12-chloro-12-methyl derivativeJ87 Although the 
reaction appears to proceed by an S. 2 mechanism it has been 
reported that deliberate attempts to produce the C-12 
carbonium ion resulted in degradation of the steroid.117' 
When methandrostenolone was reacted with phosphorus 
pentachloride in ether 187 at room temperature for 48 hours 
extensive degradation occurred, indicated by the poorly 
resolved n.m.r. spectrum and loss of the carbonyl absorption 
in the infrared spectrum of the product. A similar reaction 
of methandrostenolone in chloroform 188 containing calcium 
carbonate for 1 hour at 0° gave predominantly unreacted 
steroid. The less polar 17,17_dimethyl-18-norandrOsta 1,  
4,13(14)-trien-3--one was also isolated but the mass spectra 
of both products showed no trace of a compound in which the 
17-hydroxyl group had been substituted by a chlorine atom. 
The failure of methandrostenolone to form a 17a-chloro-
17-methyl product by reaction with phosphorus pentachloride 
was probably due to steric hindrance which would prevent the 
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formation of a colinear 0. C ...... 01 transition state. 
3-13-vi-J . Conclusion 
The results described in this section showed that 
any reaction of methandrostenolone, such as that in sulphuric 
acid, in which a 0-17 carbonium ion was formed led to the 
17, l7_dimethyl_l8_nor_Al34)_ derivative by dehydration 
with 0-18 methyl migration. EpimerisatiOn could only 
proceed from the C-17 carbonium ion if this migration could 
be prevented. A reaction such as that of methandrostenolone 
with phosphorus pentachloride, in which a C-17 epimeric chloro 
compound might have been produced by a mechanism not involving 
a carbonium ion presumably did not proceed because of steric 
hindrance to the formation of the required transition state. 
Consequently the epimerisation of methandrostenolone by 
chemical means was impossible whereas it is feasible that an 
enzyme, by virtue of its stereochemistry, might block 0-18 
methyl migration and introduce a hydroxyl group from the 
a-side of the molecule thus forming 17_epimethandrostenolone. 
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3.14. Experimental section 
3.14.1. Reaction of methandrostenolone with 
sodium methoxide 
Sodium (ca. 200mg) was added to a solution of 
methandrostenolone (102.5mg) in methanol (50m1) and refluxed 
for 2 hours under nitrogen, during which time the colour of 
the solution darkened. Methanol was removed by evaporation 
in vacuo and the residue was dissolved in ether. The 
solution was washed with water until neutral, dried over an-
hydrous magnesium sulphate and evaporated to dryness to 
yield a brown glass (127.3mg); t.1.c. showed a spot with 
the same polarity and colour reaction as methandrostenolone 
• and faint traces of two more polar components; n.m.r. (100 
M Hz) 79.07 (0-18 methyl), 8.82 (C-20 fly), 8.75 (0-19 
methyl), 3.94 (d, 2 Hz, 4-H), 3.79 (d of d, J12 10 Hz, J24  
2 Hz, 2-H), 2.94 (d, 10 Hz, 1-ij identified the product as 
unchanged methandrostenolone. 
3.14.11. Reaction of methandrostenolone with sodium 
hydroxide in ethanol'89  
• A solution of methandrostenolone (105.7) in ethanol 
(30m1) containing 20% sodium hydroxide solution (2 drops) 
was refluxed for 2 hours. The ethanol was removed by 
evaporation in vacuo and the residue dissolved in ether, 
washed with water until neutral, dried over anhydrous mag-
nesium sulphate and evaporated to dryness to yield a brown 
glass (126.6mg). T.1.c. and n.m.r. spectroscopy (100 M Hz) 
indidated that the product was methandrostenolone; t9.07 
(C-lB methyl) 8.82 (C-20 8.76 tC-19 3.93 
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(d, 2 Hz, 4-H), 3.78 (d of d, J12 10 Hz, J24 2 Hz, 2-H), 
2.94 (d, 10 Hz, 1-H). 
3.14.iii. Reaction of methandrostenolone with aqueous sulphuric 
acid 
Methandrostenolone (46.8mg) and 20% aqueous sulphuric 
acid (loml) were heated at 100 o__  for -for 2 hours. When cool the 
aqueous phase was extracted twice with ether, the combined 
ether extracts were washed with saturated sodium bicarbonate 
solution and with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to give a brown glass 
(53.5mg), the major component of which was 17,l7-dimethy-
18-norandrosta-1, 4,13(14)-trien-.3-one; vmax1665cm,  nm.r. 
(100 M Hz) ¶9.08, 9.04 (C-17,17 dimethyl), 8.80 (c-19 methyl), 
3.87 (d, 2 Hz, 4-H), 3.72 (d of d, J12 10 Hz, J24 2 Hz, 2-H), 
2.84 (d, 10 Hz, 1-H); g.l.c., Retention time, 5.64 minutes 
(2350). 3-Hydroxy--1, 17,17-trimethyl-18-noroestra-1, 3,5(10), 
13(14)-tetraene and 1-hydroxy-4, 17, 17-trimethyl-18--noroestra-
1,3,5(10),13(14)-tetraene were also formed; n.m.r. ¶3.5-3.0 
(aromatic protons); g.l.c., Retention times, 13.36 and 
14.60minutes (235°). 
The crude product was chromatographed on alumina 
(lOg) to give 17,17-dimethyl-18-norandrosta-1, 4,13(14)-trien-
3-one as a low polarity glass; vmaxl665cm;  mws spectrum, 
m/e 282 (100%), m/e 267 (719/6), m/e 239 (3%) [see figure llb]. 
3.14. iv. Reaction 2L17-e  imethandrostenolone with aqueous 
sulphuric acid 
A suspension of 17-epimethandrostenolone (8.9mg) in 
0 204 aqueous sulphuric acid (2m1) was heated at 100 for 
1 
-I- 
2 hours. The product, a brown glass (12.2mg) was extracted 
as described in section 3.14.iii. T.l.c. showed that com-
plete reaction had occurred to give a low polarity product 
the n.m.r. spectrum of which was identical to that of the 
product of the corresponding reaction of methandrostenolone 
(section 3.14.iii). 
- 
3.14.v. Reaction of methyltestosterone with aqueous 
sulphuric acid 
Methyltestosterone (53.1mg)  and 20% aqueous sulphuric 
acid (10ml) were heated at 1000  for 13 hours and the product 
(52.1mg), a brown glass, was extracted as described in 
.section 3.14.iii. The major product (ca. 86%) was 17,17-di-
methyl-18-norandrosta-4,13(14)-dien-3-.one; t.1. c., low 
polarity; n.m.r. (100 M Hz) i9.06,  9.04 (C-17,17 dimeths), 
8.85 (C-19 methyl), 4.24 (4-H) with unreacted methyltesto-
sterone (ca. 14%); n.m.r. ¶9.09 (C-18 methyl), 8.79 (C-19 
methyl), 8.79 (C-20 methyl), 4.25 (4-H). 
3.14.vi. Reaction of methandrostenolone with sulphuric acid 
in acetic acid 
20%. Aqueous sulphuric acid (loml) was added to a 
solution of methandrostenolone (106.8mg) in glacial acetic 
acid (2m1). The light precipitation was dissolved by the 
addition of glacial acetic acid (6m1) and the solution was 
heated at 1000  whereupon a red precipitate formed and was not 
redissolved by the addition of further glacial acetic acid 
(5m1). After 2 hours the mixture was allowed to cool, 
extracted with ether and the ether solution neutralised 
with saturated sodium bicarbonate solution, washed with water, 
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dried over anhydrous magensium sulphate and evaporated to 
dryness. The product, a dark brown glass (110.6mg) con- 
tained no unreacted methandrostenolone. The major component 
was l-hydroxy-4, 17,17-trimethyl-18-noroestra-1, 3, 5(10),13(14)--
tetraene; n.m.r. (100 M Hz) c9.02, 8.99 (0-17,17 dimethyl), 
7.86 (C-4 methyl), 5.04 (broad, 1-OH), 3.48, 3.14 (d,d, 8 Hz, 
8 Hz, 2-H, 3-H) with some 3-hydroxy-1,17,17-trimethyl-18- 
noroestra-1,3,5(1O),13(14)-tetraene n.m.r., 73.5-3.0 (small 
peaks). 
3.14.vii. tenolone wi 
oxychloride' 
Freshly distilled phosphorus oxychioride (0.05m1) was 
added to a solution of methandrostenolone (112.5mg) in dry 
pyridine (2m1), whereupon fuming occurred and a yellow colour 
was generated. After 18 hours at room temperature the dark 
red solution was poured into a mixture of ice and water and 
the steroid extracted into chloroform, washed with water, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to yield a dark brown glass (80.7mg), which contained 
no carbonyl band in its infrared spectrum; n.m.r. (100 M Hz) 
¶5.38 (17 = OH2),4.75 (16-H), 6:1; further purification and 
characterisation was not undertaken because of the tar-like 
nature of the product, which had obviously suffered extensive 
degradation. 
3.14.viii. Synthesis of 17-methyleneandrosta-1,4-dien-3-one 
A solution of 17-methyleneandrost-4-en-3-one (49.4mg). 
and DDQ (42.6mg) in dioxane (12m1) was refluxed for 20 hours. 
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The dioxane was removed by evaporation in vacuo and the 
residue was dissolved in benzene, filtered through alumina 
(lg) and evaporated to dryness to yield the crude product 
(54.3mg) which was chromatographed on alumina (2g). Elution 
with benzene gave a mixture (31.7mg) containing equal amounts 
of the starting material and 17-methyleneandrosta--1,4-dien-
3-one; v max 1665cm; n.m.r. (60 M Hz) ¶9.18 (C-18 methyl), 
8.77 (C-19 methyl) Al 4_dien_3_one and ¶9.16 (C-18 methyl), 
8.80 (C-19 methyl) A4-en-3-one. 
3.14.ix. Reaction of 
with .phosphorus oxychlorid 
Phosphorus oxyctiloride (0.025m1) was added to a 
solution of the product of the previous reaction (30mg) in 
dry pyridine (lml). After 18 hours at room temperature the 
reaction mixture was poured into a mixture of ice and water 
and the steroids were extracted into chloroform, washed with 
water, dried over anhydrous magnesium sulphate and evaporated 
to dryness to yield a brown glass (27mg); \)max1675cm', no 
band at 1665cm;  n.m.r. (100 M Hz) T 5.36 (17 = CH2), 4.27 
(4-H), no protons in ¶2-3 region (614_dien_3_one). 
3.14.x. Acetylation of methandrostenolone 
a. Acetic anhydride and pyridine at reflux temperature for 
2 hours 89  
A solution of methandrostenolone (49.6mg) in pyridine 
(0.6m1) and acetic anhydride (0.6m1) was refluxed for 2 hours, 
cooled and poured into dilute acetic acid (1:4, 20m1). After 
30 minutes the steroid was extracted into chloroform, washed 
with saturated sodium bicarbonate solution and with water, 
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dried over anhydrous magnesium sulphate and evaporated to 
dryness to give a brown glass (55.6mg); vmaxl730, 65cm; 
n.m.r. (100 M Hz) ¶9.09 (0-18 methyl), 8.76 (0-19 methyl), 
8.62 (0-20 methyl), 8.03 (C0.0H3), 3.94 (a, 2Hz, 4-H), 3.79 
(d of d, J12 10 Hz, J24 2 Hz, 2-H), 2.95 (d, 10 Hz, 1-H). 
A signal at T5.37 showed that the product contained a trace 
of the 17-methylene compound arising from exocyclic de-
hydration (ca. 4%). 
Acetic anhydride and pyridine at reflux temperature for 
6 hours 89 
Methandrostenolone (53.5mg) was reacted by the pro- 
cedure described above, except that the reaction time was 
increased to 6 hours. The t.l.c., infrared and n.m.r, 
spectra of the product (57.1mg), a brown glass, were similar 
to those of the product of the 2 hour reaction. The amount 
of the 17-methylene compound (ca. 49/6) in the product had not 
increased after the longer reaction time. 
Acetic anhydride and toluene-p-sulphonic acid at room 
temperature 185 
Acetic anhydride (0.08m1) and toluene-p-sulphonic 
acid (4mg) were added to a solution of methandrostenolone 
(44.5mg) in acetic acid (0.4m1). After 7 hours t.l.c. 
indicated that all the methandrostenolone had reacted. 
Water was added and the steroid extracted into ether, neu-
tralised with saturated sodium bicarbonate solution, washed 
with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness to yield a brown glass (58.8mg). The 
infrared and n.m.r. spectra of the product were similar to 
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those of the preceding acetylation reactions except that 
no dehydration had occurred and there was a small amount 
of A-ring rearrangement ('r3..5-3.0, small peaks). The 
major product, methandrostenolone acetate was of low polarity 
compared to methandrostenolone and there was a trace of a 
less polar component. Mass spectrum, m/e 342 (M+,  12%), 
nile 282 (M-AcOH, 83%) methandrostenolone acetate; m/e 384 
(30/6), m/e 340 (15%), m/e 324 (17%) probably 4,17a-dimethyl--
oestra-1, 3, 5(lo)-triene-1,17-diol diacetate. 
3.14.xi. Reaction of methjltestosterone with dim 
sul-phoxide and dj21ohexylcarbodiimide 
Methyltestosterone (502mg) was dissolved in a mixture 
of dimethyl sulphoxide (6m1) and benzene (20m1) containing 
dicyclohexylcarbodiimide (1..02g). Pyridine-trifluoroacetic 
acid adduct (50mg)was added and the reaction vessel stoppered. 
After 2 hours ether and oxalic acid (0.541g) were added. 
When gas evolution had ceased water was added and the pre- 
cipitated dicyclohexylurea removed by filtration. The 
filtrate was washed with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to yield the product 
(0.579g) which contained unreacted methyltestosterone and 
a less polar band. The crude product was chromatographed 
on 5% deactivated alumina (17g) and a white crystalline 
material(234mg) was eluted with petrol-benzene (3:1 to 3:2). 
The n.m.r. spectrum (100 M Hz) showed that the fraction 
contained a 1:1 mixture of 17-methylene (T5.36) and A'6-
compounds (r4.74) which accounted for 70% of the sample. 
The methyl signals were assigned to 17,17-dimethyl-18- 
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norandrosta-4,13(14)-dien-3-one, ¶9.05, 9.04 (C-.17,17• 
8.85 (c-19 methyl); 17-methyleneandrost-4-en-3-one, ¶9.18 
(c-is methyl), 8.79 (c-19methyl) and 17-methylandrosta-4, 
16-dien-3-one, ¶9.22 (c-18 methyl), 8.79 (C-19 methyl), 
8.36 (c-.20 methyl). Unreacted methyitestosterone was 
eluted from the column with benzene. 
3.14.xii. n of metha th dimethvi- 
sulphoxide and di cyciohexylcarbodiimide 
Methandrostenolone (53.0mg) was dissolved in a 
mixture of benzene and dimethylsulphoxide (3:1, lml) 
containing dicyclo.hexylcarbodiimide (0.1g). Pyridine-tri--
fluoroacetic acid complex (5mg) was added and the reaction 
vessel was stoppered. After 1 hour at room temperature 
the reaction mixture was diluted with ether and oxalic acid 
(65.7mg) was added. The product (63.6mg) was isolated as 
described in the previous section and t.l.c. indicated that 
the major component was unreacted methandrostenolone. No 
other compounds were detectable in the n.m.r. spectrum of 
the crude product. Chromatography on 5% deactivated 
alumina (4g) and elution with petrol-benzene (3:2) gave a 
low polarity fraction (4mg); n.m.r. (100 M Hz) 'r5.37 (17 = 
cR2), 4.75 (16-H) 1:1 mixture, The methyl signals could 
not be assigned because of the low intensities due to the 
small sample size. 
The reaction was repeated fot 60 hours. T.l.c. of the 
reaction mixture after 3 hours showed that very little 
reaction had occurred whereas after 60 hours most of the 
methandrostenolone had reacted to give a low polarity band. 
140 
The product, a yellow glass, contained a 1:1 mixture of the 
17-ethy1ene (T5.36) and A16_compounds (i4.74), accounting 
for ca. 70% of the sample. The methyl signals in the n.m.r. 
(100 M Hz) spectrum of the product were assigned to 17,17-
dimethyl-18--norandrosta-1, 4,13(14)-trien-3-one, ¶9.07, 9.03 
• (0-17,17 dimethyl), 8.78 (0-19 methyl), 17-methyleneandrosta-
1,4-dien-3-one, ¶9.14 (0-18 methyl), 8.75 (C-19 methyl) and 
17-methylandrosta-J, 4, 16-trien--3-one, ¶9.19 (0-18 methyl), 
8.75 (0-19 methyl), 8.36 (0-20 methyl). G.1.c, indicated 
that the ratio of the 17,17-dimethyl-(5.56 minutes),17-methy- 
• lene-(7.04 minutes) and 17_methyl_A1E_(6.52 minutes) products 
was a. 0.4:1:1 (235°C). 
3.14.xiii. 17- with 
and lcarbodiimi 
17-Epimethandrostenolone (6.5mg) was dissolved in a 
mixture of benzene and dimethyl sulphoxide (3:1, 0.2m1) 
containing dicyclohexylcarbodiimide (20mg). Pyridine-tri-
fluoroacetic acid adduct (1mg) was added and the reaction 
vessel stoppered. After 3 hours, t.1.c. of the reaction 
mixture indicated that all the steroid had reacted. Ether 
and oxalic acid (11.8mg) were added and the product, a yellow 
glass (17.1mg) isolated as described in section 3.14.xi. 
The n.m.r. spectrum of the product was similar to that of 
the preceding reaction of methandrostenolone except that the 
ratio of 17-methylene- to A16- products was greater than 
unity. The ratio of 17,17-dimethyl-(5.72 minutes), 17-
methylene-(7.12 minutes) and 17_methyl_616_(6. 60 minutes) 
compounds was a. 2:5:3 from g.1.c. at235°C. 
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3.14.xiv. Reaction of methandrostenolone with phophorus 
pentachloride 
aJ88 Phosphorus pentachloride (ca. 100-200mg), which had 
been sublimed at 80-900 (ca. 0.04 mm Hg) was added to a 
solution of methandrostenolone (104.9mg) in chloroform 
(20m1) containing calcium carbonate (521.5mg) in a dry box. 
The solid reagents had been dried over phosphorus pentoxide 
in vacuo and the chloroform over molecular sieve. The 
flask was stoppered and removed from the dry atmosphere into 
an ice bath. Upon addition of the phosphorus pentachloride 
the chloroform solution became orange-coloured. After 1 
hour at 00 saturated sodium bicarbonate solution was added 
to the reaction mixture, which was then extracted with 
chloroform. The organic phase was washed repeatedly with 
base to neutralise the acid produced by slow hydrolysis of 
the excess reagent. - It was then washed with water, dried 
over anhydrous magnesium sulphate and evaporated to dryness 
to yield a dark rust-coloured glass (145.6mg). T.l.c. 
showed that the product contained two components, the major 
of the same polarity as methandrostenolone and the other of 
lower polarity. Preparative t.l.c. of the crude product 
gave two fractions; the least polar was identified as 17,17-
dimethyl-18-norandrosta-1, 4,13(14)-trien-3--one (16.1mg); 
n.m.r. (100 M Hz) t9.07, 9.03 (0-17,17 dimethyl), 8.78 (0-19 
methyl), 3.90 (d, 2 Hz, 4-H), 3.75 (d of d, J12 10 Hz, J24 2 
Hz, 2-H), 2.85 (d, 10 Hz, 1-H); mass spectrum, m/e 282 (65%), 
m/e 267 (29%), m/e 239 (6%) and the other as unreacted 
methandrostenolone (40.6mg), from its n.m.r. and mass spectra. 
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187 b. Freshly sublimed phosphorus pentachloride (ca. 100- 
200mg) was added to a solution of dry methandrostenolone 
(66.3mg) in sodium-dried ether (20m1) in a dry box. A 
yellow colour was generated when the reagent was added 
but after 1* hours at 00  it had not dissolved. The reaction 
was thus, 
 left at room temperature for 48 hours when a dark- 
coloured solution was obtained. Ether and water were added, 
the organic layer was washed with saturated sodium bi-
carbonate solution and with water, dried over anhydrous 
magnesium sulphate and evaporated to dryness to give a dark 
rust-coloured glass (94.7mg). T.1.c. indicated that the 
crude product contained three components of low polarity 
compared to methandrostenolone. The carbonyl function, 
cmax1665cm' was absent from the infrared spectrum and the 
n.m.r. spectrum showed that much degradation had occurred; 








3.15. Miscellaneous reactions 
3.15.i. The reactions of 17a,20- and 17p,20-epoxides with 
boron trifluoride 
17ct, 20-oxido-21.-norpregn-4-en-3-one[68] was synthes- 
ised during the preparation of 17-epimethandrostenolone 
(section 3.1,). In order to compare the reactions of 17a,20-
and 17,20-epoxides with boron trifluoride-etherate 17,20-
oxido-21-norpregn-5-en-3$-01[125] was prepared from dehydro-
epiandrosterone[48] by the method of Franzen and Driessen.19°  
The product of the epoxidation reaction appeared to be homo-
geneous by t.1.c. and its n.m.r. spectrum contained the 
expected two proton pair of doublets at ¶7.40. and 7.10 (J = 
6 Hz). However the mass spectrum at 1200  contained not Only 
the molecular ion of the epoxide (m/e 302, 100%) but also an 
intense ion at m/e 316 (75%). At higher temperatures, 140, 
160 and 1700 the intensity of the latter ion fell to 20, 7 
and 3% of the m/e 302 ion, respectively 
Dimethylsulphonium methylide does not usually react to 
generate cyclopropanes 2e whereas dimethyloxosulphoniun 
methylide has been shown to react with a,-unsaturated 
ketones to give cyclopropyl ketones. 2 Since the com-
ponent with M, m/e 316 could only be detected by mass 
spectrometry at 120° a small proportion of the A5-en-3-ol 
may however react with dimethylsulphonium methylide to 
form a 5,6-.cyclopropyl-17$.,20-ep0xide[126](M, m/e 316). 
The preparation of 17 , 20-oxido-21-norpregn-4-efl-3-one 
by the oppenauer oxidation of the 65-en-3-ol has been 



















spectrum of the product showed that degradation of the 
epoxide function had occurred. 
17 , 20-0xido-2l-norpregn-5-en-3-o1[125] was reacted 
with boron trifluoride-etherate in acetamide at ca 1000  for 
1 hours. The n.m.r. spectrum of the crude product con-
tained two pairs of doublets at76.70, 6•60AB 10 Hz) and 
at ¶5.83, 5.73 (JAB  11Hz), the former pair of which were 
assigned to the 0-20 methylene protons of 17a-hydroxymethyl-
l7-methy1-18-norandrosta-5,l3(l4)-dien-3--ol[l27] (cf. 17a-
hydroxymethyl-17-methyl-18-norandro sta-4f,13(14) -di en-3-one, 
described in section 3.16.ii., ¶6.70, 6.60, JAB  10 Hz,. -CH 2OH). 
Since the l7,20-epoxide. function[68] was shown to open under 
acid conditions to give a 17a-hydroxy-17-hydroxymethyl com-
pound [78] (section 3.1.v.), t6.43, 6.38, JAB  11 Hz, 
-CH 2OH the pair of doublets at 15.83, 5.73 were ascribed to 
the 0-20 methylene protons of 17ct-hydroxymethylandrost-5--ene- 
3,17-dio])92[128]. This compound [128] and the 17a-hydroxy-
methyl-17-methyl diol [127] were present in the crude product 
in approximately equal proportions as calculated from the 
n.m.r. spectrum. However crystallisation from acetone gave 
pure 17a-hydroxymethyl-17-methyl-18-nOrandrO.sta-5, 13(14)-dien-- 
3-ol[127], ¶6.70, 6.60, -CH 2OH. Reaction of the 17,20- 
epoxide [125] with boron trifluoride in benzene for 24 hours 
gave a red glass, the n.m.r. spectrum of which showed that 
considerable degradation had occurred although 17a-hydroxy- 
methy1_l7_rnethyl_l8_norandrosta-5,l3(l4)-dien-30l[l27],  
¶6.65 (small peak, -CH 2OH), 9.02 (0-17 methyl), 9.02 (0-19 
methyl) was probably present. Within five minutes of the 
l'+5 
addition of boron trifluoride the reaction solution had 
changed from colourless through deep orange and deep red 
to violet, accompanied by the deposition of black material. 
Consequently the products were not further investigated. 
Reaction of 17a, 2O-oxido-2l-noxregn-4-en-3-one[68] 
with boron trifluorode-etherate in acetamide under the 
conditions described above gave only 17cx-hydroxymethyl-. 
l7_methyl_l8_norandrosta_L,l3(l4)_dien_3_one[79]. The 
n.m.r. spectrum of the crude product showed no trace of 17w- 
hydroxy-17-hydroxymethylandrost-4-en-3-one[78]. When the 
reaction was carried out in benzene for 24 hours the n.m.r. 
spectrum of the crude product showed that degradation had 
occurred although the 17a-hydroxymethyl-17-methyl compound 
[791 was formed. The reaction mixture quickly changed 
from pale yellow to orange, rust red and black with depo- 
sition of material. The reaction was repeated in benzene 
for two minutes, when a yellow solution was obtained. The 
n.m.r. spectrum of the crude product showed only 17a-hydroxy--
methyl-17-methyl-ls--norandrosta-4,13(14)-dien-3-one[79], 
although t.l.c. indicated traces of several other components. 
Boron trifluoride is a Lewis acid and is thus able to 
react with a polar solvent to form a Lewis base accompanied 
by the generation of protons. Protonation of an epoxide 
leads to an electron deficient carbon centre which is readily 
attacked by an anion or solvent molecule with cleavage of 
the epoxide ring. The product of such a reaction is 
generally a trans diaxially substituted compound with the 




















Diagram 17. The possible products 
of cleavage of 17a, 










to the configuration of the epoxide. Attack by a nucleo-
phile, in this case OH, at the 17-position [a. in diagram 
17] of the 170,20-epoxide [125] would give the 17a-hydroxy-
17-hydroxymethyl product [129] whereas attack at 0-20 [b. in 
diagram 171 would lead to the epimeric product [128] in 
which the epoxide oxygen is pseudoequatorial. This latter 
is, indeed, the observed product, showing that the lack of 
steric hindrance to attack at 0-20 compared to 0-17, and the 
only pseudoequatorial nature of the epoxide oxygen in the 
product outweighs the requirement for diaxial ring cleavage. 
In the case of the 17a,20-epoxide [68] attack at 0-17 
[a', in diagram 17], presumably hindered by the 0-18 methyl 
group would give  1-hydroxy-17-hydroxyniethy1 product [130] 
whereas attack at 0-20 [b'. in diagram 17] would give the 
epimeric configuration [78] in which the epoxide oxygen forms 
a pseudoaxial hydroxyl grOup. This is the product formed by 
acid-catalysed cleavage of the 17a,20-epoxide (section 3.1.v), 
although in the boron trifluoride-catalysed reaction only 
17a-hydroxymêthyl-17-methyl-18-nOraIdrOsta-4, 13(14)-dien-3-
one[79] was formed. 
The formation of products with the 17m-hydroxymethyl- 
17-methyl-18-nor-613(14 systems [131] from both 17a,20-
[132] and 17,20-epoxides[133] in acetamide and particularly 
in benzene is not surprising since the tendency for migration 
of the 0-18 methyl group to 0-17 under conditions which tend 
to produce a positive centre at the 17-position has been 
discussed already (section 3.13). 
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3.15-ii. The reaction of 17a-hydrox-17-hydroxyrneth- 
androst-4-en--3-one with sulflc acid 
When a mixture of 17a-hydroxy-17-hydroxymethylandrost- 
4-en--3-one[78] and aqueous sulphuric acid was heated at 1000 
a red-green fluorescence was observed. N.m.r. spectro-
scopy showed that the major product after 2 hours was 17a-
hydroxymethyl-17-methyl-18--norandro sta-4,13(14) -di en- 3-one 
[79], t6.70, 6.60, -CH 2OH, accompanied by the unreacted 
17a-hy4roxy-17--hydroxymethyl compound. However t.1.c. of 
the crude product showed a complicated mixture of spots 
similar to that observed after the attempted epoxidation of 
17-methyleneandrost-4-en-3-one under excessively acid 
conditions, described in section 3.1.v. Consequently the 
fluorescence observed in the latter reaction was probably 
also due to the generation of 17a-hydroxymethyl-17--methyl-
18-norandrosta-4, 13(14)-dien-3-one. 
3.15-iii. The attempted preparation of 17a-phenyl-5a- 
androstane-, 17-diol 
The synthesis of 17a-phenyl-5a-androstane-3P,17-diol 
[134] was attempted so that the reactions of a tertiary 17$-
hydroxy-17-phenyl centre might be compared with those of the 
17$-hydroxy-17-methyl function of methandrostenolone 
(described in section 3.13). 
T.l.c. and n.m.r. spectroscopy of the crude product 
isolated after the reaction of a refluxing mixture of epi-
androsterone [135]  and phenylmagnesium bromide [136] in ether 
for 15 minutes indicated that little, if any, reaction had 
occurred. Consequently, the reaction was repeated with the 
use of tetrahydrofuran as the solvent for the steroid and 
the reaction time was extended to 17* hours. When the 
steroid solution was added dropwise to the brown ethereal 
solution of the Grignard reagent precipitation occurred, 
which dissolved on swirling. Considerable heat was 
evolved during mixing of the reagents. When all the steroid 
had been added a precipitate was formed which did not dissolve 
when the mixture was heated. Approximately half of the 
ether used for preparation of the phenylmagnesium bromide 
was removed by distillation and the mixture was then re- 
fluxed for 17* hours. 
The weight of the crude product, a viscous orange oil 
(3.059) obtained after destruction of magnesium complexes 
with ice-cold sulphuric acid was ca. 150% in excess of the 
theoretical yield (1.29g), assuming 100% formation of the 
desired product. Crystallisation gradually occurred but 
crystals could not be isolated by filtration and so the 
crude product was chromatographed on alumina. A mixture 
of two low polarity compounds was eluted with petrol and 
with benzene-petrol (1:1). T.l.c. of the mixture showed 
two spots, both of which were visible under ultraviolet 
light but only one, the minor, more polar component was 
visible, as a yellow spot, after sulphuric acid development. 
The n.m.r., infrared and mass spectra of this fraction enabled 
identification of the major component as diphenyl [1371. 
The more polar component of the previous fraction was 
obtained by further elution with benzene-petrol (1:1). The 






















aromatic absorptions and the n.m.r. spectrum showed that 
three types of protons were present in the ratio 1:1:10, 
the latter being aromatic protons. Mass spectrometry 
indicated that the molecular weight of the compound was 184 
and the only structure consistent with all the information 
was that of diphenylcarbinol [1341(lit.j9 m.p. 69°). The 
melting point of the fraction, 62.5-63.5°, was probably low 
because of contamination from diphenyl. 
Elution with benzene and then with ethanol gave a 
fraction containingseveral components, the major of which 
was obtained pure by crystallisation from acetone. This 
compound was visible under ultraviolet light and gave a 
bright orange spot (Rf 0.46) which was slightly less polar 
than epiandrosterone (Rf 0.41, purple spot). Its infrared 
spectrum indicated that it contained a hydroxyl group, vm,x 
3350cm together with a carbonyl function in a six-membered 
ring, \)  max  l72Ocm. 
The n.m.r. spectrum showed that the 
C-3 hydroxyl group was present, ¶6.40, 3a-H, and the presence 
of a series of small doublets between 'r7.75 and 7.00 suggested 
that the carbonyl group was in the U-ring (cf. similar 
absorptions in the n.m.r. spectra of epiandrosterone and 
androsterone). The n.m.r. spectrum also showed that the 
compound contained five aromatic protons. Mass spectrometry 
gave a molecular weight of 378, ten in excess of that of 
17a-phenyl-5a-androstane-3$ , 17-diol. The only structure 
which appeared to be consistent with all the data was that 
of D-homo-3 -hydroxy-17aS -methyl-17a-phenyl--18-norandrost- 
13(14)-en-17-one[139]. Also consistent with this structure 
were the formation of an acetate of molecular weight, 420, 
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and its complete lack of reaction with aqueous sulphuric 
acid, with a mixture of sulphuric and, acetic acids .and with 
dimethyl sulphoxide-dicyclohexylcarbodiimide under the 
conditions described in section 3.13. 
A very small fraction was finally removed from the 
column with ethanol. This fraction contained several 
components, only one of which was visible under ultraviolet 
light' and the n.m.r. spectrum indicated the presence of 
aromatic protons and the 3-hydroxyl group. The mass 
spectrum contained a very intense ion at m/e 292 (100%) and 
a small ion (3%) at m/e 368, the molecular weight of 17ct- 
:. phenyl-5a-androstane-3,17--diol[134]. Consequently it 
would appear that the desired product was present in this 
final fraction and the low intensity of its molecular ion 
in the mass spectrum may have been due to an intense frag-
mentation or, more probably, to masking by a minor, more 
volatile component of the mixture. 
The explanation for the formation of diphenylcarbinol 
[138] and D-homo-3-hydroxy-17a-methyl-l7a-pheny1-l8-nor-
androst_l3(lL)_en.-l7._one[139] among the products of the 
reaction of epiandrosterone [135] andphenylmagnesium 
bromide [136] is at present unknown. The origin of the 
additional carbon atom is obviously a key question; con-
sequently the purity of the bromobenzene used in the above: 
reaction and in a repeat reaction, in which the same product 
mixture was obtained, was ascertained by refractometry. 
Since the steroidal starting material was pure attention must 
focus on the solvents, sodium-dried ether and tetrahydrofuran, 
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which was refluxed over and distilled from lithium aluminium 
hydride. '2 Further experiments will be necessary to 
determine whether the tetrahydrofuran was the source of the 
extra carbon atom. 
A reaction' 7 which leads to •a product analogous 
to a compound which might be considered as a precursor of 
the D-hbmo-17a-methyl-17a-phenyl.-17-ketone[139] is the ID- 
homo rearrangement of a 17-hydroxy-20-ketone of the pregnane 
series [1/40]. Lewis acid-catalysed rearrangement of such 
a compound leads to a D-homo-17a-hydroxy-17a--methyl-17-
ketone[141]  and the alkaline-catalysed. reaction to the 17a- 
epimeric product [142]. By analogy, the rearrangement of 
a compound in which the 21-methyl group was replaced by a 
phenyl ring might lead to a D-homo-17a-hydroxy-17a-phényl-
ketone, the acid-catalysed dehydration of which might occur 
with migration of the C-lB methyl group to C-17a and 
formation of a A13(14)_double  bond. However the origin of 
any intermediate containing the additional carbon atom is 
unknown although it must surely be linked to the formation 
Of diphenylcarbinol. 
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3.16. Experimental section. 
3.16.i. l7 ,20-0xido-2l-noregn-5-en-3-ol[l25]190  
A solution of potassium t-butoxide (0.4g) in dimethyl 
sulphoxide (3m1) was added dropwise to a stirred, water-
cooled solution of 3$-hydroxyandrost75-en-17-one (500.3mg) 
and trimethylsulphonium iodide (474.8mg) in dimethyl 
sulphoxide (5m1)  under nitrogen. After 2* hours the flask 
was cooled during the slow addition of water, the steroid 
was extracted into ether, washed with water, dried over 
anhydrous magnesium sulphate and evaporated to dryness to 
yield white crystalline 17$,20-oxido-21-norpregn-5-en-3$-ol 
(478.8mg); m.p. 162-165° (lit., 
 191  172-1760); t.l.c., one 
spot, slightly less polar than the starting material; n.m.r. 
(ioo P4 Hz) i9.12 (C-18 methyl), 8.99 (C-19 methyl), 7.40, 
7.10 (d,d,6 Hz, 6 Hz, -ocH2), 6.48 (m, Wi 25 Hz, 3m-H), 
4.64 (6-H); mass spectrum, M, m/e 302 (160°c). 
3.16.ii. 17$, 20-0xido-2l-noregn-4-en-3-one191  
17$, 20-0xido-21-norpregn-5-en-3$-ol (146.9mg) was 
dissolved in toluene (12m1) and cyclohexanone (2m1). 
Toluene (2m1) was removed by distillation prior to the 
addition of aluminium isopropoxide (293.8mg)  in toluene 
(loml). The mixture was refluxed gently for 3 hours, water 
was added and steam distillation carried out with a Soxhlet 
extractor for 11 hours. The aqueous mixture in the reaction 
flask was extracted with chloroform, washed with very dilute 
hydrochloric acid, saturated sodium bicarbonate solution and 
with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness. The product, an oil, smelled strongly 
153 
of cyclohexanone. Prolonged evaporation in vacuo and with 
a stream of nitrogen produced crystals which were filtered 
and washed with acetone to give a product (39.0mg, ca. 25%); 
n.m.r. (100 M Hz) showed that the 65-en-3-01 system had 
been oxidised to the A4-en-3-one, 74.26(4-H) but that the 
epoxide function had been degraded; the doublets at T7.40, 
7.10 (6 Hz) were absent. 
3.16.iii. Reaction of 17,20-oxido--2l-norpregn-5--efrol 
with boron trifluoride 
A. In acetamide 
Melted acetamide (lOg) was dried over molecular sieve 
•and added to 17,20-oxido-21-norpregn--5-en-3$-ol (103.3mg). 
The mixture was warmed until a solution was obtained where-
upon redistilled boron trifluoride_etherate194  (0.04m1) was 
added and the mixture heated at ca. 100  for 11 hours. 
Water was added and the steroid extracted into ether, washed• 
with saturated sodium bicarbonate solution and with water, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to yield a crude product (122.7mg); n.m.r. (100 M Hz) 
¶6.70, 6.60 (d, d, JAB  10 Hz, -CH20H), 5.83, 5.73 (d, d, JAB  
11 Hz, -0H2 0H), containing approximately equal amounts of 
17-hydroxymethyl-17-methy1-18-norandro sta-5,13(14) -di en-
3-ol and 17a-hydroxymethylandrost-5-ene-3 ,17-diol,192  
respectively. Crystallisation from acetone gave pure 17ct- 
hydroxymethyl-17-methyl-18-norandrosta-5 , 13(14)-dien-3S-ol 
(18.5mg); m.p. 167-1690; t.l.c., •one spot; n.m.r. (100 MHz), 
T9.02 (C-19 methyl), 9.02 (C-20 methyl), 6.70, 6.60 (d, d, 
AB 10 Hz, -CH 2OH), 6.46 (m, 3a-H), 4.59 (6-H). 
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b. In benzene195  
Redistilled boron trifluoride-etherate194 (0.04m1) was 
added to a solution of 17,20-oxido-21-norpregn-5--en-3-o1 
(96.7mg) in anhydrous benzene (3m1). After 24 hours at 
room temperature ether was added. The solution was washed 
with sodium bicarbonate solution and with water, dried over 
anhydrous magnesium sulphate and evaporated to dryness to 
give a red glass (97.5mg). T.1,c. indicated that the 
product contained at least five components and the n.m.r. 
spectrum showed that much degradation had occurred. Peaks 
at 79.02 (c-19 9.02 (C-20 methyl), 6.65 (-CH2OH) 
showed that 17-hydroxymethyl-17-methyl-18-norandrosta-5,13 
(14)-dien--3-o1 was formed in the reaction. Because of the 
degradation which had occurred the product was not further 
studied. 
3.16.iv. Reaction of 17a, 20-oxido-21-norpregn-4-en-3-one 
with boron trifluoride 
In acetamide 
17a, 20-oxido-21-norpregn-4-en--3-one (96.3mg) was 
reacted with boron trifluoride-etherate194 (0.04m1) in 
acetamide (lOg) as described in section 3.16.iiia to give 
17a-hydroxymethyl-17-methyl-18-norandro sta-4, 13(14 )-dien-
3-one (100.7mg) as the major product, identified by its 
n.m.r. spectrum (100 N Hz); 79.03 (0-20 methyl), 8.86 (0-19 
methyl), 6.70, 6.60 (d, d, J AB 10 Hz, -CH 2OH), 4.26 (4-H). 
In benzene195  
17a, 20-Oxido-21-norpregn-4-en-3-one (98.6mg) was 
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reacted with boron trifluoride_etherate194 (0.04m1) in 
benzene (3m1) as described in section 3.16. fib. The 
product, a red glass (100.3mg), was a complicated mixture 
which contained 17a-hydroxymethyl-17-methyl-18-norandrosta-
4,13(14)-dien--3-one; n.m.r. (100 M Hz) T 6.70, 6.60 (d, d, 
JAB 10 Hz, -CH20H) and many products of degradation which 
were not further studied. 
The reaction was repeated, but allowed to proceed for 
a much shorter time. 17a,20-0xido-21-norpregn-4-en-3-one 
(143mg) was dissolved in dry benzene (14.3m1)  and boron 
trifluoride-etherate (2 drops) was added to the stirred 
solution. After 2 minutes the reaction mixture was poured 
into ether and water, the ether solution was washed with 
water, dried over anhydrous magnesium sulphate and evaporated 
to dryness to give a yellow glass (157.2mg). T.1.c. and 
n.m.r. spectroscopy (100 M Hz) showed that the major product 
was 17a-hydroxymethyl-17-methyl-18-norandrosta-4, 13(14)-dien-
3-one, t9.02 (C-20 methyl), 8.85 (0-19 methyl), 6.70, 6.60 
(d, d, J AB 10 Hz, -C;-H2  OH), 4.27 (4-H). 
3-16.v. Reaction of 17a-hydroxy-17-hydroxethylandrost-4- 
en-3-one with sulphuric acid 
A mixture of 17a-hydroxy-17-hydroxymethylandrost-4-en-
3-one (34.1mg, prepared in section 3.2.v) and 20% aqueous 
sulphuric acid (6m1) was heated at 100° for 2 hours. When 
cool, ether was added and the organic extract was washed 
with saturated sodium bicarbonate solution and with water, 
dried over anhydrous magnesium sulphate and evaporated to 
.dryness to give a red glass (43.1mg); t.l.c. showed a 
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complicated mixture; n.m.r. (100 M Hz) showed that the 
major product was 17a-hydroxymethyl-17-methyl-18-notandrosta-
4,13(14)-dien-3-one, 79.01 (C-20 methyl), 8.84 (C-19 methyl), 
6.70; 6.60 (d, d, J AB 10 Hz, -CH 2OH), 4.25 (4-H). 
3.16.vi. _Attempted synthesis of 17a-phenyl-5a-androstane-- 
• fi,17-diol 
A pbrtion of a mixture of bromobenzene (5.42g, 3,61m1) 
and ether (20m1) was added to dry magnesium turnings (0.839) 
in ether (5m1). A crystal of iodine was added and gentle 
heat supplied until turbidity was observed. The remainder 
of the bromobenzene solution was then slowly added and the 
mixture refluxed for 15 minutes. A solution of epiandros- 
terone (1.0039) in tetrahydrofuran (50m1) was added dropwise 
to the solution of Grignard reagent with swirling. A white 
precipitate which formed on addition of the steroid solution 
dissolved on mixing and considerable heat was generated 
during the process. During removal of ether (loml) by 
distillation of the brown solution precipitation occurred. 
The white precipitate and yellow liquid were stirred and 
refluxed for 17* hours. The reaction mixture was then 
poured into a mixture of ice, water and concentrated 
sulphuric acid (4m1). Ether was added and the aqueous layer 
reextracted with ether. The combined ether extracts were 
washed with saturated sodium bicarbonate solution and with 
water, dried over anhydrous magnesium sulphate and evaporated 
to dryness to give a viscous orange oil (3.05g). T.l.c. 
showed that the crude product contained at least six com- 
ponents. Gradual crystallisation occurred on standing 
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but crystals could not be obtained by filtration. Con- 
sequently the crude product was dissolved in benzene and 
chromatographed on 5% deactivated alumina (90g). 
Elution with petrol (60_800) and with benzene-petrol 
(1:1) gave a mixture (0.2g) containing two components of 
low polarity and low melting points (40.5-630). The major 
component of the fraction was identified as diphenyl from 
its infrared and n.m.r. spectra; Mass spectrum, M+, m/e 154. 
Continued elution with benzene-petrol (1:1) gave a 
single component (1.2g), identical with the more polar com-
ponent of the previous fraction and identified as diphenyl-
carbinol; m.p. 62.5_63.50 (lit.,193 690);  v max3650cm' 
and aromatic bands; n.m.r. (100 M Hz) T7.59 (s, 11-j, CH), 
4.23 (s, 1H, -CH), 2.69 (s, 10 H, ArH); red solution with 
concentrated sulphuric acid;193 Mass spectrum, M+,  m/e 184. 
Elution with benzene and then with ethanol gave 
material (0.88g) which was shown, by t.1.c., to contain a 
mixture of several components. Crystallisation of this 
fraction from acetone gave a single compound (93mg),  the 
only component of the crude fraction visible under ultra-
violet light; t.1.c., R  0.46 (cf. epiandrostercine, R  0.41); 
m.p. 175.5-177.5°; Vmai3350 2950,l72O,1635,l050,780,70Ocm; 
n.m.r. (ioo M Hz) t9.13 (C-19 methyl), 9.05 (C-17a methyl), 
7.75-7.00 (7 doublets, 2 H, C-16 H), 6.40 (m, 3a-H), 2.70-
2.40 (m, 5 H, At-H); Mass spectrum, P4k, m/e 378; calculated 
for C26H3402 378.255866, found 378.255759. This product 
was thus tentatively identified as D-horno-3 -hydroxy-l7a --
methyl-17a-phenyl-18-norandrost-13(14)-en-17-one which 
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structure was consistent with the data. 
The column was stripped by further elution with 
ethanol to give a mixture (0.08g) containing several polar 
components, one of which was visible under ultraviolet 
light; \max345O295O97lOcm 1; n.mr. (lOOM Hz) ¶9.2+ 
(C-la jfl), 9.18 (C-19 methyl), 6.38 (m, 3a-H), 2.68 
(Ar H); Mass spectrum, intense ion at m/e 292 (l00%) and 
ion at m/e 368 (3%,  M of 17ct-phenyl-5ct-androstane-3,17- 
diol). This fraction may therefore have contained 17ct-
phenyl-5a-androstane-3 , 17-diol. 
The major product of the above reaction, assumed to be 
D-homo-3p-hydroxy-l7a--methyl-l7a-phenyl-l8--norandrost-
13(14)-en-17-one was acetylated with acetic anhydride and 
pyridine at room temperature for 2* hours to give the 35-
acetate; m.p. 226-228°; \)max1730,1720cm1 ; n.m.r. (100 M Hz) 
• 79.12 (0-19 methyl), 9.06 (C-17a methyl), 8.00 (COCH3), 
5.33 (m, 3a-H), 2.70-2.40 (Ar H); Mass spectrum, M, m/e 420. 
HO, 














4.1. The synthesis of the 17a-methyl-5a-androstane-2,3,17- 
triols as standards for the metabolites of oxymetholone 
4.1.1. Following the administration of oxymetholone to 
normal men Adhikary32 isolated two major metabolites, both 
of which were more polar than the drug. High temperature 
catalytic reduction of all three compounds gave products 
with the same retention times as those obtained from 
steroids with. the 17-methylandrostane skeleton. Consequently 
it could not be determined whether the C-2 substituent in 
oxymetholone was removed during metabolism or retained in 
the metabolites and removed during carbon skeleton chromato-
graphy. 
Adhikary32 reported that the more polar of the two 
metabolites (0-1) was not reduced with potassium borohydride 
but that the less polar metabolite (0-2) was reduced to a 
product with the same polarity as 0-1. He thus suggested32  
that 0-2 might contain a 2-hydroxy-3-keto function [143,144] 
and 0-la 2,3-91ycol system [145-148]. Because of the polar 
nature of the metabolites of oxymetholone purification was 
difficult;32 consequently the synthesis of the six 17-hydroxy-
17-methyl-5a-androstanes containing the above substituents 
[143-148] was attempted to provide compounds for comparison 
with the metabolic extracts. 
4.1. ii. 17a-Methyl-5a-androst-2-en-17-ol 
The most convenient intermediate for the synthesis of 
the 2,3-dioxygenated compounds [143-148]  was 17a-methyl-5a-
androst-2--en-17-ol, which was prepared by a route starting 
from dehydroepiandrosterone. Hydrogenation of this 
compound with a palladium-charcoal catalyst by the method of 
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Pettit et al  196  gave 3-hydroxy-5a--androstan-17-one as the 
major product. Alumina chromatography of the crude 
reduction product gave a low polarity material (5.3%) 
which was identified as a mixture of 5a-androstan-17-one, 
T9.17 (C-19 methyl), 9.12 (C-18 methyl), (lit., 110 ¶9.19, 
9.14) with a small amount of 5-androstan-17-one, 79.05 
(C-19 methyl), 9.12 (C-18 methyl), (lit. ,110  79.05, 9.15). 
It has been reported  196  that hydrogenolysis (ca. 5%) of the 
C-3 function generally accompanies catalytic reduction of 
65-en-3-ols. 
35-Hydroxy-5a-androstan-17-bne tosylate was prepared 
by the standard procedure  112c and adsorbed onto alumina in 
an attempt to obtain the A2-ene. Although the synthesis of 
5a-cholest--2-ene in 70% yield by the reaction of the 3-
tosylate on alumina has been reported,197 under similar 
conditions 5a-androst-2-en-17-one was obtained in only 6.5% 
yield. Iriarte et al 198  have, however, examined the 
reaction of 35-hydroxy-5a-androstan-17-one tosylate with 
sodium acetate in acetic anhydride and acetic acid as a 
means of preparing 3a-hydroxy-5a-androstan-17-one and 
obtained 5a-androst-2-en-17-one in 54% yield together with 
3a-hydroxy-5a-androstan-17-one acetate (39%). Consequently, 
5a-androst-2-en-17-one was prepared by this method and 
reacted with a ten-fold excess of methylmagnesium iodide 
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1t.1. iii. 17a.-Methyl--5a-androstane-2a,3a, 17-, 2ci, 3 ,17-, 
2 , 3a, 17- and 2 , , 17-trio1[145-14]. 
Procedures for the stereospecific synthesis of the four 
steroid 2,3-glycols were devised many years ago and are well 
established. In 1957, Henbest and Smith 200 prepared the 
four cholestane-2,3-diols, the 2a,3a-, 2,3- and 2a,3 -
isomers for the first time, by methods similar to those used 
for the synthesis of corresponding dials in the sapogenin 
series. The configurations in the cholestanes were assigned 
• by analogy with the sapogenin series. 
• Marker and Plambeck201 prepared the 2,3a-dio1 in the 
cholestane series by the action of hydrogen peroxide on the 
t2-ene. During the synthesis of a variety of 2,3-oxygen- 
ated-17ct--methyl--5ct-androstan-17--ols Klimstra 
202 prepared 
17a-methyl-5a-androstane-2 , 3a, 17-triol 2-acetate[149] by 
the acetic acid cleavage of the 2ct,3a-epoxidell1501 obtained 
from the 2-ene[151]. Consequently 17a-methyl-5a-androstane- 
28,3a,17-triol[147] was prepared by hydrolysis of the 2-
acetate[149] obtained by the above route. 
17a-Methyl-5a-androstane--2 , 3 , 17-triol[l48] was 
prepared by the reaction of iodine and silver acetate with 
17a_methyl-5a-androst-2-en-17-o1[151]. The reagents serve 
as a source of positive iodine which reactsfl7k 203 with the 
olefin [151] to form the 2a,3a-iodinium ion [152]. This 
species is attacked by the acetate ion to form an iodo-
acetate [153] which is converted to the 2,3-acetonium 
bridged ion [154]  by Ag-catalysed loss of the iodide ion 
in anhydrous acetic acid. The addition of water to the 
acetonium ion [154] leads to rapid formation of the two mono- 
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acetates of the 28.38-diol [155.1561 which are then hvdro1vse 7k 
to the free glycol [147]. 
17a-Methyl-5a-androstane--2a, 3 , 17-triol[146] was 
prepared by epimerisation of the axial 28-hydroxyl group 
in the corresponding 2,3-g1ycoi[148] to the more stable 
equatorial position with sodium in ethanol.  200  The 
reaction1171'200 of 17a-methyl-5a-androst-2-en-17-ol[151] 
with osmic acid was used for the preparation of the cis 
2a,3a-glycôl [145]. 
The n.m.r. spectra of the four triols [145-148] were 
obtained in deuteriochioroform solutions although their 
solubility was poor, so that the C-lB and C-19 methyl 
positions could be compared with the theoretical values 
computed from tables of substituent shifts 110,204a  [table 111. 
The agreement between the theoretical and observed positions 
was good except for the 2 ,38-glycol. Other characteristics 
of the compounds are described in section 4.3. 
4.1.iv. 28 ,17$-Dihydroxy-17-methyl-5a--androstan-3-one 
2-acetate 
K1imstra292 prepared 28 , 178 -dihydroxy-17-methyl-5a- 
androstan-3-one 2-acetate by chromic acid oxidation of the 
28-acetoxy-3ar-ol. This reaction was carried out a number 
of times in an attempt to prepare the 2-hydroxy-3-ketone by 
hydrolysis of the 2-acetoxy-3-one but in each case the 
product of the oxidation reaction was an intractable gum. 
In the light of results described in section 4.3 attempts to 
prepare this compound were not continued. 
T (cnc13) 2a;  3a 2m, 30 2, 3m 2, 3 
19-H 18-H 19-H 18-H 19-H 18-H 19-H 18-H 
5a, 14a- 110 9.22 9.31 9.22 9.31 9.22 9.31 9.22 9.31 
170_OH,17_Me2o4a -0.01 -0.15 -0.01 -0.15 -0.01 -0.15 -0.01 -0.15 
2a-0H °  -0.02 0.00 -0.02 0.00 - - - - 
2-0H 0  - - - - -0.26 -0.01 -0.26 -0.01 
3a-0H11°  0.00 -0.01 - - 0.00 -0.01 - - 
3-0H'1°  - - -0.03 -0.01 - - -0.03 -0.01 
Calculated 9.19 9.15 9.16 9.15 8.95 9.14 8.92 9.14 
Found 9.19 9.17 9.17 9.17 8.97 9.14 9.00 9.18 
Table 11. The theoretical and observed t values of the C-18 and C-19 methyl resonances 




4.2. Experimental Section. 
4.2.1. Tdroxy_5a_androstan_17_one196  
10% Palladium on charcoal (2.309)  and 72% perchloric 
•
acid (0.2m1) were added to a solution of 3-hydroxyandrost 
5-en-17-one (20g) in absolute ethanol (250m1) and hydro-
genated. . The reaction was continued for 4 hours although 
90% of the hydrogen was consumed within the first hour. 
The solution was filtered through a layer of Celite and the 
filtrate was concentrated to dryness in vacuo. The residue 
was dissolved in chloroform, washed with water, saturated 
sodium bicarbonate solution and with water again, dried over 
anhydrous magnesium sulphate and evaporated to dryness -to 
give a product (19.01g)  containing two components. The 
major component was of similar polarity to the starting 
material and the other of lower polarity. The product was 
chromatographed on alumina (3509) and the low polarity 
fraction (1.519, 5.39/6) éluted with benzene. and with benzene-
chldroform (4:1); , n.m.r. (60 M Hz) 79.17 (C-19 methj), 9.12 
(C-18 methyl), 5a-drostan-17-one (lit.,  110 t9.19, 9.14); 
and 79.12 (C-la methyl), 9.05 (C-19 methyl), 5-androstan- 
1.7-one (lit.,110 79.15, 9.05). The polar product (15.21g) 
was eluted with chloroform and crystallised from chloroform-
hexane (1:2) to give pure 3-hydroxy-5.a-androstan-17-one 
(14.7g, 73%); m.p. 173-174.50 (lit., 196 176-177.50); v max 
3450,2930,1730,1380,1045cm 1; n.m.r. (100 MHz) 79.17 (C-19 
methyl), 9.15 (c-is niethyl), 6.41 (sp, 10,10,5,5 Hz, 3a-H). 
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4.2. ii. ellxroxy_5a_androstan-17-one_tosyiatefl2C  
A solution of freshly purified toluene-p-sulphonyl 
chloride  112c  (20g) in dry pyridine (looml) at 0 was added 
to a solution of 3$-hydroxy--5a--androstan-17--one (14.7g) in 
pyridine (200m1) also at 0°. The mixture was maintained 
at 00  for 48 hours when the solution was a deep red-orange 
colour, indicative of formation of the derivative. 112c 
The solution was poured into an ice-water mixture and stirred 
until all the ice had melted. The precipitated tosylate was 
recovered by filtration, washed with very dilute hydrochloric 
acid and with water and dried in vacuo to give 3-hycIroxy-5ct-
androstan-17--one tosylate (20.719, 92%); t.l.c., one spot of 
low polarity in comparison to the free alcohol; m.p. 160-161
0  
(lit. 198 163-164°); Vmax292017355  1380,1195,1180cm'; 
n.m.r. (60 M Hz) 79.21 (C-19 methyl), 9.18 (0-18 
7.57 (Ar-CH3), 5.56 (m, 3a-H), 2.71, 2.23 (d, d, 8.4, 8.4 
Hz, 4H, Ar-H). 
4.2.iii. 5a-Androst-2-en-17-one 
a. Reaction of 3$_hydroxy_5a-an4p nos late 
3-Hydroxy-5a-androstan-17-one tosylate (5-93g) was 
dissolved in ñ small volume of benzene and adsorbed onto 
a column of alumina (200g). After 36 hours the column was 
eluted with benzene to give 5a-androst-2-en-17-one (0.39g, 
6.5%); vmax3000,1735,1655675cm' n.m.r. (60 M Hz) T9.23 
(0-19 methyl), 9.14 (C-18 methyl)., 4.40 (d, 1.2 Hz, 2-H, 3-H). 
Elution with ethanol gave a compound (4.879, 82%); max450' 
1735,1380,1045,1035,1020cm1; n.m.r. (60 M Hz) 19.17 (C-19 
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methyl), 9.15 (c-is methyl), 6.41 (m, 3a-H) which was 
thus identified as 3-hydroxy-5a--androstan-17-one rather 
than the 3a-hydrwqr epimer(lit., 0 3-H, ¶5.9-6.0). 
b. stan-17- 
sodium 
A solution of 3-hydroxy--5a-androstan-17-one tosylate 
(19.52g) and anhydrous sodium acetate (19.52g) in glacial 
acetic acid (173.6m1) and acetic anhydride (17.36m1) was 
refluxed for 5 hours. chloroform and water were added, 
the layers were separated and the aqueous layer reextracted 
with chloroform.. The combined organic layers were washed 
with saturated sodium bicarbonate solution and with water, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness. The residue was chromatographed on silica gel 
(750g) and elution with benzene (41) gave 5a-androst--2-en-17-- 
one (E.919, 57%) as crystalline plates; m.p. 99-100.5 (lit}?8  
105-1060); vmax3000,l735,l655,675cm'; n.m.r. (60 M Hz) 
¶9.24 (c-19 methyl), 9.15 (c-18 methyl), 4.41 (d, 1.2 Hz, 2-H, 
3-H). Elution with benzene-ether (2:1,11)gave 3a-hydroxy-
5a-androstan-17--one acetate (5.77g, 39%); m.p. 163-1640  
(lit. ,198 164-1650); max1735cm n.m.r. (60 M Hz) ¶9.19 
(C-19 methyl), 9.15 (c-ls methyl), 7.96 (c0cH3), 4.99 (m, 
4. 2.iv. 17a-Methyl-5a-androst-2-en-17-01[1511 
A solution of methyl iodide (34.1g, 15m1)  in dry 
ether (120ml) was added to magnesium turnings (5.76g)  in 
ether (40m1) and refluxed for 15 minutes to give methyl- 
magnesium iodide. A solution of 5ar-androst-2-en-17-one 
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(6.539) in ether (200 ml) was added dropwise to the cooled 
Grignard reagent and refluxed for 15 minutes. It was then 
poured into a mixture of ice, concentrated sulphuric acid 
and water and stirred until the ice had melted. The 
layers were separated, the aqueous layer extracted with 
ether and the combined organic extracts washed with dilute 
hydrochloric acid, sodium metabisulphite solution and with 
water until neutral, dried over anhydrous magnesium sulphate 
and evaporated to dryness to give a yellow glass (6.8359) 
which was chromatographed on alumina (240g). iJnreacted 
5a-androst-2-en-17-one (2.52g) was eluted with benzene and 
identified by its n.m.r. and infrared spectra. Elution 
with benzene-chloroform (1:1) gave 17a-methyl-5a-androst--2-
en-17-01 (4.22g, 61%); m.p. 144-1460 (lit.,199 147°); 
n.m.r. (100 M Hz) ¶9.23 (C-19 methyl), 9.15 (C-18 thy) 
8.80 (C-20 methyl), 4.42 (d, 2 Hz, 2-H, 3-H). 
4.2.v. 2a, 3a_Oxido_17a_methyl_5a-androstan-17-Ol[150]205  
A solution of m-chloroperbenzoic acid (1.461g) in 
ether (40m1) was added to a solution of 17a-methyl-5a-andrOst- 
2-en-17-01 (0.992g) in ether (lOoml). After 48 hours at 
room temperature the excess peracid was destroyed with 
sodium sulphite solution and ether was added. The organic 
phase was .washed twice with sodium bicarbonate solution and 
then with water, dried over anhydrous magnesium sulphate and 
evaporated to dryness. Crystallisation from methanol gave 
2a, 3a-..oxido-17ct-methr1-5a-androstan-l7-ol (0. 635g, 60%) 
as needles; m.p. 197-2000 (lit., 
 202  205-2070); n.m.r. (100 
N Hz) ¶9.24 (c-19 methyl), 9.17 (C-iS methyl), 8.81 (C-20 
methyl), 6.85 (2-H, 3-H). 
4.2.vi, 17a-Methy1-5a-androstane-2 , 3a,17-triol 2-acetate 
[l49J202  
2a, 3a-oxido-17a-methyl-5a-andr05tat117 01 (0.4g) was 
dissolved in glacial acetic acid (8m1) and heated at 100°  
for 6 hours. When cool, ether and water were added, the 
ether extract was washed with saturated sodium bicarbonate 
solution and with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to give 17ct-methyl-5a--
androStane-2,3,17-ttiol 2-acetate; n.m:.r. (60 P4 Hz) ¶9.15 
(C-18.  methyl), 9.07 (C-19 methyl), 8.79 (C-20methyl), 7.96 
(C0CH3), 6.13 (m, 3-H), 5.10 (m, 2a-H);\)maxl7locm
1 
. 
The product was partially purified by alumina chromatography. 
4. 2.vii. 17a-Mejyl-5a-añdrostane-2 , 3a,17-tri01L1471 
The product of the previous reaction, eluted from 
alumina with benzene-ethanol (19:1) was dissolved in 
methanol (lml) with potassium hydroxide (0.159). After 4 
hours at room temperature the methanol was removed by 
evaporation in vacuo and the residue was dissolved in ether. 
The solution was washed with dilute hydrochloric acid, 
sodium bicarbonate solution and with water, dried over 
anhydrous magnesium sulphate and evaporated to dryness to 
give a crude product; m.p. 200-207°. Crystallisation from 
acetone gave 17a-methyl-5a-androstane--2$ , 3a,17-triol (0.159); 
m.p. 217-218°; n.m.x. (50 M Hz) i9.14 (C-18 methyl), 8.97 
(c-ig methyl), 8.78 (C-20 methyl), 6.33 (m, 3$-H), 6.12 (m, 
2a-H); Mass spectrum, M, m/e 322; calculated for 
C20H3403 322.250781, found 322.249746. 
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4.2.viii. 17a-Methyl-5a-androstane-2$ 2 3 , 17-triol[148]20° 
Freshly prepared silver acetate (0.77g) and iodine 
(0.49g) were added to a stirred solution of 17a-methyl-5a-
androst-2-en-17-ol (0.59) in glacial acetic acid (looml). 
When all the iodine had dissolved water (1 drop) was •added 
and the mixture was stirred at 950  for 20 hours. Sodium 
chloride (lg) in water (iml) was added to the cooled mixture 
which was then filtered and the filtrate evaporated to 
dryness. The residue was hydrolysed with potassium 
hydroxide (1.59) in methanol (75m1) at room temperature 
for 12 hours. The methanol was removed by evaporation 
in vacuo and the residue dissolved in chloroform, washed 
with water until neutral, dried over anhydrous magnesium 
sulphate and evaporated to dryness. The crude product was 
dissolved in benzene and chromatographed On alumina. Material 
of relatively low polarity, eluted with ether-methanol (49:1) 
was discarded. Elution with ether-methanol (1:1) gave 17a-
methyl-5a-androstane-2 , 3 , 17-triol (0.379) which was 
crystallised from methanol to give needles; m.p. 201-202°; 
n.m.r. (60 M Hz) i9.18(C-18 methyl), 9.00 (C-19 methyl), 
8.82 (C-20 methyl), 6.37 (m, 3a-H), 5.99 (m, 2a-H); Mass 
spectrum, M, m/e 322; calculated for C20H3403 322.250781, 
found 322.250656. 
4. 2.ix. 17a-Methyl-5a-androstane-2a, 3,17-triol[14j200  
17a-Methyl-5a-androstane-2$ , 3 ,17-triol (50mg) was 
dissolved in ethanol (6m1) containing sodium (ca. 200mg) and 
refluxed for 5 hours. The ethanol was removed and the 
residue dissolved in ether, washed with sodium bicarbonate 
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solution and with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to give 17a-methyl-5a--
androstane-2a,3,17-triol which was crystallised from 
acetone; m.p. 190-192; n.m.r. (60MHz) t9.17 (C-19 
methyl), 9.17 (C-18 methyl), 8.81 (C-20 metyfl, 6.54 (m, 
3c.-H), 6.04 (m, 2-H), Mass spectrum, M 
+
, m/e 322; calculated 
for C20H3403 322.250781, found 322.249306; 17a7methyl-5a-
androstane-2a,3,17-triol 2,3-acetonide, M, m/e 362; 
calculated for C23H3803 362.282079, found 362.282610; 14-15, 
m/e 347, calculated for C22H3503 347.258605, found 347.258286. 
4.2.x. 17a-Methyl-5a-androstane-2a, 3a,17-trioi[145]202  
A solution of 17a-methyl-5-androst-2-en-17-01 (0.59) 
in dry benzene (15m1) was added to a solution of osmic acid 
(0.59) in pyridine (25m1). After 5 days at room temperature 
the mixture was saturated with hydrogen sulphide, the 
solvents were removed by evaporation in vacuo and the 
residue was dissolved in benzene. The solution was 
filtered twice through Celite and the filtrate evaporated to 
dryness. Crystallisation from methanol gave 17a-methyl-5a-
androstane-2a,3a,17-triol; m.p. 197-199°; n.m.r. (100 M Hz) 
T9.19 (C-19 methyl), 9.17 (C-18 methyl), 8.81 (C-20 methyl), 
6.27 (m, 2-H), 6.06 (m, 3-11); Mass spectrum, M, m/e 322; 
calculated for C20H3403 322.250781, found 322.250342. 
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Figure 13. The mass spectra of a) 17a-niethyl-5a--androstafle-2a,3a,17-tri6l and b) 17a-methyl-5a--
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Figure 13. The mass spectra of c) 17a-methyl-5a-androstane-2$,3a,17-triol and d) 17a-methyl-5a-
androstane-2$ , 3 ,17-triol. 
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4.3. The comparison of the 17a-methyl-5a-androstane-2,3, 
17-triols with the metabolites of oxymetholone. 
The four 17a-methyl--5a-androstane-2,3,17-triols were 
examined by t.l.c. in benzene-ethanol (9:1) and chloroform- 
methanol (9:1) solvent systems. When the plates were 
developed with sulphuric acid and heated the compounds gave 
yellow-brown spots of slightly differing polarities. The 
R  values of the 2a,3a-, 2a,30-, 2,3a- and 2,3 - compounds 
relative to that of oxymetholone expressed as 1.00 were 
0.54, 0.41, 0.39 and 0.59 in the former solvent system and 
0.70, 0.63,0-54 and 0.68 in the latter.. All were con-
siderably more polar than oxymetholone although the 2a,3-
glycol appeared to contain a trace of material (relative R  
1.07) of lower polarity than oxymetholone; this was not 
present in any of. .the other compounds. Comparison of the R  
values of the four triols and a sample of the more polar 
metabolite of oxymetholone showed that the metabolite 
(relative R  0.46 in CHC13-MeOH) was more polar than any of 
the standard triols. Since a 2,3-glycol is expected to be 
more polar than the corresponding 2-hydroxy-3-ketone doubt 
was thus cast upon the suggested32 identities of 0-1 and 0-2. 
The mass spectra of the four synthetic triols [figures 
13a, 13b, 13c, 13d] were compared prior to examination of the. 
spectra of metabolic samples. The 2a,3ct-, 20,3a- and 2,3 - 
glycols [see figures 13a, 13c, 13d] gave the correct molecular 
ion for a 17a-methyl-5a-androstane-2,3,17-triOl, at m/e 322. 
The most intense ions in the spectra of these epimers were 
those at low m/e values; in the high mass range each . 
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Figure 14. The relative intensities of characteristic ions 
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Diagram 18. Mass spectral fragmentations of 17a-methyl-5a-
androstane-2, 3, 17-triols 
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values but of different intensities relative to one another 
[figure 14]. Metastable ions were available to show that 
these ions arose from loss of a methyl group We 307) and. 
of water (m/e 304) from M+,  loss of water from m/e 307 
We 289) and of a methyl group from m/e 304 (m/e 289) and 
of water from m/e 289 (m/e 271). An alternative fragment- 
ation involved loss of an uncharged species of mass 58 from 
M to give m/e 264 (D-ring fragmentation) which fragment 
then lost either water (m/e 246) or a methyl group (m/e 249) 
[Diagram 18]. The patterns of the relative intensities of 
these seven ions and M+, shown in figure 14, were different 
for each epimer. The stability of the molecular ion of 
each triol, as reflected by its intensity was unexpected in 
view of the relatively low intensities of the molecular ions 
of methandrostenolone and its 17-epimer. This difference 
can, however, be explained by the lack of any system to 
promote ring fragmentation in the saturated androstanetriols 
in contrast to the intense B-ring fragmentation caused by an 
A-ring dienone system. 
The mass spectrum of a sample of 17ct-methyl-5a-andro-
stane-2a,317-triol [figure 13b] differed from those of 
the other three triols. Maximum ion pressure was obtained 
from the sample at 105-140 in contrast to 170-1800  for the 
latter compounds and the intensities of all ions in the high 
mass region were less than 10% of a very intense peak at 
m/e 347. The molecular ion of the triol .(m/e 322, 3.5%) 
was present at 105 and, at 140
0, the intensity of this ion 
relative to m/e 347 had risen to 11.5%; the ions at m/e 307 












and m/e 304, characteristic of the other three triols were 
also detectable at this temperature. The spectra of the 
2a,3,17-triol were rationalised when a very low intensity 
ion (ca. 1% of m/e 347 at 1050) at m/e 362 was taken into 
account. This showed that spontaneous formation of the 
acetonide [157] of the diequatorial glycol system of 17a-
methyl-5a-androstane-2a, 3 , 17-triol[146] had occurred during 
crystallisation from acetone. Loss of a methyl group from 
the acetonide (Mt, m/e 362) thus gave rise to the very 
intense ion at m/e 347 [158]. Exact mass measurement of 
the ions at m/e 362 and m/e 347 gave values in error of 
less than 0.1 p.p.m. and 1 p.p.m. for the 023113803  and 
022113503 structures, respectively. 
A sample of the 2a,3-glycol which had been re-
crystallised from acetone was dissolved in ethanol and water, 
heated and benzene was added. The solvents were removed by 
evaporation in vacuo, benzene was added and the evaporation 
repeated. The resulting material was examined by mass 
spectrometry at 1400  and four spectra were recorded at 
intervals of one minute between each. The relative in- 
tensities of the M-15 ion of the acetonide We 347) and 
of the triol (m/e 322) reversed during the time in which the 
spectra were recorded [see table 12], showing that the 
greater volatility of the acetonide was responsible for the 
lack of evidence of the triol in the spectrum obtained at 
1050. Thus, as confirmed by t.l.c. and n.m.r. spectroscopy, 
the original sample of the triol contained only a small 
amount of the volatile acetonide derivative which masked the 
presence of the free triol. 











































































Figure 15. Mass spectra of samples of the less 
polar metabolite of oxymetholone (c and d) 
and of the more polar metabolite (e). 
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Spectrum Time (mins.) m/e 347 m/e 322 m e322 
me 37 
1 0 21 4 0.19 
2 1 10 5 0.50 
3 2 5.5 6.5 1.18 
4 3 7.5 3.75 
Table 12. Variations in the intensities of the ions at 
We 34 andme 322 in mass spectra of 17ct-
methyj-5a-androstane-2a,3 ,17-triol with time. 
Metabolic samples were obtained by thin layer and 
paper chromatography of urine extracts following the 
administration of 10mg doses of oxymetholone. Carbon 
skeleton chromatography was used to locate those fractions 
containing material with a 17a-methylandrostane skeleton 
and each metabolic sample was thought to contain only one 
of the two previously located32 metabolites. Five such 
samples were examined by mass spectrometry and all gave 
spectra indicative of impure mixtures [figures 15a, 15b, 
15c, 15d, 15e]. Many intense ions were present in each 
spectrum up to ca. m/e 306 but beyond this mass value those 
ions which might characterise metabolites of oxymetholone 
were of low intensity. However, the only region of the 
spectrum which could be used for characterisation of the 
metabolites was that above m/e 306 because the metabolites 
of oxymetholone, being presumably fully ring-saturated like 
the drug, were not expected to produce any characteristic 
• medium mass ions of high intensity, such as the m/e 122, 
m/e 121 pair given by methandrostenolone and its metabolites. 
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None of the samples of metabolites gave ions at 
m/e 322 which might have indicated a 2,3,17-triol, nor were 
the characteristic m/e 307 and m/e 304 ions [see figures 13a, 
13b, 13c, 13d] present. Consequently it was concluded that 
a 17a-methyl-5a--androstane-2,3,17-triOl was not a metabolite 
of oxymetholone and that a 2,1m-dihydroxy-17-methyl--5a-
androstan-3-one was also unlikely to be formed during 
metabolism. 
Four of the spectra of the metabolites showed ions 
at m/e 334 [figures 15a, 15b, 15c, 15d]. In view of the 
reported microbial reductions 83,84 of a series of 2-hydroxy--
methylene-A4-en-3-ones in the androstane series to the 2-
hydroxymethyl- 4-ene-3-ketones the observation of. ions at 
m/e 334 in the spectra of metabolites of oxymetholone 
suggested that the 2-hydroxymethylene function might be 
metabolised to give a 17-hydroxy-2-hydroxymethyl-17-methyl-
5-androstan-3-one (M, m/e 334). A spectrum [figure 15e] 
of a sample of the most polar metabolite of àxymetholone. 
contained an ion at m/e 336 which could be assigned to a 
2_hydroxymethyl-17-methy-5a-andrOstane-3, 17-diol (rIi, m/e 
336), formed by reduction of the 0-3 carbonyl function of 
oxymetholone as well as the 2-hydroxymethylene system. It 
would thus appear that during metabolism of oxymetholone 
the additional carbon atom at 0-2 is retained. . The re-
ductions of oxymetholone with a variety of reagents, to 




























Figure 16. The mass spectrum of oxymetholone at 1200 
17$ 
4.4. The synthesis and chemical reductions of oxymetholone 
4.4.i. Svnthesis of oxymetholone 
Oxymetholone was synthesised to provide a more 
readily available source of the compound in greater quantity 
than that obtained by extraction of commercial tablets of 
the drug. The preparation of oxymetholon[5] was first 
described by Ringold et al.20 and is achieved by condensation 
of ethyl formate with the 62-enolate anion [159] of 17- 
hydroxy-17-methyl-5a--androstan-3-one [160]. The product is 
precipitated as the enolate salt 11611 from the non-polar 
solvent and then acidified to give  117m  the free hydroxymethy- 
lene compound [5]. 17-Hydroxy-17-methyl--5a-androstan-3- 
one[160] was prepared from 30-hydroxy--5a--androstan-17--one 
by reaction with methylmagnesium iodide followed by chromic 
acid oxidation of the C-3 hydroxyl group of 17a-methyl-5a-
androstane-3 , 17-diol. 
In the mass spectrum of oxymetholone [figure 16] the 
molecular ion (M+,  m/e 332) was also the base peak and no 
~ 
other ions were greater than 40% of M . The intensities of 
M-18 (m/e 314, 7%) and M-18-15 (m/e 299, 7%) reflect the low 
tendency of the 17-hydroxy-17-methyl function to lose water, 
whereas the medium intensity ion at. m/e 274 (M-58, 38%) shows 
that fl-ring fragmentation is more favourable for this con-
figuration (cf. m/e 242 in the spectrum of methandrostenolone 
[figure 5a]). The ion at m/e 275 (36%) presumably arises 
from fission of the 2,3-bond, hydrogen transfer and loss of 
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Diagram 19. The products of the reduction, of oxymetholone 
with metal hydrides. . . . 
+HoHfcj3 +j1I  Ho 
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4.4.ii. Reduction of oxymetholone with lithium aluminium 
hydride 
Oxymetholone was reduced with lithium aluminium 
hydride at room temperature as described by Knox and 
Velarde.206 When the product was isolated by the addition 
of sodium sulphate and removal of the salt cake by filtration 
as described 206 by these authors only 87% of the steroid was 
recovered. Consequently, the salt cake was dissolved in 
water and extracted with ether by which means the remaining 
product, rich in the most polar, least ether-soluble 
component was isolated. 
T.l.c. showed that both product fractions contained 
the same four compounds, the least polar of which was unreacted 
oxymetholone[5]. The other three components were identified 
by comparison with the products obtained by Knox and Velarde?06 
In order of increasing polarity these were 17a-methyl-2-
methylene-5a-androstane-3$ , 17-diol[163], 178-hydroxy-2-
hydroxymethyl-17-methyl-5cL-androstan-3-one[ 164] and 2a-
hydroxymethyl-l7a-methyl-5a-androstane-3 , 17-diol[165J. 
Crystallisation of the major fraction from acetone gave 17-
hydroxy-2ct-hydroxymethyl-17-methyl-5ct-andro stan-3-one [164], 
m.p. 183-1850 (lit., 206 188_1900) which was shown by t.l.c. 
to be slightly contaminated with 17ar-methyl-2-methylene-5a- 
androstane-3 , 17-diol[165]. Pure 2a-hydroxymethyl-17ct- 
methyl-5a-androstane-3 ,17-diol[165], m.p. 280-2820 
206 
280-2829) was obtained by crystallisation of .the minor 
fraction from acetone. 
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Figure 17. The mass spectra of a) 17-hydroxy-2a-hydroxymethy1-17-methy1-5a-androstan33-
one and b) 2a-hydroxymethy1-17-methyl-5a-androstane-3,17-dio1 both at 160 C. 
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178 
4.4.iii. Reduction of_ymetho1one with lithium tri-t-butyi- 
oxyaluminium hydride 
Oxymetholone[5] was reduced with lithium tri-t-butyl-
oxyaluminium hydride to give a crude product from which a 
mixture of 1_hydroxy-2a-hydroxymethyl-17-methy1-5a-androStan-
3-one[164]  and 2a_hydroxymethy1-17a-methy1-5a-andro5tane-3, 
17-diol[165] was crystallised as the major product. The 
crude product contained some unreacted oxymetholone and a 
small amount of the 2.-methylene-3-o1[163]. 
The 2m_hydroxymethyl-3-ketone[164] was more volatile 
than the 2a-hydroxymethy1-3-o1[1651, bass spectrometry of 
r 
the mixture giving spectra with M
+  at m/e 334 [Figure 17a, 
1600] and at m/e 336 (1800). The base peak in the spectrum 
[figure 17a] of the former compound was at m/e 277, formed 
by loss of a fragment of mass 57 from the molecular ion. 
One • of the major peaks in the spectrum of oxymetholone [fig-
ure 16] was likewise formed by loss of a mass 57 fragment. 
The other important ions in the spectrum of the 2ct-hydroxy-
methyl-3-ketone were formed by loss of water from the 
molecular ion (m/e 316) and of water (m/e 298) or a methyl 
group (m/e 301) from this ion. 
Acetylation of the mixture of the 2a-hydroxymethyL-3-
ketone and the 2a-hydroxymethyl-3-ol with acetic anhydride 
in pyridine at room temperature gave a mixture containing 
two low-polarity components, the mass spectrum of which 
contained the molecular ions of the monoacetate We 376) 
and the diacetate (m/e 420). Under these conditions the 
tertiary 17-hydroxy1 function was not acetylated. 
179 
The mixture containing the 2a-hydroxymethyl-3--
ketone and the 2a-hydroxymethy1-3-01 was reduced with 
sodium borohydride. T.1.c. of the product showed that 
the less polar 3-ketone 11641 had been reduced to the 2cr 
hydroxymethyl-3 -o1[l65] and a trace of a slightly more 
polar compound which was presumed to be the epimeric 2ct- 
hydroxymethyl-3a-01[166], This was confirmed by mass 
spectrometry of the product which showed only a molecular 
ion at m/e 336 in spectra obtained at a variety of temper- 
atures. [see figure 17b]. Other characteristic ions in 
the spectra of the 2a-hydroxymethyl-3-01 were those arising 
from loss of water or a methyl group from the molecular ion 
We 318 and m/e 321, respectively) and from loss of water 
from both of these ions (m/e 300 and m/e 303). 
The product of the sodium borohydride reduction was 
acetylated to give a product which showed one low-polarity 
spot on t.1.c. and gave a mass spectrum with the molecular 
ion of a 2-acetoxymethyl-3--acetate (m/e 420). The spectrum 
contained no trace of the molecular ion of the monoacetate 
at m/e 376. 
4.4.iv. Reduction of oxymetholone with sodium borohydride 
Oxymetholone [5]  was reduced with sodium borohydride 
to give a crude product, the components of which were 
identified by t.l.c. against standards from the preceding 
reductions. The product contained unreacted oxymetholone 
[51, 17-hydroxy-2a-hydroxymethy1-17-methy1-5a-androstan-
3-one[164] and a mixture of the two epimeric 2a-hydroxy-
methyl-17ct-methyl-5a-androstane-3,17-diols [165,166] 
4.4.v.. Reduction of oxymetholone with sodium dihydro-bis 
( 2-methoxyethoxy) aluminate 
Reduction of oxymetholone with sufficient sodium 
dihydro-bis(2-methoxyethoXy)alUminate for reaction of the 
2-hydroxymethylene and 3-carbonyl functions gave a crude 
product containing no unreacted oxymetholone. However, 
the major product was identified by t.l.c. as 17 -hydroxy 
2a_hydroxymethy1_l7_methyl-5--andro5tan3One [164] accom- 
panied by only traces of more polar components. Use of 
sufficient reagent for complete reduction of Only one of 
the functions gave a mixture containing unreacted oxymeth-
dlone traces of pblar components and the 2a-hydroxymethyl-
3-ketone[164] as the major product. 
4.4.vi. Discussion 
The reductions of oxymetholone with lithium aluminium 
hydride, lithium tri-t-butyloxyaluminium hydride, sodium 
borohydride and sodium dihydro-bis(2-methoxyethoXY)aluminate 
are of interest because of the different product mixtures 
obtained and the nature of the products. 
The major product of the reduction with all four re-
agents was 178 _hydroxy_2a_hydroxymethy1-17-methyl- aandrO5tan 
3-one. Isolation of a ketonic product from a reduction in 
which excess reducing agent was employed must be ascribed 
to the relationship of the two reducable groups in the oxy- 
metholone molecule. Thus, conjugation of the hydroxy- 
thethylene double bond with the 3-carbonyl function leads to 
a positive centre at C-2' because of polarisation towards 


























a hydride ion [167] with the generation of a 62-double bond 
and formation of an 0-Al bond at C-3 [168]. Consequently, 
further attack by W cannot occur and the addition of water 
leads to hydrolysis of the 0-Al bond with formation of an 
enol [169]  which then isomerises to give the 2a-hydroxymethyl-
37keto compound [164]. 
The formation of 3-hydroxy-2a-hydroxymethyl compounds 
may be explained by hydride reduction of the 2-aldehyde 
function [170] present in equilibrium with the 2-hydroxy-
methylene system [5]  ma proportion (ca. 2256, by calculation 
from n.m.r. spectra  204b)  of the sample, followed by reduction 
of the 3-carbonyl group. Alternatively the latter function 
may be attacked by a hydride ion with destruction of the 
hydrogen bonding with the 2-hydroxymethylene system and con-
sequent isomerisation to the aldehyde which is then reduced. 
The 2-methylene product [163]  is formed by elimination of the 
21_OAl substituent from the intermediate to the 2a-hydroxy--
methyl-3-alcohol[171]. 
Sodium dihydro-bis(2-methoxyethoxy)aluminate reacted 
with oxymetholone to give only the 2a-hydroxymethyl-3-one. 
Consequently the low yields of the 2a-hydroxymethyl-17a-
methyl-5a-androstane-3,17-diols in the reactions with the 
other three reagents must be due to a combination of the 
faster hydride attack at C-21 , because of the conjugated 
enone system, than at C-3 and to the steric requirements 
for the formation of the two 0-Al bonds. . . 
The reduction of oxymetholone to a 2a-hydroxymethyl- 
3-alcohol with lithium aluminium hydride and with lithium 
182 
tri-t-butyloxyaluminium hydride and of both oxymetholone 
and 17 -hydroxy-2a-hydroxymethyl---17-methyl-5at--andro stan-3-
one to mixtures of the 3a- and 3-  alcohols with sodium 
borohydride is not surprising. The anion from lithium 
aluminium hydride in ether is much less heavily solvated 
than that from sodium borohydride in a hydroxylic solventll?a 
o that Dauben's "steno approach factor"  207  is smaller for 
the former reagent than the latter. Consequently more of 
the thermodynamically less stable alcohol is formed by 
reaction with sodium borohydride. Eliel and Renick 208  
observed that sterically unhindered 3-ketones and analogues 
such as 4-t-butyl cyclohexanone gave a greater proportion 
of the equatorial alcohols by reduction with lithium 
aluminium hydride in ether than with sodium borohydride in 
hydroxylic solvents. 
Dreiding and Hartman 209 studied the lithium aluminium 
hydride reduction of 2-cárbethoxycyclohexanone and 2-hydroxy-
methylenecyclohexanone and suggested a mechanism whereby the 
enolised portions of the compounds reacted to give enolate 
salts whereas the non-enolic portions were reduced normally 
to give diols. They isolated 2-methylenecyclohexanol, 1- 
cyclohexenemethanol and 2-hydroxymethylcyclohexanol in the 
ratio 5:2:1 from the reductions of the above compounds. 
However no 2-hydroxymethyl--62-ene has been found among the 
reduction products of oxymetholone. 206 
4.4.vii. Comparison of the metabolites of oxymetholone with 
• 170-hydroxyydroxymethyl-17-methYl-5a-andrO stan- 
)-one and the 2a-hydroxymethyl-17a-metyl-5a-
androstane-3, 17-diols. 
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Diagram 20. The mechanism of the formation of the 
m/e. 147 fragment in the mass spectra 
of compounds containing two adjacent 
trimethylsilyl ether fractions. 
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metabolite of oxymetholone [figures 15a, 15b, 15c, 15d] con-
tained ions at m/e 334 (M of l7-hydroxy-2a-hydroxymethy1-
17-rnethyl-5a-androstan-3-one, [figure 17a]) and fairly prominent 
ions at m/e 316 (M-18). The sample of the most polar meta-
bolite [figure 15e] gave an ion at m/e 336 (P4 of 2a-hydroxy-
methyl-17a-methyl-5a--androstane-3, 17-diol, [figure 17b11) and a 
pronounced ion at rn/c 318 (M-18). Spectra 15d and 15e 
corresponded to the two metabolite-containing fractions 
obtained after a single administration of oxymetholone. 
Both fractions were chromatographed on a thin layer plate 
against 17_hydroxy_2a_hydroxyrnethyl-17-methyl-5a-andrO5tan 
3-one (Rf 0.53), 2a_hydroxyrnethyi-17a--methyl-5ct-androstane-
3,1-7-dio1 (Rf 0.38) and 2a-hydroxymethyl-17a-methyl-5a- 
androstane-3ct,17-diol (Rf 0.31) as standards. The sample 
containing the most polar metabolite gave a spot at Rf 0.38 
and that containing the least polar metabolite gave a spot 
at Rf 0.50 with others at 0.44 and 0.24. 
Mass spectrometry of the trimethylsilyl derivatives 
of the samples from which spectra 15d and 15e were obtained 
tended to confirm the proposed structures of the metabolites. 
The sample containing the more polar metabolite gave a 
relatively intense ion at m/e 147, not present in the 
spectrum of the free steroid. Such an ion is formed 210 by 
the interaction of the trirnethylsilyl functions of two 
adjacent hydroxyl groups through a cyclic intermediate with 
expulsion of the SiMe30iMe2 fragment (m/e 147) [see diagram 
201. An ion at m/e 147 was not observed in the spectrum of 
the derivative of the less polar metabolite. An intense 
WMA 
ion at m/e 143, characteristic of the 17-hydroxy--17-methyl 
system was not found in the spectrum of either derivative, 
possibly due to more intense fragmentations, such as that 
giving m/e 147, induced by the silyl groups in the A-ring. 
Carbon skeleton chromatography of a sample of 2a-
hydroxythethyl-17a-methyl-5a--andro stane-3 , 17-diol, obtained 
by lithium aluminium hydride reduction of oxymetholone (section 
4.5.iv), gave only reduced products with the retention times 
of 17-methylandrostanes. Thus, the 2a-hydroxymethyl-, like 
the 2-hydroxymethylene-function is removed during high 
temperature catalytic reduction and consequently all available 
evidence indicates that the two metabolites of oxymetholone 
in normal man are 1-hydroxy-2a-hydroxymethyl-17-methyl--5ct-
androstan-3--one and 2a-hydroxymethyl-17w-methyl-5a-afldrO stane-
3$,17-diol, although the analysis of further samples is 
desirable. 
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4.5 erimental Section 
4.5 , i 17a-Methyl-5a-androstane-33 , 17-diol 
A solution of methyl iodide (52g, 23m1) in dry ether 
(150m1) was added to magnesium turnings (9g) in ether (50m1) 
and the mixture refluxed for 15 minutes. 3-Hydroxy.--5ct-- 
androstan-17-one (lOg, for preparation, see section 4.2.1.) 
was dissolved in ether (500m1)  and a small volume of tetra-
hydrofuran and added dropwise to the stirred solution of 
methylmagnesium iodide. Aftr refluxing for 15 minutes the 
reaction mixture was poured into ice, water and concentrated 
sulphuric acid (40m1) and stirred until all the ice had 
melted. The layers were separated and the aqueous layer 
was extracted three times with chloroform-ether (1:9). The 
combined organic extracts were washed with sodium sulphite 
solution, saturated sodium bicarbonate solution and with 
water, dried over anhydrous magnesium sulphate and evapor-
ated to dryness to give the product (9.6659), a mixture of 
the starting material and the diol. Pure 17a-methyl-5a- 
androstane-3,17-diol (7.711g, 730/6) was obtained by recry-
stallisation from acetone; m.p. 211.5-212.5 (lit.,211  206-
2090); n.m.i'. (60 M Hz) ¶9.18 (0-19 methyl), 9.16 (0-18 
methyl), 8.80(0-20 methyl), 6.45 (m,3ar-H). 
4.5. ii. 17-Hydroxy-17-methyl-5a--androstan-3-one 
SN Chromic acid solution (5m1) was added to a stirred 
solution of 17a-methyl-5a-androstane-3,17-diol (2.502g) in 
acetone (500m1). The reaction was allowed to proceed for 
1.5 minutes and then quenched with methanol (500m1). Water 
(500m1) was added and the mixture neutralised with saturated 
Iwo 
sodium bicarbonate solution. The organic solvents were 
removed by evaporation in vacuo, the aqueous phase was 
extracted twice with ether and the combined organic extracts 
were washed with water, dried over anhydrous magnesium 
sulphate and evaporated to dryness to give a yellow solid. 
Crystallisation from acetone gave pure 1-hydroxy-17-methyl- 
III 
5-androstan-3-one (1.674g) as needles; m.p. 192-190 (litb 
1930); vmal7l0cm; n.m.r. (60 M Hz) t9.I4 (C-18 methyl), 
8.98 (0-19 methyl), 8.81 (C-20 methyl). 
4.5-iii. Oxyrnetholo[j20  
Sodium hydride (2g,. 60% dispersion in oil) was washed 
free from oil with petrol (60-800) and then with benzene and 
added to & stirred mixture of 170-hydroxy-17-methyl-5a-andro-
stan-3-one (1.009g), dry benzene (20m1) and ethyl formate 
(2m1) under nitrogen. After 5 hours the green reaction 
mixture was filtered, the precipitate was washed with benzene 
and with hexane, dried and added to ice-cold dilute hydro- 
chloric acid (50m1). The lumps were crushed and the mixture 
was again filtered. The precipitate was washed with water, 
dissolved in ether and the solution washed twice with water, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to give a yellow glass. Crystallisation from acetone 
gave pure oxetholone (0.660g); m.p. 174-178°  (lit., 20 178- 
180); vmax3380,2920,1640 945cm
1; n.m.r. (100 M Hz) 
79.23 (0-19 methyl), 9.14 (0-18 8.80 (C-20 methyl), 
- / 20L4h 
1.41 (s, average of -CO.0 = C.H.OH and -C.OH = C.CHO 
Mass spectrum, M+  and base peak, ni/e 332. 
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4.5.iv. Reduction of oxymetholone with lithium aluminium 
hydride 206  
A fine suspension of oxymetholone (501.6mg) in ether 
(50m1) was added dropwise to a stirred suspension of lithium 
aluminium hydride (497.1mg) in ether (150m1)  and the mixture 
was stirred, at room temperature for 1* hours. Excess hydride 
was destroyed with ethyl acetate and then saturated aqueous. 
sodium sulphate (lml) was added, followed by sufficient 
sodium sulphate to give a clear supernatant ether solution. 
The mixture was filtered, the salt cake was washed with 
ether and the combined filtrate and washings were evaporated 
to dryness to give a product (436.6mg, 87%). The salt cake 
was dissolved in water, the solution extracted twice with 
ether and the combined organic extracts washed with water, 
dried over anhydrous magnesium sulphate and evaporated to 
.dryness to give a sparingly soluble white material (81.7mg, 
16%). T.l.c. of both products showed the same four major 
components, in order of increasing polarity; oxymetholone, 
17 -methyl-2-methylene-5 -androstane-3 ,17-diol, 17-hydroxy-
2a-hydroxymethyl--17-methyl-5a-androstan-3-one and 2cz-hydroxy- 
methyl-17a-methyl-5ct-androstane-3 ,17-diol. The smaller 
fraction (81.7mg) extracted from the salt cake appeared to 
be richer in the latter compound and crystallisation from 
acetone gave pure '2a-hydroxymethyl-17a-methyl-5a-androstane-
3,17-dio1; m.p. 280-282° (lit.,206 280-2820). 
. 
,The major 
component of the other fraction was the 2ct-hydroxymethyl-3-




(lit.,206 188-1900);. t.1.c.,' slightly contaminated with 17a- 
I..'.] 
methyl-2-methylene-5a-androstane-3 , 17-diol; v  max  l700c&'; 
n.m.r. (100 M Hz) T9.16 (C-19 methyl), 9.14 (C-18 methyl), 
8.81 (C-20 methyl), 6.34 (in, 2-H), 6.14 (m, -CH2OH); Mass 
spectrum, M+, m/e 334. 
4.5.v. Reduction of oxymetholone with lithium tri-t-butyl- 
oxyaluminium hydride 212  
Dry t-butanol (1.32m1)  was added dropwise to  
solution of lithium aluminium hydride (179.4mg) in tetra- 
hydrofuran (5.9m1). This solution was • then added dropwise 
to a solution of oxymetholone (592.2mg) in tetrahydrofuran 
(5.9m1) at 0°C and the reaction maintained at this temper- 
ature for 15 minutes. Excess reagent was decomposed with 
501/0 acetic acid (70m1) and the steroid was extracted into 
ether, washed with sodium bicarbonate solution and with water, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to give the crude product (571.5mg). Crystallisation 
from acetone gave a mixture of 17$-hydroxy-2a--hydroxymethyl-
17-methyl-5a-androstan-3-one (Rf 0.34) and 2ct-hydroxymethyl-
17a-methyl-5a-androstane-3,17-diol (Rf 0.21, compared with 
oxymetholone, Rf 0.45, in benzene-ethanol, 9:1); Mass 
spectrum, M, m/e 334 (1600); M, m/e 336 (1800). 
4.5-vi. 
• -5a-androstan-one and 2a-hydroxymethyl- 
17a-methy1-5a-androstane-3 ,17-diol. 
• The product of the above reaction (18mg) containing 
a mixture of the 2a-hydroxymethyl-3-ketone and 2c7-hydroxy-
methyL-30-01 was dissolved in pyridine (0.05m1) and acetic 
anhydride (0.lml). After 12 hours at room temperature 
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ether and water were added, the ether layer was washed with 
saturated sodium bicarbonate solution, dried over anhydrous 
magnesium sulphate and evaporated to dryness to yield 2a-
acetoxymethyl-17 -hydroxy-l7-methyl-5a-androstan_3_oe and 
2a-acetoxymethyl-17a-methyl-5-androstane....3 ,17-diol 3-
acetate (17.2mg); t.l.c., two spots, both less polar than 
the starting materials; vmaxl740,1710cm; Mass spectrum, 
M of monoacetate, m/e 376; M. of diacetate, m/e 420. 
4.5-vii. Reduction of 17P-hydroxy-2a--ymethyi-17- 
• 5a-andro stan- 3-one and 
17a-m2Thyl-5a--androstane-3_,17-diol with sodium 
borohvdride 
The product of reaction 4.5.v. (1.1mg) containing a 
mixture of the 2a-hydroxymethyl-3-ketone and 2a-hydroxymethyl--
3-ol was dissolved in methanol (0.05m1) and ethyl acetate 
(0.olml) and mixed with a solution of sodium borohydride 
(0.3mg) in methanol (0.05m1) and ethyl acetate (0.olml). 
After 12 hours at room temperature glacial• acetic acid (3 
drops) and dilute hydrochloric acid were added. The 
steroid was extracted into ether, washed with sodium bi-
carbonate solution and with water, dried over anhydrous 
magnesium sulphate and evaporated to dryness to yield a 
white crystalline material (1.0mg); m.p. 260°; t.l.c., no 
spot corresponding to the 2a-hydroxymethyl-3-one but a spot 
corresponding to the 2ct7hydroxymethyl-30-ol and a very faint, 
• slightly more polar spot presumed to be 2a-hydroxymethyl-
17t-methyl-5a-androstane-3cs, 17-diol; Mass spectrum, M, 
m/e 336. 
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4-5-viii. Acetylation of 2a-hydroxymethy1-17a-m- 
5a-androstane-3 ,17-diol 
The product of the above reaction (1mg) was dissolved 
in pyridine (3  drops) and acetic anhydride (6 drops). After 
7 hours the product was isolated as described in section 
4-5-vi. to give 2a-acetoxymethy1-17a--methy1-5a-androstane-3, 
17-diol 3.-acetate (1mg); t.1-C., one low polarity spot; 
Mass spectrum, M+,  m/e 420, with no trace of the mono-
acetate (M , m/e 376). 
4.5.ix. Reduction of oxymetholone with sodium borohydride 8  
A solution of sodium borohydride (73.1mg)  in methanol 
(8m1) and ethyl acetate (2m1) was added to a solution of 
oxymetholone (260.7mg) in methanol (8m1) and ethyl acetate 
(2m1). After 24 hours at room temperature glacial acetic 
acid (4m1) and dilute hydrochloric acid were added and the 
product (266.2mg) isolated as described in section 4-5-vii. 
T.1.c. showed that it was a mixture of unreacted oxymeth-
olone, 175-hydroxy-2a--hydroxymethyl-17-methyl-5a--androstan-
3-one, 2a-hydroxymethy1-17a-methyl-5a-androstane-3 , 17-diol 
and 2arhydroxymethyl-17a-methyl-5a--androstane-3a, 17-diol by 
comparison with the appropriate standards from the preceding 
reactions. 
4.5.x. Reduction of oxymetholone with sodium dihydro-bis- 
(2-methoxyethoxy ) aluminate 
A 70% solution of sodium dihydro-bis(2-methoxyethoxy) 
alurninate in benzene (0.5m1, ca. 4 equivalents of H, 
Cambrian Chemicals Ltd., Croydon) was added dropwise to a 
stirred solution of oxymetholone (268.1mg) in benzene (25m1). 
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After 1 hour excess reagent was destroyed by the addition 
of water. Ether and sodium bicarbonate solution were 
added and the aqueous phase was extracted twice with ether. 
The combined organic extracts were washed with water, 
dried over anhydrous magnesium sulphate and evaporated to 
dryness to give a pale yellow glass (275.2mg). T.l.c. 
showed that no unreacted oxymetholone remained and that 
the major product was 1_hydroxy-2a-hydroxymethyl-17-iflethyl-
5a-androstan--3-one, with traces of several more polar 
components. 
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5.1. The reactions of 
and rnethandrostenolone with liver alcohol dehydrogenase 
5.1.i. Chemica1206 and microbial 83,84 reductions of the 2-
hydroxymethylene substituent of steroids in the androstane 
series have been shown to produce the 2a-configuration of 
the resulting hydroxymethyl function, the equatorial 
conformation of the large group being thermodynamically more 
stable than the axial. Consequently; by analogy, the hydroxy-
methyl function in any metabolite of oxymetholone may be 
assigned the 2m-configuration. In contrast, the configur-
ation of the 3-hydroxyl group in a metabolite of molecular 
weight 336, in which both the hydroxyrnethylene and 3-carbonyl 
functions are reduced, cannot he as easily assigned although 
the evidence presented in section 4.4 suggested a 3-hydroxyl 
group. 
Studies with rats have shown that testosterone is 
metabolised 213 to androstanetriols containing the 3a-hydroxyl 
and the 3-hydroxyl configurations and that an epimerase 
system which catalyses the transformation of 5a-androstane-
3a,17-diol to 5a-androstane-3,17-diol can be induced. 214,215 
Consequently, although biochemical reduction of a 5a-3-keto-
steroid often leads to formation of the corresponding 3- 
alcohol the configuration of a 3-hydroxyl group in a meta-
bolite of oxymetholone cannot be assigned by analogy, 
particularly since the effect of the 2-hydroxymethyl substit-
uent is unknown. The biochemical reduction of oxymetholone 
was thus investigated with the hope that sufficient of one 
of the 2a-hydroxymethyl-17-methyl-5-androstane_3, 17-diols 
would be formed to enable its characterisation and hence, by 
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analogy, the tentative identification of the more polar 
metabolite of oxymetholone in man. 
Liver alcohol dehydrogenase (LADH) has been shown to 
be specific for the dehydrogenation of the 3-hydroxyl group 
of 3-hydroxy-5-Oholanic acids and to accomplish the reverse 
reduction of the ketone to the 3_alcohol.216  Data was not 
available for the reduction of 5a-3-ketosteroids with this 
enzyme system and consequently the reaction of 5-androstane-
3,17-dione was examined prior to the attempted reduction of 
oxymetholone to establish whether the reaction conditions 
were suitable. 
Ultraviolet spectroscopy is often used to follow the 
course of enzymatic reductions by the disappearance of the 
340 nm band of -dihydro nicotinarnide adenine dinucleotide 
(NADH) due to simultaneous oxidation of this cofactor. 216 
However this method requires an excess of.steroid so that• 
the change in reduced cofactor concentration is significant, 
whereas the attempted reductions described in this section 
were best performed with a large excess of NADH. Conse-
quently, reduction was monitored by t.l.c. and g.l.c. of the 
products extracted after incubation with the enzyme. 
5.1.ii. The reaction of 5-androstane-3,17-dione with LADH 
50-Androstane-3,17-dione was incubated with LADH and 
NADH in 2-amino--2-methylpropan-l-ol buffer (AMP, pH 10.5) at 
30 0 for 12 hours. A control reaction, containing all the 
ingredients except the steroid was treated likewise 
Prior to termination of the incubation a small sample 
of the steroid reaction mixture was withdrawn., diluted with 
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buffer and incubated for 30 minutes with acetaldehyde. 
The ultraviolet spectrum of this solution did not contain 
a band at 340 nm whereas the spectrum of the reaction 
mixture which was not incubated with acetaldehyde possessed 
this band. Thus the enzyme system had remained active 
throughout the 12 hour incubation with steroid and was 
able to catalyse the reduction of acetaldehyde to ethanol 
with simultaneous oxidation of NADH to NAD. The enzyme in 
the control mixture was also shown to be active after 12 hours. 
Following denaturation of the protein the reaction and 
control mixtures were extracted with ethyl acetate and the 
extracts were examined by t.l.c. The extract from the 
control reaction contained three components which were the 
same as the most polar and the two least polar of the five 
components in the extract of the steroid reaction. Conse-
quently all but two components of the latter extract could 
be eliminated as non-steroidal substances. The major 
component was the unreacted 5-androstane-3,17--dione which 
when developed with sulphuric acid gave a characteristic 
yellow spot fringed by blue and later changing to a purple 
spot. The final spot in the extract from the steroid 
reaction corresponded to the epimeric 3-hydroxy-5-androstan-
17-one standards. All had the same polarity and gave a 
scarlet spot fringed by blue, which changed to deep purple. 
The free and the trimethylsilylated extract con-
taining the reduced steroids was examined by g.l.c. Chromato-
graphy of either the free or the trimethylsilylated 3-hydroxy-
5-androstan-17-one standards gave two peaks for each steroid, 
probably due to thermal elimination. Similar behaviour was 
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observed when free epiandrosterone and androsterone were 
chromatographed under the same conditions. However, it 
was possible to tentatively identify the product (retention 
times, 5.92 and 7.12 minutes) of the enzymatic reduction 
of 5-androstane-3, 17-dione as 3-hydroxy-5-andrOstan-17-one 
(retention times, 5.92 and 7.12 minutes). 3a-Hydroxy-5-
androstan-17-one gave peaks with retention times of 6.40 
and 7.36 minutes. The identification of the reduction 
product as the 3-a1coho1 is in accordance with the obser-
vations of Wailer et al. 216 that LADH is stereospecific 
for 3-hydroxy-5$-cho1anic acids. 
5.1.iii. Attempted reduction of oxymetholone with LADH 
Oxymetholone was incubated with LADH and NADH as 
described for 5-androstane-3,17--dione except that the 
reaction was continued for 70 hours, after which time the 
enzyme was shown to be still active. In contrast to 5-
androstane-3,17-dione which gave a suspension in AMP buffer 
oxymetholone was completely soluble. 
T.l.c. of the product extract after incubation of 
oxymetholone with the enzyme showed ten components with 
considerable streaking, indicative of degradation. One 
spot corresponded to unreacted oxymetholone and one was of 
the same polarity as 17-hydroxy-2a-hydroxymethyl-17-methyl- 
5crandrostan-3-one. The two least polar components 
corresponded -to the non-steroidal contents of the control 
extract and the most polar spot was visible under ultra-
violet radiation but invisible after sulphuric acid develop- 
ment of the plate. The remaining five spots were more 
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polar than oxymetholone but none appeared to match either 
of the 2a-hydroxymethyl-17a-methyl-5a-andrO stane-3, 17-diols. 
Oxymetholone and its chemical reduction products were 
gas chromatographed both as free steroids and as their 
trimethylsilyl derivatives but in both cases many unidenti- 
fiable peaks were obtained. Adhikary32 also observed that 
oxymetholone and its metabolites were thermally unstable. 
Because of the low conversion to reduced products in the 
enzymatic reaction and the poor gas chromatography of this 
class of steroids no further information about the structure 
of the enzymatic reduction products was obtained. 
In view of the streaking observed in the t.l.c.. of 
the extract of the enzyme reaction oxymetholone was incubated 
in a pH 10.5 buffer solution with no LADH or NADH to assess 
the extent of degradation produced by the alkaline medium. 
To determine whether the extraction procedure was responsible 
for degradation one sample was neutralised with very dilute 
hydrochloric acid after incubation but prior to extraction. 
However there was no difference between the final extract 
from this sample and that from a sample which had not been 
so neutralised. Both contained three components, one of 
which was oxymetholone, one was less polar and the other 
more polar. All three components were present in the 
extract obtained after incubation of the steroid with enzyme 
but the most polar component from the incubation without 
enzyme did not correspond to 1-hydroxy-2a-hydroxymethyI-17- 
methyl-5ct-androstan-3-one. Consequently, this compound was 
tentatively identified as a product of the enzymatic 
reduction of oxymetholone, but the original object of the 
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experiment, to obtain information concerning the configur-
ation of the 3-hydroxyl group in the most polar metabolite 
of oxymetholone in man was not fulfilled. 
5.1.iv. Attempted reaction of methandrostenolone with LADH 
As described in the introduction (section 1, pages 14-
16), the 41"-dien-3-one system has been shown to be 
exceptionally resistant to enzymatic reduction, although 
reductions to the 3a-hydroxy-4,5i -dihydro-, 3a-hydroxy-4,5a-
dihydro- and the 1-ene-3-one-4,5$-dihydro-- A-rings have been 
observed. Methandrostenolone was thus incubated with LADH 
under the same conditions as those described for oxymetholone 
to examine whether reduction would take place with this 
enzyme system. 
T.l.c. of the product showed that methandrostenolone 
and a trace of a slightly more polar component were present. 
Gas chromatography of the free and the trimethylsilylated 
extract also showed methandrostenolone with two very small 
peaks at shorter retention times. However both these peaks 
were present in chromatograms of the extract from incubation 
of methandrostenolone in buffer with no LADH or NADH. Con- 
sequently, as expected, the Al_dien_3_one system was 
resistant to reduction by LADH. The trimethylsilyl deriva- 
tive of the extract after the enzyme reaction also showed 
that no 17-epimethandrostenolone was formed. 
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5.2. Experimental Section 
5.2.i. Reaction of 5-androstane-3,17--dione with liver 
alcohol dehydrogenase 
5-Androstane-3,17-dione (4.73mg, 16.4 pmole, Sigma 
Chemical Co.) was ground to a fine powder and transferred 
to a flask with 2-amino-2--methylpropan-l-ol buffer (AMP, pH 
10.5, 0.1M, 20m1). Solutions of -dihydro nicotinamide 
adenine dinucleotide (NAPH, 24.25mg,  31.6 Mmole) in AMP 
buffer (2.5m1) and horse liver alcohol dehydrogenase (LADH, 
activity 2.2 units/mg of. protein, 1.95mg)  in phosphate buffer 
(pH 7, lml) were added to the steroid suspension. The flask 
was- stoppered, shaken to mix the contents and placed in a 
water bath at 30°, where it was gently agitated. Acontrol, 
identical but for the omission of the steroid, was set up. 
After 12 hours 0.25m1 aliquots of the steroid reaction 
mixture and the control were transferred to separate tubes, 
diluted with AMP buffer (lml) and acetaldehyde (0.035m1) was 
added to each. The tubes were incubated at 30° for 30 min-
utes, the contents of each were diluted to 20m1, samples were 
transferred to cuvettes and the ultraviolet spectra recorded. 
The disappearance of the NADH absorption at 340 rim indicated 
that the enzyme had remained active throughout the reaction 
period. - 
The steroid was isolated by addition Of the reaction 
mixture to ethanol (400m1) which solution was heated to 
boiling, cooled and filtered. The ethanol was removed by 
evaporation in vacuo to near dryness and water was added. 
The aqueous phase was extracted twice with ethyl acetate, 
the combined organic extracts were, washed three times with 
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water, dried over anhydrous magnesium sulphate and 
evaporated to dryness to give a brown oily residue (9.8mg). 
Extraction of the control in the same way gave a similar 
residue (8.2mg). 
T.l.c. of both residues showed that the two least 
polar and the most polar components in the steroid extract 
corresponded to the only three components in the control. 
Of the two other components in the steroid product the major 
was identical in colour and polarity (Rf 0.58) to the starting 
material and the last spot, small in comparison to that of 
5-androstane-3,17-dione, was of the same polarity (Rf 0.36) 
and gave the same colour reaction as the epimeric 3-hydroxy-
5a-androstan--17-ones. G.l.c. of the steroid extract showed 
peaks at 7.48 (major), 7.12 and 5.92 minutes. The retention 
times of the three standard compounds were:- 5-androstane-
3,17-dione, 7.48 minutes, 3$-hydroxy-5--andrOstan-17-one, 
7.12 and 5.92 minutes and 3a-hydroxy-5$-androstan-17-one,  
7.36 and 6.40 minutes. Consequently the product was 
tentatively identified as 3-hydroxy--androstan-17-one. 
5.2.ii. Attempted reduction of oxymetholone with LADH 
Oxymetholone (5.0mg, 15.53 kimole) was treated with 
NADH (25.95mg) and LADH (3.15mg) as described in the pre- 
ceding section. The reaction was continued for 70 hours 
at 30°C. After 68 hours samples of the steroid and control 
mixtures were tested for enzyme activity by incubation with 
acetaldehyde. The tests were positive. 
Bright yellow residues (12.5mg and 8.3mg) were obtained 
after extraction of the steroid and control mixtures, 
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respectively. T.l.c. of both extracts showed that the 
two least polar components in the steroid extract were the 
only two components in the control. The steroid extract 
contained at least eight other components with streaking, 
indicative of degradation. One of the spots (Rf 0.28) was 
of the same polarity as 1-hydroxy-2a--hydroxymethyl-17-
methyl-5a-androstan-3-one. 
The reaction was repeated and the same product mixture 
obtained. 
5.2-iii. Examination of the stability of oxymetholone at 
pH 10.5. 
Oxymetholone (5.7mg) was dissolved in AMP buffer 
(22.5m1) and phosphate buffer (lml) and incubated at 300  
for 72 hours. A second flask containing oxymetholone (5.0 
mg) in the same solvent mixture was treated similarly. 
After incubation the contents of the first flask were 
neutralised with dilute hydrochloric acid. Both reactions 
were then extracted as described in section 5.2.i. to give 
residues (13.3mg and 13.6mg) from the neutralised and un-- 
neutralised samples, respectively. T.l.c. showed that 
both extracts contained the same three spots, one corres-
ponding to oxymetholone, one less polar and one more polar, 
all of which were present in the steroid extract after 
incubation with LAPH (section 5.2.ii.). Neither of the 
extracts obtained after incubation of oxymetholone without 
enzyme contained a component with the same polarity as 17-
hydroxy_2a-hydroxyxnethyl-17-methyl-5a-androstan-3--One. 
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5.2.iv. Attempted reaction of methandrostenolone 
with LADE. 
Methandrostenolone (4.9mg) was treated with NADH 
(25.0mg) and LADH (3.82mg)  as described previously 
(section 5.2.i.). Two controls, one containing all the 
ingredients but the steroid and- the other containing the 
steroid but no LADE and NADH were set up. All three 
flasks were incubated for 72 hours, after which period the 
activity of the enzyme was confirmed by reaction with 
acetaldehyde. 
The contents of the three flasks were extracted as 
describedin section 5.2.i. to give residues (27.3mg, 
24.1mg and 27.1mg)  from the steroid + enzyme, enzyme alone 
and steroid alone mixtures, respectively. T.l.c. of each 
extract showed two low polarity spots identical to those 
observed in the control and steroid extracts in the pre- 
ceding reactions. The major component in both the steroid-
containing extracts had the same polarity as methandrosten-
clone and both showed a trace of a slightly more polar 
component. 
G.l.c. of the extract of the steroid + enzyme in-
cubation showed that the major component had a retention 
time of 15.56 minutes. Two small peaks at 8.36 and 6.12 
minutes were also present. The trimethylsilyl derivative 
of this extract gave a peak at 14.92 minutes and very small 
peaks at 9.04 and 6.24 minutes. Standard methandrosten- 
olone trimethylsilyl ether had a retention time of 14.92 
minutes in contrast to that of 17-epimethandrostenolone 
202 
trimethylsilyl ether, 11.00 minutes. The reaction 
extract contained no trace of such a peak. The tn-
methylsilyl derivative of the extract obtained after in-
cubation of methandrostenolone in buffer alone gave the 
same peaks as the extract from the steroid + enzyme in- 
cubation. 
The reaction was repeated with similar results. 
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ABSTRACT 
The more polar of the two major urinary metabolites of 
methandrostenolone, 17S-hydroxy-17-methyl-1, bandrostadien-3-one, 
in man has already beejn identified as 6-hydioxymethsndrcstenolone, 
68, 11$-dihydroxy-17-methyl-1, 14-androstadi en-3-one. The other 
metabolite has now been identified as the 17-epimer of methan- 
dros ten clone ,17a-hydroxy-ll-methyl-1 , Lt-androstadi en-3-one. The 
compound was isolated from the freely extractable neutral fraction 
of urine following the administration of 5 mg of the drug to normal 
men. The relevant chromatographic fractions Prom thin layer 
and gas liquid systems were identified by carbon skeleton chromato- 
graphy. The 17-epimer has been synthesised, details of which are 
included, and the previously unidentified metabolite was found to 
be identical with the synthetic comnound. 
The characterisation of the 1T-epimer defines a hitherto 
apparently unknown biochemical pathway. 
INTRODUCTION 
The metabolism of the anabolic steroid methandrostenoione 
(Dianabol) 17S-hydro-17-methyl-1 ,14-androstadi en-3-one  has been 
previously studied by Rongone and Segaloff (i). Extraction, 
after 8-glucuronidase hydrolysis, of the urine from a woman with 
advanced adenocarcinoma of the lung following administration of 
g of the drug afforded two metabolites which accounted for 
7.25% of the dose. 80% of the extracted material was identified 
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Theldentificatlonof 1 7-Hydroxy- I7-methy1-
androsta-1,4-dien-3-one as a Metabolite of 
17- Hydroxy- 17a- methylandrosta- 1,4- then - 
3-one in Man - 
By B. S. MACDONALD, P. J. Sviacs, P.M. ADIIIKARY 
and B. A. HKRKNESS. (Departments of Chemistry, 
Clinical Chemistry and Paediatric Biochemistry, 
University of Edinburgh, Edinburgh, U.K.) 
After the administration of the anabolic steroid 
17fl . hydroxy- l?a . methylandrosta-1,4 -dien-3-one 
(methandrostenolone) to man, two major meta-
bolites have been found in the chloroform extract 
of fresh urine. The least polar metabolite has now 
been identified as 17a-hydroxy-179-methyl-
androsta-1,4-dien-3-one, the 17-epimer of meth-
androstenolone. The polar metabolite has already 
been identified as 6/3-hydroxymethandrostenolone 
by Rongone & Segaloff (1963). 
The 17-epimer was synthesized from 3fl-hydroxy-
androst-5-en-17-one by reaction with triphenyl-
methylphosphonium bromide to form the 17-
methylene derivative, which was oxidized and then 
isomerized to form the 4-en-3-one; this was oxidized 
with m-chloroperoxybenzoio acid to yield 179-
methyl-17a,20-oxidoandrost-4-en-3-one. The oxido-
ketone was reduced with lithium aluminium 
hydride to a 3fl,17a-diol, which was oxidized and 
dehydrogenated in one step with diohlorodicyano- 
benzoqurnone to give 17a-hydroxy-179-methyl-
androsta4,4-dien-3-one. This Was clearly dis. 
tinguished from methandrostenolone by its n.m.r. 
spectrum and melting point, 2210C, which was 
similar to that of the metabolite isolated by 
Rongone & Segaloff (1963). 
The freely extractable neutral fraction was 
obtained from a fresh 24h collection of urine from a 
normal man after oral administration of 5mg of 
methandrostenolone. The component with the 
same 'carbon skeleton' as methandrostenolone 
(Adhikary & Harkness, 1969), which behaved 
chromatographically like methandrostenolone. was 
separated by t.l.c. followed by g.l.c. and then sub-
jected to mass spectrometry (A.E.I. MS 902). The 
epimer and metabolite showed a characteristic and 
similar pattern; for example, the molecular-ion peak 
at m/e 300 was always smaller than the peak at 
mle 282. This was reversed for methandrostenolone. 
No 17-epimer was found in the administered drug, 
nor was there any detectable conversion during the 
isolation procedure. It therefore seems justifiable 
to conclude that the 17-epimer is a metabolite 
apparently produced by a new pathway, which is 
relatively important since about 3.5% of an oral 
dose can be recovered as the epimcr. 
Adhikary, P.M. & Harkness, B. A. (1969). Analyt. Chem. 
41,470. 
Rongone, B. L. & Segaloff, A. (1963). Steroids, 1, 179. 
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The analytical techniques which proved of greatest use 
in distinguishing the 17-epimers in this investigation were 
n.m.r., g.1.c. and mass srectrornetry. 
Nuclear Magnetic Resonance Spectroscop 
100 MHz spectra were run in deuteriochloroform solutions 
using a Varian HA 100 instrument. The spectra of the epimers 
are identical but for the position of the C-lB methyl reson-
ance which is at 9.07 t in the spectrum of methandrostenolone 
and at 9.26 r in that of its 17-epimer. This difference in chemical 
shifts is due to the effect of the orientation of the 17-hydroxyl 
group on the 18-methyl group. Similar observations have been 
reported by Ananchenko et at (10). 
Gas Li quid Chromatogranhy 
G.l.c. was used initially to show that N was a metabolite 
of methandrostenolone rather than unchanged drug (3). However, 
this separation was difficult; in later exoeriments methandrosten-
olone and authentic 17-epi7-ethancirostenolcne were chromatographed 
on QF-1 and SE-30 columns, separately and as mixtures. 
Fractionally different retention times were obtained when the corn-
pounds were chromatograohed s enarately, methandrostenolone having 
the longer retention time. Mixtures of equal amounts of the 
epimers gave fractional separation of the tops of the peaks, 
whereas mixtures of unequal amounts gave rise only to a single 
peak. No peak separation could be achieved using 0V-1 columns, 
These steroids were, therefore, only separable on columns of very 
high resolving power, as in the initial experiments. 
The trimethylsilyl ether (TMHE) derivatives of both epiners 
were prepared according to the method of Nakita and Wells (11) 
and chrcmatograhed on OV-1 columns at 2350C. The retention 
time of methandrostenolone TMSE derivative relative to methan-
drostenolone was 1.08 and of 17-epirnethandrostenolone TMHE 
derivative relative to its parent comoound was 0.78. The meta- 
bolite M was also converted to its TMSE derivative and was 
similarly chromatographed. The corresponding retention time 
ratio was 0.78, indicating M to be 17-epimethandrostenolone. 
Mass Spectrometry 
Mass spectrometry was carried out using an AEI MH 902 
instrument operated at 70 e.V. Spectra of microgram samples 
of metabolite N were obtained by dissolving the entire sample 
in dry ether (10-20 p1). A syringe was used to transfer a 
portion (2-3 p1) of this solution to a quartz probe and the 
solvent was gently evaporated with a hair dryer. This process 
was repeated several times until sufficient material (ca. 10 pg) 
had been transferred to the probe, which was then inserted 
directly into the spectrometer. Spectra obtained in this way 
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and 3.83 (J = 2 cps), (2-H), 3.92 (J = 2 cps), (t-H), 8..77 
(c--19 methyl), 8.82 (0-20 methyl), 9.26 (0-18 methyl); LaID + 30 
(c = 0.50). Analysis by accurate mass measurement, calc. for 
020H2302 300.208919, found 300.210430. 
Instruments used were: melting points (corrected) - Kofler 
block; infra red spectra - Unlearn S.F. 200 spectrophotometer; 
n.m.r. spectra Varian HA 100; mass spectra - AEl, M$902; gas 
liquid chromatography - Perkin-Elmer model l; optical 
rotations - measured at 200 in methanol using a Perkin Elmer 
model 141 automatic polarimeter. 
IDENTIFICATION 
The less polar metabolite, N, from several studies was 
pooled until 100 jig was available. However, even after pre- 
parative gas liquid chromatography it could not be obtained 
entirely pure. It therefore became necessary to investigate 
the efficiency of the various methods of detection available 
with regard to establishing conclusively the structure of N. 
In view of the similarity between their structures, the 
stectral, chromatographic and other physical behaviour of 
methandrostenolone and its 17-epimer was examined. Pure 
methondrostenolonc and 17-epimethandrostenolone prepared as 
previously described were used for this purpose. 
The Rf values of the epimers on silica gel thin layer chromato- 
graphy were identical in all the solvent systems investigated. 
Both compounds produced an orange-brown spot after development 
with 5% sulphuric acid in ethanol spray and heating and a blue 
spot with 8% w/v phosphomolybdic acid in methanol spray. The 
infra red spectra of the compounds in carbon disulphide 
solution were very similar except for slit differences in the 
fingerprint region, the adsorption maximum for the 1,4-dienone 
carbonyl being at 1665 cm.' 
Rongone and Segaloff (1) quoted the melting point of 
their unidentified metabolite as 222-2240. The melting 
point of authentic 17-epimethandrostenolone is 2210  and that 
of methandrostenolone is 1630C. Similar differences in the 
melting points of pairs of 17-epimers are shown by testo-
sterone, m.p. 1550 and 17-egitestosterone m.p. 2210  and by 
methyltestosterone m.p. 164 and 17S-methylepitestosterone, 
m.p. 1820 (8). 
The optical rotations of the following pairs of 17- 
epimeric compounds have been recorded:- methyltestosterone, 
+760 and 17$-methylepitestosterone, +670 (a) ; 17-methyl-4- 
androsten-38,175-diol, +114°, and 17-methyl-14-andros ten- 35, 
17a-diol, +80; methandrostenolone, +120  and 17-epimethandrostenolone, 
+30. The differences between the rotations of each pair of 
epimers are of the sane sign and order of magnitude. Thus 
compounds V and VI and their respective epimers behave as 
would be expected (9). 
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ethanol was removed. The steroid was extracted into ether, 
washed with saturated sodium bicarbonate solution, and water, 
and finally dried over anhydrous maesium sulphate. Crystal- 
lisation from acetone afforded white needles of III, (0.76 g); 
M.P. 129_1310 (lit. 129_1310 L7]); infra red (C5) 895, 1655 
(17-methylene), 1675 cnc- (carbonyl); n.m.r. (03013) t 9.16 
(0-18 methyl), 8.80 (0-19 methyl), 5.36 (J = 4 cps) (0-17 
methylene), 4.27 (J = 6 cps)-(4--H). 
1I.20-0xido-21-nor--pregnen-3-one (Iv) - The enone (iii, 0.5 g) 
was dissolved in methylene chloride (20 ml) and rn-chloroperoçrbenzoic 
acid (0.35 g) was added. The reaction was allowed to proceed for 
2 hrs at room temperature. Excess peracid was destroyed with 10% 
sodium sulphite solution until starch-iodide paper remained white 
when moistened with a drop of the reaction mixture. The solu- 
tion was neutralised with saturated sodium bicarbonate solution, 
washed with water and dried over anhydrous magnesium sulphate. 
Evaporation to dryness and recrystallisation from acetone gave 
the oxide (0.45 g) ; m.p. 18o-184o (lit. M.P. 179-1820C [71); 
infra red (062) 1675 cn71 (carbonyl); n.m.r. (03013) r 4.28 (1-ii), 
7.30 (epoxide), 8.82 (0-19 methyl) and 9.1 (0-18 methyl). 
17-Methyl-!I-andros ten- 33,ljg-diol (V) - The oxide (iv, 0.45 g) 
was dissolved in sodium-dried ether and was slowly added to 
lithium aluminium hydride (0.2 g) in ether (20 ml). The 
mixture was refluxed for 30 min and excess reagent was destroyed 
with water. The steroid was extracted into ether, washed with 
water and dried over anhydrous magnesium sulphate. Evaporation to 
dryness and recrystallisation from acetone gave the diol (0.36 g); 
M.P. 225-2280; infra red (032) 3410 cnrJ- (hydroxyl); n.m.r. 
(03013) r 4.72 (14-H), 5.8b (3e-H), 8.82 (0-20 methyl), 8.94(C-19 
methyl), 9,31 (0-18 methyl); [J + 80 (C = 0.18). Analysis by 
accurate mass measurement, calc: tor C20H3202 304.240217, found 
301.239655. 
17c*-Hydroxy-17-methyl-1,4Nandrostadj... (vi) - The dial (v, 
0.35 g)  and  2,3-dichloro-5,6-dicyu- o-1,4-benzoquinone (o.si g) in 
dry dioxan (20 ml) were refluxed for 6 hr. The solvent was 
then removed by evaporation, the residue was taken up in benzene 
and was filtered through a layer of alumina to remove insoluble 
quinol. The crude product was chromatographed on an alumina 
column (10 g. Spence type, activity II). Elution with 
benzene removed three compounds with no carbonyl function, 
but elution with benzene-chloroform (1:1) removed two polar 
compounds. Examination by n.m.r. and mass spectrometry 
identified the less polar compound: as l7 -hydroxy-17-methyl-4-
androsten-3-one (173-methylenitestosterone) (o.c g); 
M.P. 180-1820 (lit. 182°L8J ); infra red (032), 1675 (carbonyl), 
3l0 cm (hydroxyl); n.m.r. (03013) T 1t.28 (-s), 8.81 (0-19 
methyl, 8.81 (0-20 methyl), 9.28 (0-18 methyl) and the more polar 
compound as 17a-hydro)y-17-methyl-1,4-androstadien-3-one 
(17-epimethandrostenolone)(0.1 g); m.p. 2210; infra red (062), 
910, 1636 (alkene), 1665 (carbonyl), 3410 cm- (hydroxyl): 
n.m.r. (03013) 2.91 (J = 10 cps), (I-a), 3.73 (.1 = 2 cps) 
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17-Methylene-5-androsten.-3-one (ii)- The alcohol (.1, 3.07 g) 
was dissolved in ice-cold acetone (215 ml) ,.maintained at 0, and 
Jones Reagent (6.11 ml) was added with stirring. After 45 seconds 
the reaction was quenched with methanol (120 ml) water was added, 
the organic solvents, were removed on a rotary evaporator and the 
steroid was extracted twice into ether. The combined ether extracts 
were washed with saturated sodium bicarbonate solution and then with 
water before being dried over anhydrous magnesium sulphate. 
Evaporation to dryness yielded a crude product (2.83 g) which after 
crystallisation from ethanol gave a mixture of II and III, (0.898 g); 
m.p. 109-117°c; infra red (032) 895, 1655 (17-methylene), 1675 
(carbonyl, iii), 1715 cirr- (carbonyl, II). 
UJethdene--androsten_3_one (iii).- The mixture of enones 
(II and III, 0.85 g) from the previous stage was dissolved in. 
ethanol (50 ml) and anhydrous oxalic acid (0.2 g) was added. 
The solution was held at 600c for 30 mins, water was added and the 
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(positive fractions). These fractions were then purified by 
further chromatography on thin layers of silica gel G and finally 
by preparative gas liquid chromatogranhy. Additional confirmation 
of the carbon skeleton of the compound or compounds in these 
fractions was again obtained by gas chromatography after high 
temperature catalytic reduction. 
The More polar of the two metabolites showed the same 
chromatographic behaviour as 6-hydromethandrostenolone. The 
majo r metabolite behaved similarly to methandrostenolone on thin 
layer chromatography, but a slightly shorter retention time on 
gas chromatography (SE-30 or QF-l) indicated that the compound 
was not merely unchanged drug. 
PREPARATION OF 17-EPIMETHMDROSTENOLONE 
The preparation of lTa-hydro-l7-methyl-lt-andros ten- 3-one 
(17-methy1epitestosterone) has been described by Sondheimer et al. 
(1), using preenolone acetate as tarting material. The 
synthesis of 17-epimethandrostenolone here described is essentially 
the same although different reagents were used and the starting 
material was 3$-hydroxy- 5-ándrosten-17-one (dehydroisoandrosterone). 
Experimental 
17-Methylene-5-androsten-35-o1 (I).-  Triphenylmethylphosphonium 
bromide (25.0 g) and potassium t-butoxide t-butanol (1:1 complex, 
13.04 g) were dissolved in dry dimethylsulphoxide (80 ml) under 
nitrogen with gentle warming. A solution of 3S-hydroxy-5-androsten- 
17-one (4. oh g) in dimethylsulphoxide (80 ml) was added. The 
reaction mixture was maintained at 8000  for lhr, diluted with ice 
and 10% sodium chloride solution and extracted with ether. The 
ether layers were combined and washed with water, dried over 
anhydrous magnesium sulphate and evaporated to dryness in vacuo 
to give crude product (5.09 g) heavily contaminated with triphenyl- 
phosphine oxide. Recrystallisation from methanol yielded pure I, 
(3.17 g); zn.p. 134-1350 (lit. 133-1340C Li): infra red (Cs2) 
895, 1655 (17-methylene), 3450 cnr1(3-OH); n.m.r. (cDcl3) 
T9.20 (0-18 methyl), 8.98 (0-19 methyl), 5.36 (J = 4 cpsj 
(C-17 methylene), 4.64 (J = 6 cps) (6-H). 
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as G$-hydroxymethandrostenolone 6, 173-dihydrov-17-.methyj_1, - 
androstadjen-3--one The structure of the second metabolite was 
not established but on the basis of the evidence available Rongone 
and Segaloff suggested that it was an isomer of methandrostenolone 
rather than an oxygenated product. 
Adhikary and Harkness have studied the metabolism of small 
doses of methandrostenolone in normal man (2,3). They succeeded 
in recovering 5% of the dose as two major metabolites from the 
freely extractable neutral fraction of the urine. High temperature 
catalytic reduction with gas chromatography of the hydrocarbon 
products ('carbon skeleton chromatography' [4,5]) was used to 
locate the metabolites and to quantify them. The two compounds 
occurred in the ratio 2:1, the minor of the two being identified 
as G -hydrovmethandrostenolone (2). The 17-epirner of methan-
drostenolone 17a-hydroçr-17-methyl_1, 4-androstadien-3-one has now 
been synthesised and has been shown to be identical with the major 
urinary metabolite (M) of methandrostenolone in man (6). 
ISOLATION AND PURIFICATION 
In each study, the normal therapeutic dose of one 5 mg tablet 
of methandrostenolone was administered to a male volunteer in good 
health, and the total urine output of the following 25 hr was 
collected. Extraction of the urine with chloroform gave the - 
'free fraction'. The extracts were chromatographed on silica gel 
G coated plates using chloroform-methanol 19:1 (v/v) as mobile 
phase. Chromatographic fractions were collected as eluates from 
1 cm bands; these were halved, evaporated to dryness and one set 
of residues dissolved in 0.1 ml of ethanol. 10 pl of this 
solution from each fraction was used for high temperature catalytic 
reduction at 180_19000 using 1-3% w/w platinum catalyst. The 
reduction products were analysed by gas chromatography using 55-30 
or NGA columns with a hydrocarbon standard derived from the drug 
by the same method. From these results, chromatographic fractions 
were selected which contained the same skeleton as the drug 
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showed that several compounds were generally present in the 
metabolite samples even after repeated preparative thin layer 
chromatograohy. It was established that the mass spectra of 
synthetic methandrostenolone and its 1T-epimer were unaffected 
by gas chromatography of the compounds prior to spectrometry. 
Consequently, metabolite samples were purified by preparative 
gas chromatography, collected in glass tubes and transferred to 
the spectrometer probe as already described. 
Prior to mass spectrometry of N is was necessary to 
compare the spectra of pure methandrostenolone Fig. 2(a) and 
authentic 17-epimethandrostenolone Fig. 2(c). The base peak 
of both compounds is m/e = 122 (12). The presence of this 
ion establishes the 1,14-dienone structure of the A-ring, since 
it must arise by B-ring fragmentation with the transfer of two 
protons to the charged species, Fig. 3 (13). 
Under the conditions encountered within the mass spectrometer 
17-epimethandrostenolone readily dehydrates to give a peak at m/e = 282 
(g-H20) which is large compared with the molecular ion, M+  at 
m/e = 300. It also gives a peak at m/e = 267 (N-H20-cH3). 
Both of these peaks are present in the spectrum of methandrostenolone 
but are unimportant compared with M and the ion at m/e = 242 which 
arises from fragmentation across the D-ring. It can be seen from 
these results that, although both epimers give rise to peaks at 
the same m/e values the intensities can be used to determine which 
epimer is present (6). Ananchenko et al. (10) obtained similar 
results in their study of the mass spectra of 17-epimeric oestranes 
and 19-nortestosterones and the corresponding D-homo-17a-epimeric 
compounds. 
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The mass spectrum of the metabolite M after purification by 
preparative gas chromatography is shown in Fig. 2(b). This 
spectrum adds further support to the earlier conclusions that 14 
is not merely unchanged drug and verifies the assumption that it 
is 17—epimethandrostenolone. 
For further identification of 14 the ME derivatives of 












All three gave similar spectra with the molecular ion, at 
m/e = 372, indicating the successful formation of the derivative. 
The base peak is at m/e = 143, the origin of which is shown in 
fig. t (12). The only other ion of importance is that at 
m/e = 282. 
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Examination of Comnerci al Methondrostenolone 
Because less than 5% of administered methandrostenolone 
can be recovered as 17-epimethandros ten clone it seemed advisable 
to check that tablets of consoercial methandrostenolone do not 
contain a small quantity of the epimer. Accordingly, ten 5 mg 
tablets of methandrostenolone (Dianabol, Ciba) were ground to 
a fine powder and extracted with benzene. The insoluble carrier 
material was removed by filtration and the solvent was removed 
on a rotary evaporator. Crystals, which had a melting point 
identical with that of pure moth androstenclone were obtained. 
Gas liquid chromatography of the THEE derivative of the drug 
obtained from tablets showed no 17-epimer. 
Fig-5(a) shows the mass spectrum of a synthetic mixture 
containing 95% pure methandrostenolone and 5% ll-epimethan- 
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drostenolone. The spectrum of methandrostenolone extracted 
from tablets is shown in fig. 5(b). It is identical with the 
spectrum of pure methandrostenolone, fig. 2(a) , and differs from 
fig. 5(a). No epiner was detectable after extracting 
methandrostenolone from water and subsequent thin layer chromato- 
graphy during which the saznles were exnosed to lit. The 
compound has already been shown to be unaltered after gas 
chromatography. Since the 1T-epimer was not present in the 
starting material, nor was it produced by the isolation 
procedures, the 17-epimethandrostenolone isolated from urine after 
the administration of methandrostenolone must be of biochemical 
origin. 
DISCUSSION 
Proof that a major metabolite of methandrostenolone in 
normal man is 17-epimethandrostenolone raises the question as 
to how it arises. The epimerisation of secondary hydroxyl 
groups is well known chemically (lit) whereas epimerisation of 
the tertiary 17-hydroxyl group is unknown (15). The epimeris- 
ation of secondary steroid alcohols has previously been reported 
in biochemical systems especially when there is an adjacent 
oxygen function which can assume an oxo-form (16) but such reactions 
generally constitute minor metabolic pathways. Biochemical 
epimerisation of tertiary alcohols, to our knowledge, has not 
been previously described. 
The metabolism of methandrostenolone proceeds quite 
differently from that of 17a-methyltestosterone (17) where the 
4(5)-double bond and the 3-oxo group are both reduced. In 
addition, there is no evidence of epimerisation at C-fl. 
These findings suggest that the A-ring of methandrostenolone 
is more stable to the usual enzymatic conversions but may 
somehow facilitate the epimerisation at C17. Similar facts 
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to these have also been observed by Schubert et al. (18) in 
their work on the metabolism of the b-chloro analogue of 
methandrostenolone (Oral-Turinaboj). These, workers have 
isolated from the freely extractable fraction an unidentified 
metabolite present in relatively large amounts which may well 
be the, 17-epimer of Oral-Turinabol. 
The isolation of 17-epiinethandrostenolone from the freely 
extractable fraction rather than the conjugated 'glucuronide' 
fraction of urine is unusual; little or in some cases no meta-
bolites were obtained from urine after -glucuronida.se hydrolysis. 
In addition to the inhibition of glucuronyl transfer to the 
173-hydroç,rl group by the 17ct-methyl group the structure of the 
A-ring probably further reduces conjugation of the 17-hydroxyl 
group; this is consistent with findings of Hsiaetal. (19) 
who found that 17 -hydroxy-17-methyl-1,b-androstadien-3-one was 
four times more effective than 17S-hydroxy-17--methyl-4-androsten-
3-one in inhibiting conjugation of o-aminophenol in vitro. 
The mechanism of formation of the 17-epimer is at present 
being studied. 
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